WO2019163917A1 - S1p5受容体作動活性を有する化合物 - Google Patents
S1p5受容体作動活性を有する化合物 Download PDFInfo
- Publication number
- WO2019163917A1 WO2019163917A1 PCT/JP2019/006637 JP2019006637W WO2019163917A1 WO 2019163917 A1 WO2019163917 A1 WO 2019163917A1 JP 2019006637 W JP2019006637 W JP 2019006637W WO 2019163917 A1 WO2019163917 A1 WO 2019163917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- group
- alkyl
- azetidine
- atom
- Prior art date
Links
- XICNVBJETWVWGE-GOEBONIOSA-N C[C@@H](C1)C(CN(CC2)C[C@@H]2C(O)=O)=Cc(cc2)c1cc2OCCCC(F)(F)F Chemical compound C[C@@H](C1)C(CN(CC2)C[C@@H]2C(O)=O)=Cc(cc2)c1cc2OCCCC(F)(F)F XICNVBJETWVWGE-GOEBONIOSA-N 0.000 description 1
- NMFLEJWIBOJWNC-ADQTWTKMSA-N C[C@H](C1)C(CN(C2)CC2(C(O)=O)F)=Cc(cc2)c1cc2OC/C=C/C(F)(F)F Chemical compound C[C@H](C1)C(CN(C2)CC2(C(O)=O)F)=Cc(cc2)c1cc2OC/C=C/C(F)(F)F NMFLEJWIBOJWNC-ADQTWTKMSA-N 0.000 description 1
- XICNVBJETWVWGE-GDBMZVCRSA-N C[C@H](C1)C(CN(CC2)C[C@@H]2C(O)=O)=Cc(cc2)c1cc2OCCCC(F)(F)F Chemical compound C[C@H](C1)C(CN(CC2)C[C@@H]2C(O)=O)=Cc(cc2)c1cc2OCCCC(F)(F)F XICNVBJETWVWGE-GDBMZVCRSA-N 0.000 description 1
- CFYVFCBELHPQEI-CHWSQXEVSA-N C[C@H](COc1ccc(C=C(CN(C2)CC2C(O)=O)[C@H](C)C2)c2c1)C(F)(F)F Chemical compound C[C@H](COc1ccc(C=C(CN(C2)CC2C(O)=O)[C@H](C)C2)c2c1)C(F)(F)F CFYVFCBELHPQEI-CHWSQXEVSA-N 0.000 description 1
- OGVAMAKOSBCXRA-GFCCVEGCSA-N C[C@H](Cc1c2)C(CN(C3)CC3(C(O)=O)F)=Cc1ccc2OCCC(F)(F)F Chemical compound C[C@H](Cc1c2)C(CN(C3)CC3(C(O)=O)F)=Cc1ccc2OCCC(F)(F)F OGVAMAKOSBCXRA-GFCCVEGCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
- C07C49/252—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
- C07C49/577—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention provides a general formula (V) (Wherein all symbols have the same meanings as described later) or a pharmaceutically acceptable salt thereof (hereinafter sometimes abbreviated as the compound of the present invention).
- Sphingosine-1-phosphate [(2S, 3R, 4E) -2-amino-3-hydroxyoctadec-4-enyl-1-phosphate; hereinafter abbreviated as S1P. ] Is a lipid synthesized by intracellular sphingolipid turnover and extracellular sphingosine kinase action, and has been proposed to act as an intercellular signal transmitter and intracellular secondary signal transmitter. ing.
- the S1P 5 (EDG-8) receptor is known to be highly expressed in oligodendrocytes (oligodendrocytes) and oligodendrocyte progenitor cells, and the S1P 5 receptor When activated, it has been clarified that differentiation induction from oligodendrocyte precursor cells to oligodendrocytes is promoted (see Non-Patent Documents 1 and 2). Oligodendrocytes are a type of glial cell that binds to nerve cell axons to form myelin sheaths (myelin).
- a compound having an agonistic activity of the S1P 5 receptor promotes the regeneration of myelin (demyelination) that has disappeared in nerve cells, and thus is useful for the treatment of demyelinating diseases such as multiple sclerosis and neurodegenerative diseases. It is considered to be.
- Non-Patent Document 3 See SlP 5 receptor in natural killer (NK) cells are known to be highly expressed, by activation of SlP 5 receptor, migration of NK cells are induced.
- SlP 5 receptor since it is involved in tumor immunity is highly expressed in known Patrolling monocyte, by activation of SlP 5 receptor, possibly tumor immune activation is induced (See Non-Patent Documents 4 and 5).
- SlP 1 receptor is a receptor expressed on the cardiovascular system and lymphocytes. It is known that a compound having S1P 1 receptor agonistic activity has a concern that it exhibits a lymphocyte reduction action or a heart rate reduction action.
- the dihydronaphthalene compound having S1P receptor binding ability is represented by the general formula (a) (Wherein ring A a represents a cyclic group, Ring B a further represents a cyclic group which may have a substituent group, X a represents a spacer bond or a main chain of 1 to 8 atoms Y a represents a bond or a spacer having 1 to 10 atoms in the main chain, na represents 0 or 1, when na is 0, ma represents 1 and R 1a represents a hydrogen atom or a substituent.
- na 1
- ma 0 or an integer of 1 to 7
- R 1a represents a substituent (a plurality of R 1a may be the same or different when ma is 2 or more).
- the definition of each group was excised), and it was disclosed that the compound represented by ( 2 ) specifically binds specifically to the EDG-1 (S1P 1 ) and EDG-6 (S1P 4 ) receptors ( Patent Document 1).
- a compound represented by the general formula (b) (In the formula, ring A b represents a cyclic group, ring B b represents a cyclic group which may further have a substituent, and X b represents a bond or a spacer having 1 to 8 atoms in the main chain.
- Y b represents a bond or a main chain spacer of 1 to 10 atoms
- Z b represents an optionally protected acidic group
- nb represents 0 or 1
- mb represents 1
- R 1b represents a hydrogen atom or a substituent
- nb represents 0 or an integer of 1 to 7
- R 1b represents a substituent (a plurality of R when mb is 2 or more). 1b may be the same or different.
- An object of the present invention is to provide compounds with an improved balance of SlP 5 receptor agonist activity against S1P 1 receptor.
- the present invention provides, for example, [1] General formula (V) [Wherein L is a branched or straight chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom, and the main chain has 3 to 8 atoms.
- each group is bonded to Z by a bond indicated by an arrow
- A represents an optionally substituted C3-7 cycloalkylene group, or an optionally substituted C1-4 alkylene group
- R 1 is a C1-4 alkyl group, a C3-6 cycloalkyl group optionally substituted with halogen, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- R 2 represents a C1-4 alkyl group, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- a pharmaceutical composition comprising a compound represented by the general formula (V) according to [1], or a pharmaceutically acceptable salt thereof, [3] [1] a compound represented by the general formula (V) described, or an effective amount of a pharmaceutically acceptable salt thereof which comprises administering to a mammal, the prevention of SlP 5 mediated diseases And / or treatment methods, [4] The compound represented by the general formula (V) described in [1], or a pharmaceutically acceptable salt thereof, and [5] S1P 5 used for the prevention and / or treatment of S1P 5 mediated diseases
- Embodiments such as the use of a compound represented by the general formula (V) described in [1] above or a pharmaceutically acceptable salt thereof for producing a preventive and / or therapeutic agent for an mediated disease are provided.
- the compound of the present invention Since the compound of the present invention has a high S1P 5 receptor-selective agonist activity with respect to the S1P 1 receptor, it is useful for the treatment of S1P 5 mediated diseases such as neurodegenerative diseases, autoimmune diseases, infectious diseases, and cancer. It is.
- the halogen atom means fluorine, chlorine, bromine or iodine.
- the C1-8 alkyl group includes linear or branched C1-8 alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, isobutyl.
- the C1-6 alkyl group includes a linear or branched C1-6 alkyl group, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl.
- Tert-butyl 1-methylbutyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-methylpentyl, 1- Ethylbutyl, 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2-methylpentyl, Examples include 3-methylpentyl, 4-methylpentyl, or 2,3-dimethylbutyl group.
- the C1-5 alkyl group includes a linear or branched C1-5 alkyl group.
- methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl, tert Examples include -butyl, 1-methylbutyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl, or 2,2-dimethylpropyl groups.
- the C1-4 alkyl group includes a linear or branched C1-4 alkyl group, for example, methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, or tert-butyl.
- a butyl group is mentioned.
- the C2-7 alkyl group includes linear or branched C2-7 alkyl groups such as ethyl, propyl, butyl, pentyl, hexyl, heptyl, isopropyl, isobutyl, sec-butyl.
- the C2-5 alkyl group includes linear or branched C2-5 alkyl groups such as ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl, tert-butyl. 1-methylbutyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl or 2,2-dimethylpropyl.
- the C3-8 alkyl group includes linear or branched C3-8 alkyl groups such as propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, isobutyl, sec-butyl.
- the C3-6 alkyl group includes a linear or branched C3-6 alkyl group, and examples thereof include propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl.
- a pentyl, 4-methylpentyl, or 2,3-dimethylbutyl group may be mentioned.
- the C4-7 alkyl group includes linear or branched C4-7 alkyl groups such as butyl, pentyl, hexyl, heptyl, isobutyl, sec-butyl, tert-butyl, 1 -Methylbutyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, 4 -Methylpentyl, 2,3-dimethylbutyl, 1-methylhexyl, 1-ethyl
- the C2-7 alkenyl group includes linear or branched C2-7 alkenyl groups such as ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl, heptenyl, heptadienyl. Groups, or isomers thereof.
- the C2-6 alkenyl group includes linear or branched C2-6 alkenyl groups, such as ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl groups, or Of the isomers.
- the C2-5 alkenyl group includes a linear or branched C2-5 alkenyl group, for example, an ethenyl, propenyl, butenyl, butadienyl, pentenyl, pentadienyl group, or an isomer thereof. Can be mentioned.
- the C2-4 alkenyl group includes linear or branched C2-4 alkenyl groups, and examples thereof include ethenyl, propenyl, butenyl, butadienyl groups, and isomers thereof.
- the C3-8 alkenyl group includes linear or branched C3-8 alkenyl groups such as propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl, heptenyl, heptadienyl, octenyl. , Octadienyl groups, or isomers thereof.
- the C3-6 alkenyl group includes linear or branched C3-6 alkenyl groups such as propenyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl groups, or isomers thereof.
- the body is mentioned.
- the C4-7 alkenyl group includes a linear or branched C4-7 alkenyl group, for example, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl, hexadienyl, heptenyl, heptadienyl group, or these Of the isomers.
- the C2-7 alkynyl group includes linear or branched C2-7 alkynyl groups such as ethynyl, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl. Groups, or isomers thereof.
- the C2-6 alkynyl group includes linear or branched C2-6 alkynyl groups such as ethynyl, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl group, or Of the isomers.
- the C2-5 alkynyl group includes a linear or branched C2-5 alkynyl group, for example, an ethynyl, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl group, or an isomer thereof. Can be mentioned.
- the C2-4 alkynyl group includes a linear or branched C2-4 alkynyl group, and examples thereof include ethynyl, propynyl, butynyl, butadiynyl groups, and isomers thereof.
- the C3-8 alkynyl group includes linear or branched C3-8 alkynyl groups such as propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl, octynyl. , Octadiynyl groups, or isomers thereof.
- the C3-6 alkynyl group includes a linear or branched C3-6 alkynyl group, for example, propynyl, butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl group, or isomers thereof.
- the body is mentioned.
- the C4-7 alkynyl group includes linear or branched C4-7 alkynyl groups, such as butynyl, butadiynyl, pentynyl, pentadiynyl, hexynyl, hexadiynyl, heptynyl, heptadiynyl group, or the like Of the isomers.
- the C1-5 alkylene group includes linear or branched C1-5 alkylene, and examples thereof include methylene, ethylene, propylene, butylene, pentylene groups, and isomers thereof.
- the C1-4 alkylene group includes linear or branched C1-4 alkylene, and examples thereof include methylene, ethylene, propylene, butylene groups, and isomers thereof.
- the C1-3 alkylene group includes linear or branched C1-3 alkylene, and examples thereof include methylene, ethylene, propylene groups, and isomers thereof.
- the C2-4 alkylene group includes linear or branched C2-4 alkylene, and examples thereof include ethylene, propylene, butylene groups, and isomers thereof.
- the C2-3 alkylene group includes linear or branched C2-3 alkylene, and examples thereof include ethylene, propylene groups, and isomers thereof.
- examples of the C3-6 cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group.
- examples of the C3-7 cycloalkylene group include a cyclopropylene group, a cyclobutylene group, a cyclopentylene group, a cyclohexylene group, and a cycloheptylene group.
- the C1-4 alkoxy group includes, for example, a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, or tert-butoxy group.
- the C1-4 haloalkyl group means, for example, a fluoromethyl group, a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a trifluoromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, 2 -Chloroethyl group, pentafluoroethyl group, 1-fluoropropyl group, 2-chloropropyl group, 3-fluoropropyl group, 3-chloropropyl group, 4,4,4-trifluorobutyl group, or 4-bromobutyl group Can be mentioned.
- examples of the C2-8 acyl group include ethanoyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl, octanoyl group, and isomers thereof.
- the 3- to 7-membered nitrogen-containing heterocycle is an unsaturated or saturated 3- to 7-membered monocyclic heterocycle containing 1 to 5 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom. Of the rings, it means one containing at least one nitrogen atom.
- a 4- to 7-membered nitrogen-containing heterocycle is an unsaturated or saturated 4- to 7-membered monocyclic heterocycle containing 1 to 5 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom. Of the rings, it means one containing at least one nitrogen atom.
- the 3- to 7-membered nitrogen-containing saturated heterocyclic ring is a partially or fully saturated 3- to 7-membered member containing 1 to 5 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- these monocyclic heterocycles those containing at least one nitrogen atom are necessarily meant.
- the 4- to 7-membered nitrogen-containing saturated heterocyclic ring is a partially or fully saturated 4- to 7-membered member containing 1 to 5 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom.
- these monocyclic heterocycles those containing at least one nitrogen atom are necessarily meant.
- the chain group means a linear or branched group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom.
- the main chain means the longest linearly bonded portion including atoms bonded to the mother skeleton (dihydronaphthalene skeleton) among atoms constituting the chain group.
- the number of atoms in the main chain means the total number of carbon atoms, oxygen atoms, nitrogen atoms, and sulfur atoms contained in the main chain.
- L is a group represented by the following diagram
- the number of atoms in the main chain is 5.
- L represents a linear or branched chain hydrocarbon group having 3 to 8 carbon atoms in the main chain, or an oxygen atom instead of 1 to 3 carbon atoms in the chain hydrocarbon group.
- a heteroatom-containing chain hydrocarbon group containing 1 to 3 heteroatoms independently selected from a nitrogen atom and a sulfur atom.
- the straight chain or branched chain hydrocarbon group having 3 to 8 carbon atoms in the main chain means, for example, a C3-8 alkyl group, a C3-8 alkenyl group, or a C3-8 alkynyl group.
- R 1 is preferably a C1-4 alkyl group, a C3-6 cycloalkyl group optionally substituted with halogen, a C1-4 haloalkyl group, or a halogen atom, and is preferably a C1-4 alkyl group, C3— A 6 cycloalkyl group or a halogen atom is more preferable, and a methyl group, a cyclopropyl group, or fluorine is particularly preferable.
- R 2 is preferably a C1-4 alkyl group, a halogen atom, a C1-4 alkoxy group optionally substituted with halogen, or a hydroxyl group, and a C1-4 alkyl group, a halogen atom, C1-4 alkoxy Group or hydroxyl group is more preferable, and fluorine, methyl group, methoxy group, or hydroxyl group is particularly preferable.
- R 3 is preferably a hydrogen atom or a C1-4 alkyl group, more preferably a hydrogen atom or a methyl group, and particularly preferably a hydrogen atom.
- R 4 is preferably a hydrogen atom or a C1-4 alkyl group, more preferably a hydrogen atom or a methyl group, and particularly preferably a hydrogen atom.
- R 5 is preferably a hydrogen atom or a C1-4 alkyl group, more preferably a hydrogen atom or a methyl group.
- the halogen atom is preferably fluorine.
- L is a branched or straight chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom and a sulfur atom, and the main chain has 4 to 7 atoms.
- the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom (wherein the carbon atom in L is 1 to 13).
- L is (1) —O— (C2-7 alkyl), (2) —O— (C2-7 alkenyl), (3) —O— (C2-7 alkynyl), (4) -O- (C1-5 alkylene) -OCH 3 , (5) -O- (C1-4 alkylene) -OCH 2 CH 3 , (6) -CH 2 O- (C1-6 alkyl), (7)- CH 2 O— (C2-6 alkenyl), (8) —CH 2 O— (C2-6 alkynyl), (9) —CH 2 CH 2 O— (C1-5 alkyl), (10) —CH 2 CH 2 O- (C2-5 alkenyl), (11) -CH 2 CH 2 O- (C2-5 alkynyl), (12) -S- (C2-7 alkyl), (13) -S- (C2-7 alkenyl), (14) -S- (C2 ⁇ 7 alkynyl), (15) -NR 6 - (C
- each group may be substituted with 1 to 13 halogen atoms, and each group is bonded to the dihydronaphthalene ring by a bond indicated by an arrow).
- Z is preferably a carboxyl group or a tetrazolyl group optionally substituted with a C1-8 alkyl group, more preferably a carboxyl group or a tetrazolyl group, and particularly preferably a carboxyl group.
- ring2 is preferably a 3- to 7-membered nitrogen-containing saturated heterocyclic ring, more preferably a 4- to 7-membered nitrogen-containing saturated heterocyclic ring, particularly preferably azetidine, pyrrolidine, piperidine, or perhydroazepine, and azetidine or Pyrrolidine is more preferred.
- ring 1 is preferably a 4- to 7-membered nitrogen-containing saturated heterocyclic ring, more preferably azetidine, pyrrolidine, piperidine or perhydroazepine, and particularly preferably azetidine or pyrrolidine.
- R 1 when R 1 is bonded to an asymmetric carbon on dihydronaphthalene, the following configuration is preferable as the configuration of R 1 .
- R 1 capable of taking the configuration is more preferably a C1-4 alkyl group, and particularly preferably a methyl group.
- the oxygen atom when an oxygen atom is present at the end of the chain group represented by L, the oxygen atom may be ⁇ O or —OH.
- A represents (1) C1-4 alkyl, C1-4 alkoxy, halogen, or a C3-7 cycloalkylene group optionally substituted with a hydroxyl group, or (2) C1-4 alkyl, C1-4 A C1-4 alkylene group which may be substituted with 4 alkoxy, halogen, or a hydroxyl group is preferred, a C3-7 cycloalkylene group or a C1-4 alkylene group is more preferred, and a cyclobutane or ethylene group is particularly preferred.
- m is preferably an integer of 0 to 3, more preferably an integer of 0 to 2.
- n is preferably an integer of 0 to 2, more preferably an integer of 0 to 1.
- each hydrogen atom may be a deuterium atom or a tritium atom.
- the compound shown by these is preferable.
- the general formula (V-2) [Wherein L 1 is a branched or straight chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom and a sulfur atom, and the main chain has 4 to 7 atoms.
- the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom
- the carbon atom in L 1 may be substituted with 1 to 13 halogen atoms
- ring2-1 represents a 3- to 7-membered nitrogen-containing saturated heterocycle
- m-1 represents an integer of 0 to 2
- n-1 represents an integer of 0 to 2
- a plurality of R 1 may be the same or different
- when n-1 is 2 the same or different
- each hydrogen atom may be a deuterium atom or a tritium atom.
- the compound shown by these is preferable.
- each hydrogen atom may be a deuterium atom or a tritium atom.
- the compound shown by these is preferable.
- each hydrogen atom may be a deuterium atom or a tritium atom. ] Is more preferable.
- each hydrogen atom may be a deuterium atom or a tritium atom.
- the compound shown by these is also preferable.
- L 1 is (1) -O- (C3-6 alkyl), (2 ) -O- (C3-6 alkenyl), (3) -O- (C3-6 alkynyl), (4) -O- (C1-4alkylene) -OCH 3 , (5) -O- (C1-3 (Alkylene) -OCH 2 CH 3 , (6) -CH 2 O— (C2-5 alkyl), (7) —CH 2 O— (C2-5 alkenyl), (8) —CH 2 O— (C2-5) Alkynyl), (9) —CH 2 CH 2 O— (C1-4 alkyl), (10) —CH 2 CH 2 O— (C2-4 alkenyl), (11) —CH 2 CH 2 O— (C2 ⁇ 4-alkynyl), (12) -S- (C3-6 alkyl), (13) -S- (C3-6 alkenyl), (14)- S- (
- azetidine or pyrrolidine is more preferred.
- the compounds described in the examples are preferred, and (1) 1-[((3R) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3- Carboxylic acid, (2) 1-[((3S) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid, (3) 1-[(( 3S) -3-Methyl-6-pentoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid, (4) 1-[[(3S) -3-methyl-6- (4 , 4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid, (5) 3-fluoro-1-[[(3S) -3-methyl-6 -(3,4,4-trifluorobut
- a compound having a clearance measured by the method described in Biological Experiment Example 2 of 10 mL / min / kg or less is preferable, and a compound of 5 mL / min / kg or less is more preferable.
- a compound having an effective dose measured by the method described in Biological Experimental Example 4 of 100 mg / kg or less is preferable, a compound of 10 mg / kg or less is more preferable, and a compound of 1 mg / kg or less is particularly preferable. preferable.
- the alkyl group includes a straight chain and a branched chain.
- geometric isomers in double bonds, rings and condensed rings E-form, Z-form, cis-form, trans-form
- optical isomers due to the presence of asymmetric carbon atoms, etc. R, S-form, ⁇ , ⁇ configuration, Enantiomers, diastereomers
- optically active substances having optical activity D, L, d, l form
- polar forms high polar form, low polar form
- optical isomers in the present invention may include not only 100% pure but also other optical isomers of less than 50%.
- references to the compound of the present invention are represented by the compound represented by the general formula (V), a salt thereof, a solvate thereof, an N-oxide thereof, or a co-crystal thereof, or the general formula (V). It includes a solvate of a salt of a compound or a co-crystal thereof.
- the compound represented by the general formula (V) is converted into a corresponding salt by a known method.
- the salt is preferably water-soluble.
- the salt is preferably a pharmaceutically acceptable salt.
- Such salts include salts of alkali metals (lithium, potassium, sodium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), salts of other metals (silver, zinc, etc.), ammonium salts, pharmaceutically Acceptable organic amines (tetramethylammonium, choline, triethylamine, methylamine, dimethylamine, ethylamine, diethylamine, cyclopentylamine, benzylamine, phenethylamine, tert-butylamine, ethylenediamine, piperidine, piperazine, monoethanolamine, diethanolamine, tris ( Hydroxymethyl) aminomethane, N-benzyl-2-phenethylamine, deanol, 2- (diethylamin
- the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof can be converted into a solvate.
- the solvate is preferably low toxic and water soluble. Examples of such solvates include solvates with water and alcohol solvents (for example, ethanol and the like). In one embodiment, it is a hydrate.
- the N-oxide form of the compound represented by the general formula (V) represents an oxidized nitrogen atom of the compound represented by the general formula (V). Further, the N-oxide form of the compound represented by the general formula (V) may further be an alkali (earth) metal salt, ammonium salt, organic amine salt, or acid adduct salt.
- the compound represented by the general formula (V) or a pharmaceutically acceptable salt thereof can form a cocrystal with an appropriate cocrystal forming agent.
- the co-crystal is preferably a pharmaceutically acceptable one formed with a pharmaceutically acceptable co-crystal former.
- a co-crystal is typically defined as a crystal formed by two or more different intermolecular interactions.
- the co-crystal may be a complex of a neutral molecule and a salt.
- Co-crystals can be prepared by known methods, such as by melt crystallization, by recrystallization from a solvent, or by physically grinding the components together.
- Suitable co-crystal formers include organic acids (malic acid, succinic acid, adipic acid, gluconic acid, tartaric acid, benzoic acid, 4-hydroxybenzoic acid, 3-hydroxybenzoic acid, nicotinic acid, isonicotinic acid, etc.), Organic amines (imidazole, diethanolamine, triethanolamine, tris (hydroxymethyl) aminomethane, N-benzyl-phenethylamine, deanol, 2- (diethylamino) ethanol, 1- (2-hydroxyethyl) pyrrolidine, 4- (2- Hydroxyethyl) morpholine, N-methyl-D-glucamine, glycine, histidine, proline, etc.) and other organic compounds (caffeine, saccharin, etc.).
- Suitable co-crystal formers include those described in WO 2006/007448.
- a prodrug of a compound represented by the general formula (V) refers to a compound that is converted into a compound represented by the general formula (V) by a reaction with an enzyme, gastric acid or the like in a living body.
- a prodrug of the compound represented by the general formula (V) when the compound represented by the general formula (V) has a hydroxyl group, a compound in which the hydroxyl group is acylated, alkylated, phosphorylated or borated (for example, Compounds in which the hydroxyl group of the compound of the present invention is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated, etc.); carboxyl group of the compound represented by the general formula (V) Esterified, amidated compounds (eg, the carboxyl group of the compound represented by the general formula (V) is ethyl esterified, isopropyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivalo Iroxymethyl esterification, ethoxycarbonyloxyethyl ester
- the prodrug of the compound represented by the general formula (V) may be either a hydrate or a non-hydrate.
- prodrugs of the compounds represented by the general formula (V) are generally used under physiological conditions as described in Yodogawa Shoten 1990, “Development of Drugs”, Volume 7, “Molecular Design”, pages 163-198. It may be changed to a compound represented by the formula (V).
- the compound represented by the general formula (V) is an isotope (for example, 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 35 S, 18 F, 36 Cl, 123 I, 125 I, etc.).
- the compound of the present invention can be obtained by a known method, for example, the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 3rd Edition (Richard C. Larock, John Wiley & Sons Inc, 2018) or the method shown in the Examples. It can manufacture by improving suitably etc. and using them in combination.
- R 3 and R 4 are hydrogen atoms, one of the atoms constituting L is an oxygen atom, and ring1 is a 4- to 7-membered nitrogen-containing saturated heterocyclic ring,
- General formula (IA) (Wherein L A is a branched or straight chain group composed of atoms selected from a carbon atom, an oxygen atom, a nitrogen atom, and a sulfur atom, and the main chain has 2 to is 7, the chain group is an oxygen atom, a nitrogen atom, and may contain 1 to 2 hetero atoms selected from sulfur atom, wherein the carbon atom in L a is 1-13 Ring 1 A represents a 4- to 7-membered nitrogen-containing saturated heterocyclic ring, and other symbols have the same meaning as described above.) Can be produced by the reaction process formula 1.
- a compound in which ring 1 A is a 3- to 7-membered nitrogen-containing saturated heterocyclic ring can also be produced in the same manner by a method according to reaction process formula 1.
- X 1 represents a halogen atom, a trifluoromethanesulfonyloxy group (OTf group), a methanesulfonyloxy group (OMs group), or a toluenesulfonyloxy group (OTs)
- the reaction 1 can be carried out by subjecting the compound represented by the general formula (A) and the compound represented by the general formula (II) to a reductive amination reaction.
- This reductive amination reaction is known, for example, organic solvents (dichloroethane, dichloromethane, N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone, acetic acid, tetrahydrofuran, methanol, and mixtures thereof)
- a reducing agent sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, etc.
- the reaction 2 is performed by subjecting the compound represented by the general formula (B) and the compound represented by the general formula (III) to an etherification reaction, or a compound represented by the general formula (B), It can be carried out by subjecting the compound represented by the general formula (IV) to Mitsunobu reaction.
- This etherification reaction is known, for example, an alkali metal hydroxide (sodium hydroxide) in an organic solvent (N, N-dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t-butyl ether, etc.).
- Potassium hydroxide, lithium hydroxide, etc. potassium hydroxide, etc.
- alkaline earth metal hydroxides barium hydroxide, calcium hydroxide, etc.
- carbonates sodium carbonate, potassium carbonate, etc.
- aqueous solutions thereof or mixtures thereof Carried out at 0 to 100 ° C.
- a compound in which one of the atoms constituting L is a carbon atom, a nitrogen atom, or a sulfur atom that is, the general formula (VA) (Wherein E represents a carbon atom, a nitrogen atom, or a sulfur atom, and other symbols have the same meaning as described above.)
- the compound represented by the reaction process formula 2 shown below can be produced. It can.
- X 2 represents a halogen atom or a trifluoromethanesulfonyloxy group (OTf group), and other symbols have the same meaning as described above.
- the reaction 3 can be performed by subjecting the compound represented by the general formula (C) and the compound represented by the general formula (VI) to a transition metal catalyst cross-coupling reaction.
- This transition metal catalyst cross-coupling reaction is known, and examples of the transition metal catalyst include palladium catalyst, copper catalyst, nickel catalyst, ruthenium catalyst, iridium catalyst, rhodium catalyst, iron catalyst, platinum catalyst, silver catalyst, or gold catalyst.
- a catalyst is mentioned.
- the Suzuki coupling reaction is performed in a base (sodium ethylate, for example) in an organic solvent (benzene, toluene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane, acetone, etc.).
- a base sodium ethylate, for example
- an organic solvent benzene, toluene, dimethylformamide, dioxane, tetrahydrofuran, methanol, acetonitrile, dimethoxyethane, acetone, etc.
- Examples of the protecting group for carboxyl group include methyl group, ethyl group, allyl group, t-butyl group, trichloroethyl group, benzyl (Bn) group, phenacyl group and the like.
- hydroxyl protecting groups include methyl, trityl, methoxymethyl (MOM), 1-ethoxyethyl (EE), methoxyethoxymethyl (MEM), 2-tetrahydropyranyl (THP), and trimethylsilyl.
- TMS triethylsilyl
- TES triethylsilyl
- TDMS t-butyldimethylsilyl
- TDPS t-butyldiphenylsilyl
- acetyl (Ac) group pivaloyl group
- benzoyl group benzyl (Bn) group
- examples include a p-methoxybenzyl group, an allyloxycarbonyl (Alloc) group, and a 2,2,2-trichloroethoxycarbonyl (Troc) group.
- the protecting group is not particularly limited as long as it is a group that can be easily and selectively removed other than those described above.
- those described in T. W. Greene, Protective Groups in Organic Synthesis, Fifth Edition, Wiley, New York, 2014 are used.
- Deprotection reactions of protecting groups are well known, for example (1) alkaline hydrolysis, (2) Deprotection reaction under acidic conditions, (3) Deprotection reaction by hydrogenolysis, (4) Deprotection reaction of silyl group, (5) Deprotection reaction using metal, (6) Deprotection reaction using a metal complex and the like.
- the deprotection reaction by alkali hydrolysis is carried out, for example, in an organic solvent (methanol, tetrahydrofuran, dioxane, etc.), alkali metal hydroxide (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkaline earth It is carried out at a temperature of 0 to 40 ° C. using a metal hydroxide (barium hydroxide, calcium hydroxide, etc.) or carbonate (sodium carbonate, potassium carbonate, etc.), an aqueous solution thereof or a mixture thereof.
- organic solvent methanol, tetrahydrofuran, dioxane, etc.
- alkali metal hydroxide sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.
- alkaline earth It is carried out at a temperature of 0 to 40 ° C. using a metal hydroxide (barium hydroxide, calcium hydroxide, etc.) or carbonate (sodium carbonate, potassium carbon
- the deprotection reaction under acid conditions can be carried out by using, for example, an organic acid (acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid, etc.) in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisole, etc.) ), Or an inorganic acid (hydrochloric acid, sulfuric acid, etc.) or a mixture thereof (hydrogen bromide / acetic acid, etc.) at a temperature of 0 to 100 ° C.
- an organic acid acetic acid, trifluoroacetic acid, methanesulfonic acid, p-tosylic acid, etc.
- an organic solvent diichloromethane, chloroform, dioxane, ethyl acetate, anisole, etc.
- an inorganic acid hydroochloric acid, sulfuric acid, etc.
- a mixture thereof hydroogen bromide
- Deprotection reaction by hydrogenolysis includes, for example, solvent (ether (tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether, etc.), alcohol (methanol, ethanol, etc.), benzene (benzene, toluene, etc.), ketone System (acetone, methyl ethyl ketone, etc.), nitrile (acetonitrile, etc.), amide system (dimethylformamide, etc.), water, ethyl acetate, acetic acid or a mixed solvent of two or more thereof, catalyst (palladium-carbon, palladium black, In the presence of palladium hydroxide, platinum oxide, Raney nickel, etc.), in a hydrogen atmosphere under normal pressure or under pressure, or in the presence of ammonium formate, at a temperature of 0 to 200 ° C.
- solvent ether (tetrahydrofuran, dioxane, dimethoxyethane, dieth
- the deprotection reaction of the silyl group is performed at a temperature of 0 to 40 ° C. using tetrabutylammonium fluoride in an organic solvent miscible with water (tetrahydrofuran, acetonitrile, etc.).
- the deprotection reaction using a metal is performed, for example, in an acidic solvent (acetic acid, a buffer solution of pH 4.2 to 7.2 or a mixed solution thereof with an organic solvent such as tetrahydrofuran) in the presence of powdered zinc, If necessary, it is carried out at a temperature of 0 to 40 ° C. while applying ultrasonic waves.
- the deprotection reaction using a metal complex is carried out by using, for example, a trap reagent (tributyltin hydride, Triethylsilane, dimedone, morpholine, diethylamine, pyrrolidine, etc.), organic acids (acetic acid, formic acid, 2-ethylhexanoic acid, etc.) and / or organic acid salts (sodium 2-ethylhexanoate, potassium 2-ethylhexanoate, etc.)
- phosphine reagents triphenylphosphine, etc.
- metal complexes tetrakistriphenylphosphine palladium (0), bis (triphenylphosphine) palladium dichloride (II), palladium acetate (II) , Tris chloride (Triff Enylphosphine) rhodium (I) etc.
- a trap reagent tributyltin
- the deprotection reaction can be performed by the methods described in, for example, T. W. Greene, Protective Groups, Organic, Synthesis, Fifth Edition, Wiley, New York, 2014.
- the intended compound of the present invention can be easily produced by properly using these deprotection reactions.
- a reaction involving heating can be performed using a water bath, an oil bath, a sand bath, or a microwave, as will be apparent to those skilled in the art.
- a solid-phase-supported reagent supported on a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- a polymer eg, polystyrene, polyacrylamide, polypropylene, polyethylene glycol, etc.
- the reaction product is obtained by a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- a conventional purification means such as distillation under normal pressure or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion exchange resin, It can be purified by scavenger resin, column chromatography, washing or recrystallization. Purification may be performed for each reaction or after completion of several reactions.
- the toxicity of the compound of the present invention is sufficiently low and can be used safely as a pharmaceutical product.
- the compound of the present invention Since the compound of the present invention has S1P 5 (EDG-8) receptor agonistic activity, it is useful as a preventive and / or therapeutic agent for S1P 5 mediated diseases.
- S1P 5 mediated diseases neurodegenerative diseases, autoimmune diseases, infectious diseases, cancer and the like.
- the compound of the present invention since the compound of the present invention has S1P 5 (EDG-8) receptor agonistic activity, it is useful as a preventive and / or therapeutic agent for cancer via the tumor immune activation effect.
- neurodegenerative diseases include anxiety related diseases (social anxiety disorder, anxiety neuropathy, obsessive compulsive disorder, post-traumatic stress disorder (PTSD)), polyglutamine disease, retinitis pigmentosa, Neurosis, convulsions, panic disorder, sleep disorder, depression, reactive depression, epilepsy, Parkinson's disease, Parkinson's syndrome, Down's syndrome, schizophrenia, autonomic schizophrenia, Huntington's disease, Alzheimer's disease dementia, affective disorder ( Including depression or bipolar disorder), cognitive impairment, migraine headache, tension headache, cluster headache, dissociative disorder, amyotrophic lateral sclerosis, optic neuromyelitis, optic neuritis, acute disseminated (disseminated) Encephalomyelitis, allergic encephalomyelitis, Marchiafava-Bignami disease, Binswanger disease, progressive multifocal leukoencephalopathy, infection Posterior encephalitis, central pontine myelination, adrenal white atrophy, multiple system atrophy, Kra
- the neurodegenerative disease is preferably Alzheimer's disease type dementia, Parkinson's disease, multiple system atrophy, multiple sclerosis, or Lewy body type dementia.
- autoimmune diseases include inflammatory bowel disease, arthritis, lupus, rheumatism, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, type I diabetes, myasthenia gravis, Hashimoto's thyroiditis, ode Thyroiditis, Basedow's disease, Sjogren's syndrome, Addison's disease, Opsoclonus-myoclonus syndrome, ankylosing spondylitis, antiphospholipid syndrome, aplastic anemia, autoimmune hepatitis, celiac disease, Goodpasture syndrome, idiopathic thrombocytopenia Purpura, scleroderma, primary biliary cirrhosis, Reiter's disease, Takayasu arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegner's granulomas, psoriasis, systemic alopecia, Burchett's disease, Chronic fatigue syndrome, autonom
- infectious diseases include symptoms caused by infecting and proliferating normal cells in the body of one or more pathogenic microorganisms represented by viruses, bacteria, fungi and the like.
- pathogenic microorganisms include rickettsia, chlamydia, protozoa, parasites and the like.
- viruses related to infectious diseases include human hepatitis viruses (for example, hepatitis B, hepatitis C, hepatitis A and hepatitis E), human retroviruses, human immunodeficiency viruses (for example, HIV1 and HIV2).
- human hepatitis viruses for example, hepatitis B, hepatitis C, hepatitis A and hepatitis E
- human retroviruses for example, human immunodeficiency viruses (for example, HIV1 and HIV2).
- human T cell leukemia virus or human T lymphotropic virus eg, HTLV1 and HTLV2
- herpes simplex virus type 1 or type 2 Epstein-Barr (EB) virus
- cytomegalovirus varicella-zoster virus
- Human herpesvirus eg, human herpesvirus 6 etc.
- poliovirus measles virus, rubella virus, Japanese encephalitis virus, mumps virus, influenza virus, cold virus (eg adenovirus, enterovirus, rhinovirus etc.), severe acute Respiratory disease Viruses that develop the group (SARS), Ebola virus, West Nile virus, Flavivirus, Echovirus, Coxsackie virus, Coronavirus, Respiratory polynuclear (syncytial) virus, Rotavirus, Norovirus, Sapovirus, Parvovirus, Vaccinia virus , HTL virus, dengue virus, hapiloma virus, molluscum virus, rabies virus, JC virus, arb
- bacteria related to infectious diseases include: Vibrio cholerae, Salmonella, Escherichia coli, Legionella, Bacillus anthracis, Helicobacter pylori, Listeria, tuberculosis, nontuberculous mycobacteria, staphylococci, streptococci, pneumococci , Neisseria meningitidis, Klebsiella pneumoniae, Serratia, Diphtheria, Brucella, Bartonella hensele, Eridiperosrix luciopathia, Actinomycetes, Lyme disease, Welsh bacteria, Shigella, Plague, Tetanus, Enterobacter Etc.
- fungi related to infectious diseases include Candida, Aspergillus, Cryptococcus, Blast Myces, Coccidioides, Histoplasma, Paracoccidioides, Sporotrix and the like.
- protozoa related to infectious diseases include malaria parasites, toxoplasma parasites and the like.
- parasites related to infectious diseases include shigellosis amoeba, roundworm, babesia, cryptosporidium, rumble flagellate, helminth, helminth, schistosomiasis, tapeworm, trichinella, trichinella and the like.
- microorganisms related to infectious diseases include mycoplasma, spirochete and the like.
- the cancer includes cancers related to cranial nerves (for example, pediatric brain tumors (eg, neuroblastoma, medulloblastoma, astrocytoma (juvenile hair-like astrocytoma)), ependymoma, craniopharyngioma, Germ cell tumor, optic glioma, choroid plexus papilloma, brainstem glioma), adult brain tumor (eg adult astrocytoma, adult malignant astrocytoma, adult glioblastoma, adult ventricular ependymoma, adult malignant brain) Murine ependymoma, adult malignant oligodendroma, adult medulloblastoma, adult meningioma, adult malignant meningioma), glioma (eg astrocytoma, oligodendroglioma, ependymoma,
- Leukemia eg, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia / chronic myeloproliferative disease, adult T-cell leukemia lymph) Chronic lymphocytic leukemia / small cell lymphoma, etc.
- multiple myeloma primary macroglobulinemia, malignant lymphoma (eg, Hodgkin lymphoma, non-Hodgkin lymphoma (medium to high grade lymphoma, Burkitt lymphoma, lymphoblastic) Lymphoma, follicular lymphoma, mantle cell lymphoma, MLT (Mucosa-Associated Lymphoid Tissue) lymphoma, NK (natural killer) cell lymphoma, etc.)).
- the compound of the present invention 1) complementation and / or enhancement of the prophylactic and / or therapeutic effect of the compound, It may be administered as a concomitant drug in combination with other drugs in order to 2) improve the kinetics / absorption of the compound, reduce the dose, and / or reduce the side effects of the compound.
- the concomitant drug of the compound of the present invention and another drug may be administered in the form of a combination drug containing both components in one preparation, or may be administered in separate preparations.
- simultaneous administration and administration by time difference are included.
- administration with a time difference may be such that the compound of the present invention is administered first and the other drug may be administered later, or the other drug may be administered first and the compound of the present invention may be administered later.
- Each administration method may be the same or different.
- the disease that exerts a preventive and / or therapeutic effect by the above concomitant drug is not particularly limited as long as it is a disease that complements and / or enhances the preventive and / or therapeutic effect of the compound of the present invention.
- the concomitant drugs combined with the compound of the present invention include not only those found so far but also those found in the future.
- drugs for supplementing and / or enhancing the preventive and / or therapeutic effects of the compounds of the present invention on neurodegenerative diseases include acetylcholinesterase inhibitors, nicotine receptor modulators, ⁇ -amyloid protein production, secretion, accumulation and aggregation.
- / or deposition inhibitor eg, ⁇ -secretase inhibitor, ⁇ -secretase inhibitor, ⁇ -amyloid protein aggregation inhibitor, ⁇ -amyloid vaccine, ⁇ -amyloid degrading enzyme, etc.
- brain function activator eg, brain metabolism activator, Cerebral circulation improving drug, etc.
- dopamine receptor agonist eg, brain metabolism activator, Cerebral circulation improving drug, etc.
- dopamine receptor agonist dopamine receptor stimulant
- dopamine release promoter dopamine secretion promoter or dopamine release promoter
- dopamine uptake inhibitor dopamine agonist, dopamine antagonist, carbonic acid Lithium, serotonin agonists, serotonin antagonists (eg 5-HT 2A antagonists) , 5-HT 3 antagonist, 5-HT 4 antagonist, 5-HT 7 antagonist), monoamine oxidase (MAO) inhibitor, aromatic L-amino acid decarboxylase inhibitor (DCI), norepineph
- immunosuppressive drugs eg, dimethyl fumarate, glatiramer acetate, interferon beta-1a, interferon beta -1b, fingolimod
- steroids disease-modifying antirheumatic drugs
- elastase inhibitors cannabinoid-2 receptor stimulators
- prostaglandins prostaglandin synthase inhibitors
- phosphodiesterase inhibitors metalloprotease inhibitors
- adhesion molecules Inhibitors anti-TNF- ⁇ preparations, anti-IL-1 preparations, anti-cytokine protein preparations such as anti-IL-6 preparations, cytokine inhibitors, non-steroidal anti-inflammatory drugs, anti-CD20 antibodies and the like.
- Examples of other drugs for complementation and / or enhancement of the preventive and / or therapeutic effects on infectious diseases of the compounds of the present invention include antiviral drugs, antibiotics, antifungal drugs, antiparasitic drugs, antiprotozoal drugs and the like.
- drugs for supplementing and / or enhancing the preventive and / or therapeutic effects of the compounds of the present invention on cancer include alkylating drugs, antimetabolites, anticancer antibiotics, plant alkaloid drugs, hormone drugs, platinum Examples include compounds, anti-CD20 antibodies, and other anticancer agents.
- the compound of the present invention is usually administered systemically or locally in an oral or parenteral form.
- oral preparations include liquids for internal use (for example, elixirs, syrups, pharmaceutically acceptable solutions, suspensions, emulsions), solid preparations for internal use (for example, tablets (sublingual tablets, buccal cavity) Disintegrating tablets), pills, capsules (including hard capsules, soft capsules, gelatin capsules, and microcapsules), powders, granules, and troches.
- parenteral agents examples include liquids (eg, injections (subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, drops, etc.), eye drops (eg, aqueous eye drops (aqueous eye drops) Liquid, aqueous suspension ophthalmic solution, viscous ophthalmic solution, solubilized ophthalmic solution, etc.), non-aqueous ophthalmic solution (non-aqueous ophthalmic solution, non-aqueous suspension ophthalmic solution, etc.))), and external preparations (eg, ointment (eye ointment) Etc.)), ear drops, patches and the like.
- These preparations may be release control agents such as immediate-release preparations and sustained-release preparations. These preparations can be produced by a known method, for example, a method described in the Japanese Pharmacopoeia.
- Oral liquids for oral use are produced, for example, by dissolving, suspending or emulsifying the active ingredient in a commonly used diluent (for example, purified water, ethanol or a mixture thereof).
- this liquid agent may contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- the solid preparation for internal use as an oral preparation includes, for example, an active ingredient as an excipient (for example, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.), a binder (for example, hydroxypropylcellulose, polyvinylpyrrolidone, aluminum metasilicate). Magnesium oxide, etc.), disintegrating agents (eg, calcium calcium glycolate), lubricants (eg, magnesium stearate), stabilizers, solubilizing agents (glutamic acid, aspartic acid, etc.), etc. According to the formulation. Moreover, you may coat
- an active ingredient as an excipient for example, lactose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- a binder for example, hydroxy
- an ointment is manufactured by kneading or melting an active ingredient in a base.
- the ointment base is selected from known or commonly used ones.
- higher fatty acids or higher fatty acid esters for example, adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, etc.
- waxes E.g., beeswax, whale wax, ceresin, etc.
- surfactants e.g., polyoxyethylene alkyl ether phosphates, etc.
- higher alcohols e.g., cetanol, stearyl alcohol, cetostearyl alcohol, etc.
- silicone oils e.g., Dimethylpolysiloxane, etc.
- hydrocarbons eg, hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin, etc.
- glycols eg, ethylene glycol, diethylene glycol, propylene glycol, polyethylene
- glycols e
- the parenteral injection includes solutions, suspensions, emulsions and solid injections used by dissolving or suspending in a solvent at the time of use.
- An injection is used, for example, by dissolving, suspending or emulsifying an active ingredient in a solvent.
- the solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and combinations thereof are used.
- this injection contains a stabilizer, a solubilizing agent (for example, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifying agent, a soothing agent, a buffering agent, a preservative and the like.
- a sterile solid preparation for example, a lyophilized product, can be produced and used by dissolving it in sterilized or sterile distilled water for injection or other solvent before use.
- the compound of the present invention or the concomitant agent of the compound of the present invention and another drug for the above purpose is usually administered systemically or locally in an oral or parenteral form.
- the dose varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but is usually orally administered once to several times a day in the range of 1 ng to 1000 mg per adult per dose. Or administered parenterally once or several times a day in the range of 0.1 ng to 10 mg per adult, or continuously administered intravenously in the range of 1 hour to 24 hours per day.
- an amount smaller than the above dosage may be sufficient, or administration may be necessary beyond the range.
- each group is bonded to Z by a bond indicated by an arrow
- A represents an optionally substituted C3-7 cycloalkylene group, or an optionally substituted C1-4 alkylene group
- R 1 is a C1-4 alkyl group, a C3-6 cycloalkyl group optionally substituted with halogen, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- R 2 represents a C1-4 alkyl group, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- each hydrogen atom may be a deuterium atom or a tritium atom.
- a pharmaceutically acceptable salt thereof which is a compound represented by the above: [3] L is (1) -O- (C2-7 alkyl), (2) -O- (C2-7 alkenyl), (3) -O- (C2-7 alkynyl), (4) -O -(C1-5 alkylene) -OCH 3 , (5) -O- (C1-4 alkylene) -OCH 2 CH 3 , (6) -CH 2 O- (C1-6 alkyl), (7) -CH 2 O- (C2-6 alkenyl), (8) -CH 2 O- (C2-6 alkynyl), (9) -CH 2 CH 2 O- (C1-5 alkyl), (10) -CH 2 CH 2 O -(C2-5
- the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom
- the carbon atom in L 1 may be substituted with 1 to 13 halogen atoms
- ring2-1 represents a 3- to 7-membered nitrogen-containing saturated heterocycle
- m-1 represents an integer of 0 to 2
- n-1 represents an integer of 0 to 2
- a plurality of R 1 may be the same or different
- the plurality of R 2 may be the same or different
- Other symbols represent the same meaning as in the above [1]
- each hydrogen atom may be a deuterium atom or a tritium atom.
- L 1 is (1) —O— (C 3-6 alkyl), (2) —O— (C 3-6 alkenyl), (3) —O— (C 3-6 alkynyl), (4) — O- (C1-4alkylene) -OCH 3 , (5) -O- (C1-3alkylene) -OCH 2 CH 3 , (6) -CH 2 O- (C2-5 alkyl), (7) -CH 2 O— (C2-5 alkenyl), (8) —CH 2 O— (C2-5 alkynyl), (9) —CH 2 CH 2 O— (C1-4 alkyl), (
- the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom
- the carbon atom in L may be substituted with 1 to 13 halogen atoms
- R 1 is a C1-4 alkyl group, a C3-6 cycloalkyl group optionally substituted with halogen, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- R 2 represents a C1-4 alkyl group, a C1-4 alkoxy group optionally substituted with halogen, a C1-4 haloalkyl group, a halogen atom, or a hydroxyl group
- Z is (1) a carboxyl group which may be substituted with one C1-8 alkyl group, (2) a hydroxyl group which may be substituted with one C1-8 alkyl group, (3) 1-2 Hydroxamic acid group optionally substituted with one C1-8 al
- the chain group may contain 1 to 3 heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom
- the carbon atom in L 1 may be substituted with 1 to 13 halogen atoms
- ring1-1 represents a 4- to 7-membered nitrogen-containing saturated heterocyclic ring
- m-1 represents an integer of 0 to 2
- n-1 represents an integer of 0 to 2
- a plurality of R 1 may be the same or different
- the plurality of R 2 may be the same or different
- Other symbols represent the same meaning as in the above [21]
- each hydrogen atom may be a deuterium atom or a tritium atom.
- the point of separation by chromatography and the solvent in parentheses shown in TLC indicate the elution solvent or developing solvent used, and the ratio indicates the volume ratio.
- the parentheses shown in the NMR part indicate the solvent used for the measurement.
- the compound names used in this specification are generally computer programs for naming according to the rules of IUPAC, Advanced Chemistry Development's ACD / Name (registered trademark), OpenEye Scientific Software's Lexichem 1.4 Tol. 2 or ChemDraw (registered trademark) Ultra from PerkinElmer, Inc., or named according to the IUPAC nomenclature.
- LCMS was performed under the following conditions using a Waters i-class system.
- Example 1 6- (Benzyloxy) -3,4-dihydronaphthalen-1 (2H) -one 6-Hydroxy-3,4-dihydronaphthalen-1 (2H) -one (CAS Registry Number: 3470-50-) 6) Benzyl bromide (29.4 mL) and potassium carbonate (31.1 g) were added to a solution of (24.3 g) in acetone (160 mL) at room temperature, and the mixture was stirred at 40 ° C. for 3.5 hours. The insoluble material was filtered off and concentrated.
- Example 2 7- (Benzyloxy) -4-methyl-1,2-dihydronaphthalene
- THF tetrahydrofuran
- Diethyl ether solution 55 mL was added at 0 ° C., and the mixture was stirred at room temperature for 1 hour.
- the reaction mixture was cooled to 0 ° C. and poured into ice-saturated aqueous ammonium chloride solution. After adding 2 mol / L hydrochloric acid, the solution was stirred at room temperature for 3 hours.
- Example 3 6- (Benzyloxy) -1-methyl-3,4-dihydronaphthalene-2-carbaldehyde Phosphorus oxychloride (26.7 g) at 0 ° C. with N, N-dimethylformamide (DMF) (60 mL) was added dropwise and stirred for 20 minutes. Further, a solution of the compound prepared in Example 2 (24.8 g) in methylene chloride (DCM) (60 mL) was slowly added dropwise and stirred at room temperature for 90 minutes. The reaction mixture was cooled to 0 ° C., poured into ice, stirred for 30 minutes, and extracted with a mixed solvent of hexane-ethyl acetate (1: 2).
- DCM methylene chloride
- Example 4 6-hydroxy-1-methyl-3,4-dihydronaphthalene-2-carbaldehyde To thioanisole (35 mL) was added trifluoroacetic acid (140 mL) at 0 ° C., and the compound prepared in Example 3 ( 9.17 g) was added little by little and stirred at room temperature for 4 hours. The reaction solution was poured into ice, 5 mol / L aqueous sodium hydroxide solution was added, and the mixture was washed with MTBE. 1 mol / L hydrochloric acid was added to the aqueous layer, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated.
- Example 5 Methyl 1-((6-hydroxy-1-methyl-3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate DCM of the compound prepared in Example 4 (8.0 g) To the (340 mL) solution, methyl azetidine-3-carboxylate hydrochloride (8.4 g) (CAS registration number: 10092-39-9) and diisopropylethylamine (9.6 mL) were added and stirred at room temperature for 30 minutes. Sodium triacetoxyborohydride (11.7 g) was added to the reaction solution, and the mixture was stirred at room temperature for 16 hours.
- Example 6 Methyl 1-((1-Methyl-6- (pentyloxy) -3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate of the compound prepared in Example 5 (123 mg)
- Sodium hydride (60% in mineral oil, 17 mg) was added to a DMF (4 mL) solution, and the mixture was stirred at room temperature for 15 minutes under a nitrogen atmosphere.
- 1-Bromopentane 62 mg was added to the reaction solution and stirred for 6 hours.
- the reaction mixture was diluted with ethyl acetate, washed with water, 5% aqueous lithium chloride, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 7 1-[(1-Methyl-6-pentoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- methanol 3 mL
- 2N aqueous sodium hydroxide solution 3 mL
- the title compound (84 mg) having physical properties was obtained.
- Example 7 1-[(6-Butoxy-1-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid ammonia salt
- Example 7 (2) 1-[[1-Methyl-6-[(2S) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- Example 7 (3) : 1-[[6- (1,1,2,2,3,3,3-heptaduteriopropoxy) -1-methyl-3,4-dihydronaphthalen-2-yl] methyl Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.16, 6.74, 6.71, 3.40, 3.18, 2.59, 2.16, 2.02; LCMS: Retention time 0.79 minutes.
- Example 7 (4) : 1-[[1-Methyl-6- (2,2,3,3-tetrafluoropropoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.21, 6.87, 6.86, 6.67, 4.56, 3.60-3.00, 2.61, 2.18, 2.03; LCMS: Retention time 0.79 minutes.
- Example 7 1-[[1-Methyl-6- (3,4,4-trifluorobut-3-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3- carboxylic acid
- Example 7 1-[[1-Methyl-6- (3,3,4,4,4-pentaduteriobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 -carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 7 (7) 1-[[1-Methyl-6- (1,1,2,2,3,3,4,4,4-nonaduteriboxy) -3,4-dihydronaphthalene-2 -Yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 7 1-[[6-[(E) -but-2-enoxy] -1-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.18, 6.75, 6.73, 5.83, 5.68, 4.46, 3.60-3.00, 2.60, 2.16, 2.04, 1.70; LCMS: Retention time 0.81 minutes.
- Example 7 (9) 1-[(6-Butoxy-1-ethyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (CDCl 3 ): ⁇ 7.24, 6.73, 6.68, 4.35, 4.05, 3.96, 3.91, 3.52-3.35, 2.66, 2.30, 1.76, 1.48, 1.11, 0.97; LCMS: Retention time 0.89 minutes.
- Example 7 10-[[6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- Example 8 6-butoxy-3,4-dihydronaphthalen-1 (2H) -one 6-hydroxy-3,4-dihydronaphthalen-1 (2H) -one (CAS Registry Number: 3470-50-6) ( 2.0 g) in THF (40 mL) was added 1-butanol (2.3 mL), triphenylphosphine (6.5 g) and a 2.2 mol / L diethyl azodicarboxylate toluene solution, and the mixture was stirred at room temperature for 5 hours. .
- Example 9 1-Bromo-6-butoxy-3,4-dihydronaphthalene-2-carbaldehyde A solution of the compound prepared in Example 8 (770 mg) in chloroform (12 mL) / DMF (1.37 mL) was ice-cooled. , Tribromide phosphate (0.83 mL) was added, and the mixture was stirred at room temperature for 72 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 10 6-butoxy-1-cyclopropyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the compound prepared in Example 9 (320 mg) in toluene (5 mL) in cyclopropylboric acid (133 mg), 2 mol / L Potassium phosphate aqueous solution (1.6 mL), tricyclohexylphosphine (0.064 mL) and palladium acetate (23 mg) were added and stirred at 90 ° C. for 5 hours. The reaction mixture was filtered through Celite (trade name), and the filtrate was extracted twice with ethyl acetate.
- Example 11 1-[(6-Butoxy-1-cyclopropyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- the title compound having the following physical data was obtained by subjecting the compound prepared in Example 10 (270 mg) and methyl azetidine-3-carboxylate hydrochloride (197 mg) to the reaction of Example 5 ⁇ Example 7. (92 mg) was obtained.
- Example 12 6-Methoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde 6-methoxy-3-methyl-3,4-dihydronaphthalen-1 (2H) -one (CAS Registry Number: 5563) -21-3) To a solution of (1 g) in methanol (100 mL) was added sodium borohydride (398 mg) at 0 ° C. The reaction solution was warmed to room temperature and stirred for 2 hours, an aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated.
- Phosphorus oxychloride (2.2 g) was added to a DMF (100 mL) solution of the obtained crude product.
- the reaction solution was heated to 60 ° C. and stirred for 8 hours. Thereafter, the reaction solution was poured into ice water and stirred for 5 minutes, and then the organic layer was separated. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated.
- Example 13 6-Hydroxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the compound prepared in Example 12 (299 mg) in dichloromethane (100 mL) at 0 ° C., boron tribromide (815 mg ) was added dropwise. After stirring at 0 ° C. for 3 hours, the reaction solution was poured into ice water, and after stirring for 5 minutes, the organic layer was separated. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated.
- Example 14 (R) -6-hydroxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde
- the title compound was obtained at a retention time of about 6.9 minutes.
- Example 14 (1) : (S) -6-hydroxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde According to the optical resolution of Example 14, the second peak (retention time about 8.1 minutes) To give the title compound.
- Example 15 1-[((3S) -3-methyl-6-pentoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid (S) -methyl by subjecting the compound (2.5 g) prepared in Example 14 (1) and methyl azetidine-3-carboxylate hydrochloride (2.6 g) to the same reaction as in Example 5.
- Example 15 (1) to (87) Using the compound prepared in Example 14 or Example 14 (1), methyl azetidine-3-carboxylate hydrochloride or the corresponding amine derivative instead, and the corresponding alkyl halide instead of 1-bromopentane, Example 5-> Example 6-> The same reaction as in Example 7, or the compound prepared in Example 14 or Example 14 (1), methyl azetidine-3-carboxylate hydrochloride or equivalent Using the amine derivative and the corresponding alcohol instead of 1-butanol, the following example compounds were obtained by the same reaction as in Example 5 ⁇ Example 8 ⁇ Example 7.
- Example 15 1-[((3R) -3-methyl-6-pentoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.71, 6.68, 6.26, 3.92, 3.60-3.00, 2.84, 2.34, 1.68, 1.45-1.26, 0.89, 0.84; LCMS: Retention time 0.91 minutes.
- Example 15 (2) 1-[((3S) -6-hexoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.71, 6.67, 6.22, 3.92, 3.42, 3.21, 2.98, 2.84, 2.33, 1.68, 1.41, 1.31, 0.86; LCMS: Retention time 0.97 minutes.
- Example 15 (3) : 1-[((3R) -6-hexoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.71, 6.67, 6.22, 3.92, 3.42, 3.21, 2.98, 2.84, 2.33, 1.68, 1.41, 1.31, 0.86; LCMS: Retention time 0.97 minutes.
- Example 15 (4) : 1-[[(3S) -3-Methyl-6- (3-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.72, 6.69, 6.25, 3.96, 3.65-3.00, 2.85, 2.34, 1.72, 1.59-1.47, 1.38, 1.18, 0.90, 0.88-0.83; LCMS: Retention time 0.95 minutes.
- Example 15 1-[[(3R) -3-methyl-6- (3-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.95 minutes.
- Example 15 (6) 1-[((3S) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.71, 6.68, 6.24, 3.89, 3.60-2.90, 2.84, 2.32, 1.70, 0.96, 0.85; LCMS: Retention time 0.79 minutes.
- Example 15 (7) 1-[((3R) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.71, 6.68, 6.24, 3.89, 3.60-2.90, 2.84, 2.32, 1.70, 0.96, 0.85; LCMS: Retention time 0.79 minutes.
- Example 15 1-[((3S) -6-heptoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- LCMS Retention time 1.02 minutes.
- Example 15 (9) 1-[((3R) -6-heptoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- LCMS Retention time 1.02 minutes.
- Example 15 (10) 1-[[(3S) -3-Methyl-6-[(2R) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 -carboxylic acid
- Example 15 (11) : 1-[[(3R) -3-methyl-6-[(2R) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 -carboxylic acid
- Example 15 (12) 1-[[(3S) -3-methyl-6-[(2S) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 -carboxylic acid 1 H-NMR (CDCl 3 ): ⁇ 6.97, 6.70-6.60, 6.45, 4.46-4.22, 4.15-3.97, 3.92, 3.60-3.30, 3.02, 2.61-2.47, 1.69, 1.59-1.31, 1.28, 0.93; LCMS: Retention time 0.88 minutes.
- Example 15 (13) : 1-[[(3R) -3-methyl-6-[(2S) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 Carboxylic acid s 1 H-NMR (CDCl 3 ): ⁇ 6.97, 6.70-6.60, 6.45, 4.46-4.22, 4.15-3.97, 3.92, 3.60-3.30, 3.02, 2.61-2.47, 1.69, 1.59-1.31, 1.28, 0.93; LCMS: Retention time 0.88 minutes.
- Example 15 (14) : 1-[[(3S) -3-Methyl-6- (3-methylbutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.72, 6.69, 6.23, 3.96, 3.60-3.00, 2.84, 2.33, 1.77, 1.59, 0.93, 0.85; LCMS: Retention time 0.91 minutes.
- Example 15 1-[[(3R) -3-methyl-6- (3-methylbutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.91 minutes.
- Example 15 (16) : 1-[((3S) -6-hexane-2-yloxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.95, 6.68, 6.67, 6.23, 4.39, 3.60-2.97, 2.83, 2.33, 1.62, 1.52, 1.43-1.25, 1.20, 0.89-0.83; LCMS: Retention time 0.94 minutes.
- Example 15 (17) 1-[((3R) -6-hexane-2-yloxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- 1 H-NMR (DMSO-d 6 ) ⁇ 6.95, 6.68, 6.67, 6.23, 4.39, 3.60-2.97, 2.83, 2.33, 1.62, 1.52, 1.43-1.25, 1.20, 0.89-0.83;
- LCMS Retention time 0.94 minutes.
- Example 15 (18) : 1-[[(3S) -3-Methyl-6- (2-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.96 minutes.
- Example 15 (19) 1-[[(3R) -3-methyl-6- (2-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- 1 H-NMR (DMSO-d 6 ) ⁇ 6.97, 6.72, 6.68, 6.25, 3.80, 3.72, 3.60-2.97, 2.85, 2.34, 1.86, 1.48-1.24, 1.18, 0.96, 0.88, 0.85;
- LCMS Retention time 0.96 minutes.
- Example 15 1-[[(3S) -3-Methyl-6- (4-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.95 minutes.
- Example 15 (21) : 1-[[(3R) -3-methyl-6- (4-methylpentoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.71, 6.68, 6.26, 3.92, 3.60-3.01, 2.85, 2.33, 1.69, 1.57, 1.29, 0.89, 0.85; LCMS: Retention time 0.95 minutes.
- Example 15 (22) : 1-[[(3S) -6- (2,2-dimethylpropoxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.72, 6.68, 6.21, 3.59, 3.21, 2.96, 2.84, 2.55, 2.32, 0.99, 0.84; LCMS: Retention time 0.92 minutes.
- Example 15 (23) : 1-[[(3R) -6- (2,2-dimethylpropoxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.72, 6.68, 6.21, 3.59, 3.21, 2.96, 2.84, 2.55, 2.32, 0.99, 0.84; LCMS: Retention time 0.92 minutes.
- Example 15 (24) : 1-[[(3S) -3-methyl-6-[(2S) -4-methylpentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.68, 6.66, 6.22, 4.46, 3.60-2.90, 2.83, 2.33, 1.73, 1.59, 1.33, 1.19, 0.91, 0.88, 0.85; LCMS: Retention time 0.93 minutes.
- Example 15 (25) : 1-[[(3R) -3-methyl-6-[(2S) -4-methylpentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.69, 6.67, 6.22, 4.46, 3.60-2.90, 2.84, 2.33, 1.73, 1.59, 1.34, 1.20, 0.91, 0.88, 0.85; LCMS: Retention time 0.93 minutes.
- Example 15 (26) : 1-[[(3S) -6- (3,3-dimethylbutoxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.95, 6.71, 6.68, 6.22, 3.98, 3.24, 3.02, 2.84, 2.55, 2.33, 1.63, 0.95, 0.84; LCMS: Retention time 0.94 minutes.
- Example 15 (27) : 1-[[(3R) -6- (3,3-dimethylbutoxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.95, 6.71, 6.68, 6.22, 3.98, 3.24, 3.02, 2.84, 2.55, 2.33, 1.63, 0.95, 0.84; LCMS: Retention time 0.94 minutes.
- Example 15 (28) : 1-[[(3S) -3-methyl-6-[(2R) -4-methylpentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.69, 6.67, 6.22, 4.46, 3.60-2.90, 2.84, 2.33, 1.73, 1.59, 1.34, 1.20, 0.91, 0.88, 0.85; LCMS: Retention time 0.93 minutes.
- Example 15 (29) : 1-[[(3R) -3-methyl-6-[(2R) -4-methylpentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.96, 6.68, 6.66, 6.22, 4.46, 3.60-2.90, 2.83, 2.33, 1.73, 1.59, 1.33, 1.19, 0.91, 0.88, 0.85; LCMS: Retention time 0.93 minutes.
- Example 15 1-[((3S) -6-hexane-3-yloxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.95, 6.69, 6.67, 6.23, 4.24, 3.60-2.90, 2.84, 2.33, 1.56, 1.34, 0.88; LCMS: Retention time 0.94 minutes.
- Example 15 (31) : 1-[((3R) -6-hexane-3-yloxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.95, 6.69, 6.67, 6.23, 4.24, 3.60-2.90, 2.84, 2.33, 1.56, 1.34, 0.88; LCMS: Retention time 0.94 minutes.
- Example 15 (32) : 1-[[(3S) -3-Methyl-6- (2-methylhexane-3-yloxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carvone acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.93, 6.69, 6.68, 6.21, 4.12, 3.60-2.90, 2.83, 2.32, 1.91, 1.51, 1.39, 1.29, 0.91, 0.88, 0.86; LCMS: Retention time 0.98 minutes.
- Example 15 (33) : 1-[[(3R) -3-Methyl-6- (2-methylhexane-3-yloxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carvone acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.93, 6.69, 6.68, 6.21, 4.12, 3.60-2.90, 2.83, 2.32, 1.91, 1.51, 1.39, 1.29, 0.91, 0.88, 0.86; LCMS: Retention time 0.98 minutes.
- Example 15 1-[[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3- carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 15 (35) : 1-[[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3- carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 15 (36) : 1-[[(3S) -6-[(E) -but-2-enoxy] -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3- carboxylic acid
- LCMS Retention time 0.82 minutes.
- Example 15 (37) : 1-[[(3R) -6-[(E) -but-2-enoxy] -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine-3- carboxylic acid
- LCMS Retention time 0.82 minutes.
- Example 15 (38) : 1-[[(3S) -3-methyl-6- (3-methylbut-2-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 15 (39) : 1-[[(3R) -3-methyl-6- (3-methylbut-2-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.85 minutes.
- Example 15 (40) : 1-[[(3S) -3-methyl-6- (3,4,4-trifluorobut-3-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.74, 6.71, 6.24, 4.13, 3.75-2.95, 2.84, 2.78, 2.33, 0.84; LCMS: Retention time 0.83 minutes.
- Example 15 (41) : 1-[[(3R) -3-methyl-6- (3,4,4-trifluorobut-3-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.74, 6.71, 6.24, 4.13, 3.75-2.95, 2.84, 2.78, 2.33, 0.84; LCMS: Retention time 0.83 minutes.
- Example 15 (42) : 1-[((3S) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.72, 6.65, 6.31, 3.93, 3.85-3.05, 2.87, 2.37, 1.68, 1.48, 0.92, 0.85; LCMS: Retention time 0.84 minutes.
- Example 15 (43) : 1-[((3R) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.72, 6.65, 6.31, 3.93, 3.85-3.05, 2.87, 2.37, 1.68, 1.48, 0.92, 0.85; LCMS: Retention time 0.84 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl]
- Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.01, 6.74, 6.71, 6.31, 4.01, 3.94-3.01, 2.87, 2.40, 1.92, 0.85; LCMS: Retention time 0.83 minutes.
- Example 15 (45) 3-fluoro-1-[[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl]
- Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.01, 6.74, 6.71, 6.31, 4.01, 3.94-3.01, 2.87, 2.40, 1.92, 0.85; LCMS: Retention time 0.83 minutes.
- Example 15 (46) : 1-[[(3S) -6-[(E) -but-2-enoxy] -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] -3-fluoro Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.72, 6.69, 6.29, 5.83, 5.68, 4.44, 3.85-3.00, 2.87, 2.40-2.34, 1.70, 0.86; LCMS: Retention time 0.79 minutes.
- Example 15 (47) : 1-[[(3R) -6-[(E) -but-2-enoxy] -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] -3-fluoro Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.99, 6.72, 6.69, 6.29, 5.83, 5.68, 4.44, 3.85-3.00, 2.87, 2.40-2.34, 1.70, 0.86; LCMS: Retention time 0.79 minutes.
- Example 15 (48) 1-[((3S) -6-but-2-ynoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carvone acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.01, 6.76-6.71, 6.30, 4.70, 3.84-2.98, 2.87, 2.42-2.34, 1.83, 0.86; LCMS: retention time 0.74 minutes.
- Example 15 (49) : 1-[((3R) -6-but-2-ynoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carvone acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.01, 6.76-6.71, 6.30, 4.70, 3.84-2.98, 2.87, 2.42-2.34, 1.83, 0.86; LCMS: retention time 0.74 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6- (3-methylbut-2-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine- 3-carboxylic acid
- LCMS Retention time 0.84 minutes.
- Example 15 3-fluoro-1-[[(3R) -3-methyl-6- (3-methylbut-2-enoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine- 3-carboxylic acid
- LCMS Retention time 0.84 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6- (3,4,4-trifluorobut-3-enoxy) -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.81 minutes.
- Example 15 3-fluoro-1-[[(3R) -3-methyl-6- (3,4,4-trifluorobut-3-enoxy) -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.81 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6-[(2S) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl
- Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.98, 6.69, 6.67, 6.29, 4.41, 3.85-2.98, 2.86, 2.41-2.34, 1.61, 1.49, 1.44-1.31, 1.20, 0.89, 0.86; LCMS: Retention time 0.87 minutes.
- Example 15 3-fluoro-1-[[(3R) -3-methyl-6-[(2S) -pentan-2-yl] oxy-3,4-dihydronaphthalen-2-yl] methyl
- Azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.98, 6.69, 6.67, 6.29, 4.41, 3.85-2.98, 2.86, 2.41-2.34, 1.61, 1.49, 1.44-1.31, 1.20, 0.89, 0.86; LCMS: Retention time 0.87 minutes.
- Example 15 1-[((3S) -6-ethoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carboxylic acid
- LCMS retention time 0.71 minutes.
- Example 15 (57) 1-[((3R) -6-ethoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] -3-fluoroazetidine-3-carboxylic acid
- Example 15 (58) 3-fluoro-1-[((3S) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.78 minutes.
- Example 15 (59) 3-fluoro-1-[((3R) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.78 minutes.
- Example 15 3-fluoro-1-[((3S) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] pyrrolidine-3-carboxylic acid
- 1 H-NMR (DMSO-d 6 ) ⁇ 6.96, 6.72, 6.68, 6.29, 3.90, 3.70-3.10, 2.89, 2.36, 2.10, 1.70, 0.97, 0.88;
- LCMS Retention time 0.80 minutes.
- Example 15 3-fluoro-1-[((3R) -3-methyl-6-propoxy-3,4-dihydronaphthalen-2-yl) methyl] pyrrolidine-3-carboxylic acid
- LCMS Retention time 0.80 minutes.
- Example 15 1-[[(3S) -3-methyl-6-[(2R) -2-methylbutoxy] -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxyl acid
- LCMS Retention time 0.93 minutes.
- Example 15 (63) : 1-[[(3R) -3-methyl-6-[(2R) -2-methylbutoxy] -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxyl acid
- LCMS Retention time 0.92 minutes.
- Example 15 1-[[(3S) -3-methyl-6-[(2S) -2-methylbutoxy] -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxyl acid
- LCMS Retention time 0.92 minutes.
- Example 15 1-[[(3R) -3-methyl-6-[(2S) -2-methylbutoxy] -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxyl acid
- LCMS Retention time 0.93 minutes.
- Example 15 (66) 3-fluoro-1-[[(3S) -3-methyl-6- (2-methylpropoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carvone acid
- LCMS Retention time 0.84 minutes.
- Example 15 (67) 3-fluoro-1-[[(3R) -3-methyl-6- (2-methylpropoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carvone acid
- LCMS Retention time 0.84 minutes.
- Example 15 (68) 1-[[(3S) -3-Methyl-6- (2-methylpropoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- Example 15 (69) 1-[[(3R) -3-methyl-6- (2-methylpropoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- Example 15 1-[[(3S) -3-methyl-6- (1,1,2,2,3,3,4,4,4-nonaduterioboxy) -3,4- Dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- 1 H-NMR (CD 3 OD) ⁇ 6.97, 6.72-6.65, 6.37, 3.94, 3.87, 3.71, 3.62, 3.45, 3.38-3.29, 2.98, 2.59, 2.37, 0.92;
- LCMS Retention time 0.85 minutes.
- Example 15 (71) : 1-[[(3R) -3-methyl-6- (1,1,2,2,3,3,4,4,4-nonaduterioboxy) -3,4- Dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (CD 3 OD): ⁇ 6.97, 6.72-6.65, 6.37, 3.94, 3.87, 3.71, 3.62, 3.45, 3.38-3.29, 2.98, 2.59, 2.37, 0.92; LCMS: Retention time 0.85 minutes.
- Example 15 (72) (3R) -1-[[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] Pyrrolidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.75, 6.70, 6.28, 4.01, 3.60-3.10, 3.00-2.80, 2.60-2.35, 2.05-1.85, 0.86; LCMS: Retention time 0.84 minutes.
- Example 15 (73) (3R) -1-[[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] Pyrrolidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97, 6.75, 6.70, 6.28, 4.01, 3.60-3.10, 3.00-2.80, 2.60-2.35, 2.05-1.85, 0.86; LCMS: Retention time 0.84 minutes.
- Example 15 (74) (3S) -3-fluoro-1-[[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalene-2- Yl] methyl] pyrrolidine-3-carboxylic acid
- Example 15 (75) (3S) -3-fluoro-1-[[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalene-2- Yl] methyl] pyrrolidine-3-carboxylic acid
- Example 15 (76) 1-[[(3S) -3-methyl-6-[(E) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.00, 6.79, 6.75-6.70, 6.27-6.20, 4.72, 3.60-3.24, 2.86, 2.33, 0.85; LCMS: Retention time 0.84 minutes.
- Example 15 (77) 1-[[(3R) -3-methyl-6-[(E) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.00, 6.79, 6.75-6.70, 6.27-6.20, 4.72, 3.60-3.24, 2.86, 2.33, 0.85; LCMS: Retention time 0.84 minutes.
- Example 15 (78) 1-[[(3S) -3-methyl-6-[(Z) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid
- Example 15 1-[[(3R) -3-methyl-6-[(Z) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid
- Example 15 (80) 3-Fluoro-1-[[(3S) -6- (4-methoxybutan-2-yloxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine -3-carboxylic acid
- Example 15 3-fluoro-1-[[(3R) -6- (4-methoxybutan-2-yloxy) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl] azetidine -3-carboxylic acid
- LCMS Retention time 0.78 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6-[(E) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydro Naphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.83 minutes.
- Example 15 (83) : 3-fluoro-1-[[(3R) -3-methyl-6-[(E) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydro Naphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.83 minutes.
- Example 15 3-fluoro-1-[[(3S) -3-methyl-6-[(Z) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydro Naphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.83 minutes.
- Example 15 3-fluoro-1-[[(3R) -3-methyl-6-[(Z) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydro Naphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- LCMS Retention time 0.83 minutes.
- Example 15 (86) 3-fluoro-1- ⁇ [(3S) -3-methyl-6- (3,3,3-trifluoropropoxy) -3,4-dihydro-2-naphthalenyl] methyl ⁇ - 3-azetidinecarboxylic acid
- LCMS Retention time 0.78 minutes.
- Example 15 (87) 3-fluoro-1- ⁇ [(3R) -3-methyl-6- (3,3,3-trifluoropropoxy) -3,4-dihydro-2-naphthalenyl] methyl ⁇ - 3-azetidinecarboxylic acid
- LCMS Retention time 0.78 minutes.
- Example 16 methyl 1-(((3S) -3-methyl-6- (3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalen-2-yl) methyl) azetidine- 3-carboxylate
- methyl azetidine-3-carboxylate hydrochloride 2.6 g
- S S-methyl 1-((6-hydroxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate (3.8 g) was obtained.
- Example 17 Methyl 1-(((S) -3-Methyl-6-((R) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalen-2-yl) Methyl) azetidine-3-carboxylate and methyl 1-(((S) -3-methyl-6-((S) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalene -2-yl) methyl) azetidine-3-carboxylate
- Example 18 1-[[(3S) -3-Methyl-6-((R) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalen-2-yl] methyl ] Azetidine-3-carboxylic acid and 1-[[(3S) -3-methyl-6-((S) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalene-2 -Yl] methyl] azetidine-3-carboxylic acid
- the first peak compound (5.0 mg) or the second peak compound (6.0 mg) optically resolved in Example 17 was subjected to the same reaction as in Example 7 to give the title compound (No.
- Example 18 (1) : 1-[[(3R) -3-methyl-6-((R) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydronaphthalene-2- Yl] methyl] azetidine-3-carboxylic acid and 1-[[(3R) -3-methyl-6-((S) -3,3,3-trifluoro-2-methylpropoxy) -3,4-dihydro Naphthalen-2-yl] methyl] azetidine-3-carboxylic acid Compound prepared in Example 14, methyl azetidine-3-carboxylate hydrochloride, and 3,3,3-trifluoro-2-methyl-propane-1- Using the oar, the title compound having the following physical properties was obtained by carrying out the same reaction as in Example 5 ⁇ Example 8 ⁇ Example 17 ⁇ Example 7.
- Example 19 Methyl 1-[(6-Butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylate Compound prepared in Example 13 (250 mg) and methyl azetidine- The corresponding ester derivative was obtained by subjecting 3-carboxylate hydrochloride (242 mg) to the same reaction as in Example 5. The obtained ester derivative (100 mg) and 1-butanol (39 mg) were used for the same reaction as in Example 8 to obtain the title compound (120 mg).
- Example 20 (R) -methyl 1-((6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate and (S) -methyl 1-(( 6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate
- SFC columnumn used: Daicel Corporation CHIRALPAK ID (10 mm ID)
- the optically active form of the compound produced in Example 19 was obtained for the first peak (retention time: about 4.62 minutes) and the second peak (retention time: about 7.02 minutes), respectively.
- Example 21 1-[((3R) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid and 1-[((3S) -6- Butoxy-3-methyl-3,4-dihydronaphthalen-2-yl) methyl] azetidine-3-carboxylic acid
- the first peak compound (41 mg) or the second peak compound (38 mg) optically resolved in Example 20 By subjecting the first peak compound (41 mg) or the second peak compound (38 mg) optically resolved in Example 20 to the same reaction as in Example 7, the title compound (derived from the first peak: 21 mg, derived from the second peak: 19 mg).
- Example 23 5-Fluoro-6-methoxy-3-methyl-1,2,3,4-tetrahydronaphthalen-1-ol Hydrogen in a solution of the mixture prepared in Example 22 (3.68 g) in methanol (35 mL) Sodium borohydride (1.34 g) was added at 0 ° C., and the mixture was stirred at room temperature for 1.5 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was used in the next reaction without purification.
- Example 24 5-Fluoro-6-methoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the compound prepared in Example 23 (3.71 g) in DMF (35 mL) was added phosphorus oxychloride ( 5.0 mL) was added and stirred at 70 ° C. for 16 hours. The reaction solution was poured into an aqueous sodium hydroxide solution under ice cooling and stirred at room temperature for 30 minutes. After extracting twice with ethyl acetate, the organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 25 Methyl 1-((5-Fluoro-3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl) methyl) azetidine-3-carboxylate
- Example 5 ⁇ The reaction was conducted in the same manner as in Example 8 to give the titled compound (150 mg).
- Example 27 (R) -1-[[5-Fluoro-3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 Carboxylic acid and (S) -1-[[5-Fluoro-3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 Carboxylic acid
- the first peak compound (72 mg) or the second peak compound (52 mg) optically resolved in Example 26 was subjected to the same reaction as in Example 7 to give the title compound (first compound) having the following physical property values.
- Peak origin 43 mg, second peak origin: 39 mg).
- Example 28 3-Fluoro-1-[[5-fluoro-3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3 Carboxylic acid Compound prepared in Example 24 (370 mg), 4,4,4-trifluorobutan-1-ol (124 mg), and methyl 3-fluoroazetidine-3-carboxylate hydrochloride (48.8 mg) The title compound (34.9 mg) having the following physical data was obtained by conducting the same reaction as in Example 13 ⁇ Example 8 ⁇ Example 5 ⁇ Example 7. 1 H-NMR (DMSO-d 6 ): ⁇ 6.95-6.86, 6.32, 4.08, 3.80-2.89, 2.73, 2.47-2.37, 1.94, 0.87; LCMS: Retention time 0.82 minutes.
- Example 29 2,4,6-Triisopropylbenzenesulfonohydrazide 2,4,6-Triisopropylbenzenesulfonyl chloride (CAS registration number: 6553-96-4) (10 g) in THF (30 mL) at 0 ° C. Then hydrazine hydrate (2.3 g) was gradually added and stirred at 0 ° C. for 2 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was washed with hexane and dried to give the title compound (7.1 g) having the following physical data. 1 H-NMR (CDCl 3 ): ⁇ 5.46, 4.18, 2.92, 1.30-1.24.
- Example 30 (E) -2,4,6-triisopropyl-N ′-(6-methoxy-3-methyl-3,4-dihydronaphthalene-1 (2H) -ylidene) benzenesulfonohydrazide 6-methoxy
- Compound (7) prepared in Example 29 in a solution of -3-methyl-3,4-dihydronaphthalen-1 (2H) -one (CAS registration number: 5563-21-3) (4.0 g) in methanol (40 mL) 0.0 g) and stirred at room temperature for 72 hours.
- Example 31 4-Fluoro-7-methoxy-2-methyl-1,2-dihydronaphthalene To a solution of the compound prepared in Example 30 (2.0 g) in THF (21 mL) at ⁇ 78 ° C., 1.55 M n -A solution of butyllithium in hexane (6.0 mL) was added, and the mixture was stirred at -78 ° C for 30 minutes and at 0 ° C for 20 minutes. After cooling to ⁇ 78 ° C. again, a THF solution (6.0 mL) of N-fluorobenzenesulfonimide (3.3 g) was added and stirred at ⁇ 78 ° C. for 30 minutes and at room temperature for 18 hours.
- THF 6.0 mL
- N-fluorobenzenesulfonimide 3.3 g
- Example 32 1-Fluoro-6-methoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the mixture prepared in Example 31 (550 mg) in DMF (5 mL) was added phosphorus oxychloride (1. 2 g) was added and stirred at room temperature for 16 hours. Water was poured into the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 33 1-[[1-Fluoro-3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid Using the compound prepared in Example 32 (150 mg), methyl azetidine-3-carboxylate hydrochloride (64.1 mg), and 4,4,4-trifluorobutan-1-ol (8.2 mg) The title compound (8.1 mg) having the following physical data was obtained by conducting the same reaction as in Example 13 ⁇ Example 5 ⁇ Example 8 ⁇ Example 7. 1 H-NMR (DMSO-d 6 ): ⁇ 7.22, 6.85, 6.81, 4.05, 3.60-3.00, 2.92, 2.42, 1.93, 0.89; LCMS: Retention time 0.86 minutes.
- Example 34 1-Bromo-6-methoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde To a mixed solution of DCM (7.5 L) and DMF (1.5 L) was added phosphorus tribromide ( 1.5 L) was added dropwise at 0 to 5 ° C., and the mixture was stirred at 25 to 30 ° C. for 1 hour. A solution of 6-methoxy-3-methyl-3,4-dihydronaphthalen-1 (2H) -one (CAS registration number: 5563-21-3) (750 g) in DCM (3.75 L) dropwise at 25-30 ° C. And heated at 90 ° C. for 1 hour. The reaction was cooled to 25 ° C. and poured onto crushed ice.
- Example 35 1-Bromo-6-hydroxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the compound prepared in Example 34 (525 g) in DCM (4.2 L), 1 mol / L Of boron tribromide in DCM (5.6 L) was added dropwise at 10 to 20 ° C. and stirred at 20 to 30 ° C. for 6 hours. The reaction solution was poured into ice-cold water and stirred for 30 minutes. After adding DCM to the reaction solution, the organic layer was separated. The aqueous layer was extracted with DCM containing 10% methanol. The combined organic layers were washed with water, dried over sodium sulfate, and evaporated.
- Example 36 6-Hydroxy-1,3-dimethyl-3,4-dihydronaphthalene-2-carbaldehyde To a solution of the compound prepared in Example 35 (350 g) in 1,4-dioxane (4.9 L), argon was added. Under atmosphere, methyl boronic acid (235.2 g), potassium carbonate (726 g), Rac BINAP (2,2′-bis (diphenylphosphino) -1,1′-binaphthyl, 40.78 g) were added for 30 minutes. Stir. After adding palladium acetate (17.64 g) at 25-30 ° C., the reaction was heated at 90 ° C. for 4 hours. The resulting reaction solution was cooled to 25 ° C.
- Example 37 (R) -6-hydroxy-1,3-dimethyl-3,4-dihydronaphthalene-2-carbaldehyde and (S) -6-hydroxy-1,3-dimethyl-3,4-dihydronaphthalene -2-Carbaldehydride
- SFC column used: Daicel Corporation CHIRALPAK-IG (46 mm ⁇ 250 mm)
- flow rate 3 mL / min.
- Pressure 100 bar
- wavelength 214 nm
- column temperature 30 ° C.
- Example 38 1-[[(3R) -1,3-dimethyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carvone Acid or 1-[[(3S) -1,3-dimethyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] methyl] azetidine-3-carboxylic acid
- the optical activity of the first peak produced in Example 37 (1.0 g), methyl azetidine-3-carboxylate hydrochloride (970 mg), and 4,4,4-trifluorobutan-1-ol (85 mg)
- the title compound (112 mg) having the following physical data was obtained by subjecting to the same reaction as in Example 5 ⁇
- Example 7 1 H-NMR (DMSO-d 6 ): ⁇ 7.19, 6.77-6.72, 4.02, 3.90-2.88, 2.
- Example 39 (3S) -6-butoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde Using the compound prepared in Example 14 (1) (300 mg) and 1-bromobutane (240 mg) The title compound (351 mg) having the following physical data was obtained by conducting the same reaction as in Example 6.
- Example 39 (3R) -6-Butoxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde Using the compound prepared in Example 14 and 1-bromobutane, By subjecting to the same reaction, the title compound having the following physical property values was obtained.
- Example 40 1- ⁇ [(3S) -6-Butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-methyl-3-azetidinecarboxylic acid Compound prepared in Example 39 (55 mg) and ethyl 3-methylazetidine-3-carboxylate (25 mg) were used in the same reaction as in Example 5 ⁇ Example 7 to give the title compound (28. 6 mg) was obtained.
- Example 40 (1) to (3) By subjecting the compound prepared in Example 39 or Example 39 (1) and ethyl azetidine-3-carboxylate or a corresponding amine derivative to the same reaction as in Example 5 ⁇ Example 7. The following Example compounds were obtained.
- Example 40 1- ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-methyl-3-azetidinecarboxylic acid 1 H-NMR (CD 3 OD): ⁇ 7.06, 6.78-6.70, 6.56, 4.40, 4.34, 4.07-3.94, 3.93-3.83, 3.04, 2.66, 2.42, 1.77, 1.60-1.46, 1.01, 0.96; LCMS: Retention time 0.89 minutes.
- Example 40 (2) 1- ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-methoxy-3-azetidinecarboxylic acid 1 H-NMR (CD 3 OD): ⁇ 7.07, 6.78-6.70, 6.58, 4.46, 4.40, 4.23-4.06, 4.03-3.92, 3.36, 3.05, 2.66, 2.44, 1.77, 1.52, 1.01, 0.97; LCMS: Retention time 0.88 minutes.
- Example 40 1- ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-methoxy-3-azetidinecarboxylic acid 1 H-NMR (CD 3 OD): ⁇ 7.07, 6.78-6.70, 6.58, 4.46, 4.40, 4.23-4.06, 4.03-3.92, 3.36, 3.05, 2.66, 2.44, 1.77, 1.52, 1.01, 0.97; LCMS: Retention time 0.88 minutes.
- Example 41 (3S) -3-Methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalene-2-carbaldehyde Compound prepared in Example 14 (1) (312 mg) And 1-bromo-4,4,4-trifluorobutane (348 mg) were used for the same reaction as in Example 6 to obtain the title compound (502 mg) having the following physical property values.
- Example 41 (3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalene-2-carbaldehyde
- the compound prepared in Example 14 and 1 The title compound having the following physical data was obtained by conducting the same reaction as in Example 6 using -bromo-4,4,4-trifluorobutane.
- Example 42 3-hydroxy-1- ⁇ [(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azeti Gincarboxylic acid
- Example 42 3-hydroxy-1- ⁇ [(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] methyl ⁇ - 3-azetidinecarboxylic acid
- methyl 3-hydroxyazetidine-3-carboxylate hydrochloride By subjecting the compound prepared in Example 41 (1) and methyl 3-hydroxyazetidine-3-carboxylate hydrochloride to a reaction similar to that in Example 5 ⁇ Example 7.
- the title compound having the following physical property values was obtained.
- LCMS Retention time 0.81 minutes.
- Example 43 tert-Butyl N- ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ -N-methyl- ⁇ -alaninate
- the compound (55 mg) and tert-butyl 3- (methylamino) propanoate (47 mg) were used for the same reaction as in Example 5 to obtain a mixture (23.9 mg) containing the title compound.
- Example 43 tert-butyl N- ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ -N-methyl- ⁇ -alaninate
- Example 39 Using the compound prepared in (1) and tert-butyl 3- (methylamino) propanoate, the mixture was subjected to the same reaction as in Example 5 to obtain a mixture containing the title compound.
- Example 44 3-[ ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ (methyl) amino] propanoic acid
- dichloromethane (0.48 mL)
- trifluoroacetic acid (0.15 mL)
- Example 44 (1) to (3) Using the compound prepared in Example 39 or Example 39 (1) and tert-butyl 3- (methylamino) propanoate or the corresponding amine derivative instead, the same reaction as in Example 5 ⁇ Example 44 was carried out. By attaching, the following Example compounds were obtained.
- Example 44 3-[ ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ (methyl) amino] propanoic acid 1 H-NMR (CD 3 OD): ⁇ 7.04, 6.77-6.70, 6.57, 3.99, 3.85, 3.73, 3.32-3.24, 3.23-3.14, 3.10, 2.67, 2.59, 2.56-2.47, 1.77, 1.53, 1.04-0.97 ; LCMS: Retention time 0.95 minutes.
- Example 44 3-( ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ amino) propanoic acid 1 H-NMR (CD 3 OD): ⁇ 7.06, 6.79-6.70, 6.62, 4.08-3.94, 3.71, 3.46-3.40, 3.28-3.17, 3.11, 2.87, 2.75-2.50, 1.77, 1.53, 1.05-0.94; LCMS: Retention time 0.93 minutes.
- Example 44 3-( ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ amino) propanoic acid 1 H-NMR (CD 3 OD): ⁇ 7.06, 6.79-6.70, 6.62, 4.08-3.94, 3.71, 3.46-3.40, 3.28-3.17, 3.11, 2.87, 2.75-2.50, 1.77, 1.53, 1.05-0.94; LCMS: Retention time 0.93 minutes.
- Example 45 1-[(3S) -3-Methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] ethane-1-ol Prepared in Example 41 A solution of the compound (502 mg) in THF (2.5 mL) was cooled to ⁇ 78 ° C., a solution of 3 mol / L methylmagnesium chloride in THF (2.8 mL) was added and stirred. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure.
- Example 45 (1) 1-[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] ethane-1-ol
- the title compound having the following physical data was obtained by subjecting the compound produced in 41 (1) to a reaction similar to that in Example 45.
- Example 46 1-[(3S) -3-Methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] ethane-1-one Prepared in Example 45 To a solution of the compound (410 mg) in dichloromethane (4.1 mL) was added Dess-Martin periodinane (CAS registration number: 87413-09-0) (1.5 g) under ice-cooling, and the mixture was stirred at room temperature for 24 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
- the organic layer was washed with aqueous sodium thiosulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The obtained residue was used in the next reaction without purification.
- Example 46 1-[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydronaphthalen-2-yl] ethane-1-one
- the title compound was obtained by the same reaction as in Example 46 using the compound prepared in 45 (1).
- Example 47 1- ⁇ 1-[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] ethyl ⁇ -3-azetidinecarboxyl Acid
- the following physical properties are obtained by subjecting the compound prepared in Example 46 (40 mg) and methyl azetidine-3-carboxylate hydrochloride (39 mg) to the same reaction as in Example 5 ⁇ Example 7.
- the title compound (14.2 mg) was obtained.
- Example 47 (1) to (3) Using the compound prepared in Example 46 or Example 46 (1) and methyl azetidine-3-carboxylate hydrochloride or the corresponding amine derivative instead, the reaction is carried out in the same manner as in Example 5 ⁇ Example 7. The following example compounds were obtained.
- Example 47 1- ⁇ 1-[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] ethyl ⁇ -3- Azetidinecarboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.03-6.95, 6.73, 6.72-6.66, 6.27, 6.25, 4.01, 3.50-2.99, 2.93-2.70, 2.46-2.28, 1.92, 1.07, 1.03, 0.89, 0.83; LCMS: Retention time 0.96 minutes.
- Example 47 cis-3-( ⁇ 1-[(3S) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] ethyl ⁇ Amino) cyclobutanecarboxylic acid 1 H-NMR (CD 3 OD): ⁇ 7.07, 6.83-6.74, 6.62, 6.49, 4.07, 3.94-3.72, 3.20-3.03, 3.02-2.86, 2.75-2.26, 2.09-1.96, 1.57, 1.53, 1.00; LCMS: Retention time 0.65 minutes.
- Example 47 cis-3-( ⁇ 1-[(3R) -3-methyl-6- (4,4,4-trifluorobutoxy) -3,4-dihydro-2-naphthalenyl] ethyl ⁇ Amino) cyclobutanecarboxylic acid 1 H-NMR (CD 3 OD): ⁇ 7.07, 6.83-6.74, 6.62, 6.49, 4.07, 3.94-3.72, 3.20-3.03, 3.02-2.86, 2.75-2.26, 2.09-1.96, 1.57, 1.53, 1.00; LCMS: Retention time 0.65 minutes.
- Example 48 1- ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carbonitrile
- the compound prepared in Example 39 (80 mg), And azetidine-3-carbonitrile hydrochloride (CAS Registry Number: 345594-83-8) (58 mg) were subjected to the same reaction as in Example 5 to give the title compound (38 mg) having the following physical properties.
- Example 48 1- ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carbonitrile Prepared in Example 39 (1) The title compound having the following physical data was obtained by conducting the same reaction as in Example 5 using the obtained compound and azetidine-3-carbonitrile hydrochloride.
- Example 49 5- (1- ⁇ [(3S) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinyl) -1H-tetrazole
- Dibutyltin oxide (CAS registration number: 818-08-6) (87 mg) and trimethylsilyl azide (CAS registration number: 4648-54-8) (40 mg) were added to a toluene (2.0 mL) solution of the compound (36 mg). Stir at 4 ° C. for 4 hours.
- Example 49 (1) : 5- (1- ⁇ [(3R) -6-butoxy-3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinyl) -1H-tetrazole
- Example 48 The title compound having the following physical data was obtained by subjecting the compound prepared in (1) to the same reaction as in Example 49.
- Example 50 Methyl 1- ⁇ [(3S) -6-hydroxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate Compound prepared in Example 14 (1) (1.0 g) and methyl azetidine-3-carboxylate hydrochloride (1.0 g) were subjected to the same reaction as in Example 5 to give the title compound (1.5 g) having the following physical properties.
- Example 50 Methyl 1- ⁇ [(3R) -6-hydroxy-3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate Compound prepared in Example 14 , And methyl azetidine-3-carboxylate hydrochloride was used for the same reaction as in Example 5 to obtain the title compound having the following physical property values.
- Example 51 Methyl 1-( ⁇ (3S) -3-Methyl-6-[(trifluoromethanesulfonyl) oxy] -3,4-dihydronaphthalen-2-yl ⁇ methyl) azetidine-3-carboxylate
- Example 50 Diisopropylethylamine (2.3 mL) and N-phenylbis (trifluoromethanesulfonimide) (CAS Registry Number: 37595-74-7) (1.7 g) in a solution of the compound prepared in (1250 mg) in dichloromethane (12.5 mL) was added under ice cooling and stirred at room temperature for 24 hours.
- Example 51 (1) methyl 1-( ⁇ (3R) -3-methyl-6-[(trifluoromethanesulfonyl) oxy] -3,4-dihydronaphthalen-2-yl ⁇ methyl) azetidine-3-carboxylate
- the title compound having the following physical data was obtained by conducting the same reaction as in Example 51 using the compound prepared in Example 50 (1).
- Example 52 Methyl 1-( ⁇ (3S) -6- [butyl (methyl) amino] -3-methyl-3,4-dihydronaphthalen-2-yl ⁇ methyl) azetidine-3-carboxylate
- N-methylbutylamine 13.5 mg
- cesium carbonate 51 mg
- XPhos 11 mg
- dibenzylideneacetone dipalladium 5.5 mg
- Ethyl acetate was added to the reaction solution, filtered through aminosilica, and the filtrate was concentrated.
- Example 52 Methyl 1-( ⁇ (3R) -6- [butyl (methyl) amino] -3-methyl-3,4-dihydronaphthalen-2-yl ⁇ methyl) azetidine-3-carboxylate Using the compound prepared in Example 51 (1) and N-methylbutylamine, the mixture was subjected to the same reaction as in Example 52 to obtain a mixture containing the title compound.
- Example 53 1-( ⁇ (3S) -6- [butyl (methyl) amino] -3-methyl-3,4-dihydro-2-naphthalenyl ⁇ methyl) -3-azetidinecarboxylic acid Prepared in Example 52 The title compound (4.4 mg) having the following physical data was obtained by subjecting the obtained mixture (21 mg) to the same reaction as in Example 7.
- Example 53 1-( ⁇ (3R) -6- [butyl (methyl) amino] -3-methyl-3,4-dihydro-2-naphthalenyl ⁇ methyl) -3-azetidinecarboxylic acid
- the title compound having the following physical data was obtained by subjecting the mixture prepared in 52 (1) to the same reaction as in Example 7.
- LCMS Retention time 0.79 minutes.
- Example 54 Methyl 1- ⁇ [(3S) -6- (butylsulfanyl) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate
- Compound prepared in Example 51 1-Butanethiol (64.5 mg), diisopropylethylamine (0.15 mL), Xantphos (41 mg) and dibenzylideneacetone dipalladium (33 mg) were added to a solution of (150 mg) in 1,4-dioxane (1.5 mL). Stir at 100 ° C. for 24 hours. The reaction solution was filtered through Celite, and the filtrate was concentrated under reduced pressure.
- Example 54 (1) : Methyl 1- ⁇ [(3R) -6- (butylsulfanyl) -3-methyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate
- Example 51 The title compound having the following physical data was obtained by subjecting the compound prepared in 1) and 1-butanethiol to the same reaction as in Example 54.
- Example 55 1- ⁇ [(3S) -6- (butylthio) -3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid Compound prepared in Example 54 (77 mg ) To give the title compound (57 mg) having the following physical data.
- Example 55 1- ⁇ [(3R) -6- (butylthio) -3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid
- Example 54 The title compound having the following physical data was obtained by conducting the same reaction as in Example 7 using the compound prepared in 1. 1 H-NMR (DMSO-d 6 ): ⁇ 7.10-7.04, 7.00, 6.27, 3.55-3.17, 3.05, 2.94, 2.86, 2.57-2.52, 2.42-2.31, 1.55, 1.40, 0.88, 0.85; LCMS: Retention time 0.98 minutes.
- Example 56 Methyl 1- ⁇ [(3S) -3-Methyl-6-pentyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate
- 1,4-dioxane 1.0 mL
- tetrahydrofuran 0.95 mL
- water 0.19 mL
- pentylboronic acid 31.5 mg
- cesium carbonate (221 mg)
- 1,1′-bis ( Diphenylphosphino) ferrocene-palladium (II) dichloride dichloromethane adduct (18.5 mg) was added and stirred at 90 ° C. for 19 hours.
- Example 56 Methyl 1- ⁇ [(3R) -3-methyl-6-pentyl-3,4-dihydronaphthalen-2-yl] methyl ⁇ azetidine-3-carboxylate
- the mixture containing the title compound was obtained by carrying out the same reaction as in Example 56 using the prepared compound and pentylboronic acid.
- LCMS Retention time 1.01 minutes.
- Example 57 1- ⁇ [(3S) -3-Methyl-6-pentyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid
- the compound prepared in Example 56 (23 mg) was obtained.
- the title compound (10.7 mg) having the following physical data was obtained by conducting the same reaction as in Example 7.
- Example 57 (1) to (5) Using the compound prepared in Example 51 or Example 51 (1), and pentylboronic acid or a corresponding boronic acid derivative instead, the same reaction as in Example 56 ⁇ Example 7 was carried out. Example compounds were obtained.
- Example 57 1- ⁇ [(3R) -3-methyl-6-pentyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 6.97-6.92, 6.25, 3.50-3.15, 3.02, 2.86, 2.48-2.44, 2.40-2.29, 1.54, 1.17-1.21, 0.90-0.82; LCMS: Retention time 1.00 minutes.
- Example 57 (2) 1- ⁇ [(3S) -3-methyl-6- (propoxymethyl) -3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.09-7.05, 7.02, 6.27, 4.38, 3.50-3.10, 2.98, 2.88, 2.52, 2.46-2.32, 1.54, 0.88, 0.86; LCMS: Retention time 0.89 minutes.
- Example 57 (3) : 1- ⁇ [(3R) -3-methyl-6- (propoxymethyl) -3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid 1 H-NMR (DMSO-d 6 ): ⁇ 7.09-7.05, 7.02, 6.27, 4.38, 3.50-3.10, 2.98, 2.88, 2.52, 2.46-2.32, 1.54, 0.88, 0.86; LCMS: Retention time 0.89 minutes.
- Example 57 (4) : 1- ⁇ [(3S) -6- (2-ethoxyethyl) -3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid 1 H-NMR (CDCl 3 ): ⁇ 7.05-6.95, 6.50, 4.55-4.08, 3.92, 3.69, 3.60, 3.49, 3.00, 2.83, 2.57, 2.49, 1.19, 0.91; LCMS: Retention time 0.86 minutes.
- Example 57 (5) 1- ⁇ [(3R) -6- (2-ethoxyethyl) -3-methyl-3,4-dihydro-2-naphthalenyl] methyl ⁇ -3-azetidinecarboxylic acid
- LCMS Retention time 0.86 minutes.
- the collected cell suspension was centrifuged to remove the supernatant, suspended in phosphate buffered saline and counted.
- the cells were suspended in a Hanks solution containing Calcium 6 Assay Reagent (manufactured by Molecular Devices), 20 mM HEPES, 2.5 mM Probenecid so as to be 1.1 ⁇ 10 6 cells / mL, and incubated at 37 ° C. for about 1 hour. Thereafter, the supernatant was removed by centrifugation, and suspended in Hanks solution containing 20 mM HEPES, 2.5 mM Probenecid and 0.1% BSA so as to be 2.2 ⁇ 10 6 cells / mL.
- the suspension was seeded in a 96-well plate at 80 ⁇ L / well. Plates were set on a fluorescent drug screening system (FDSS6000), compounds and S1P were sequentially added, and the increase in intracellular calcium concentration before and after the addition was measured at an excitation wavelength of 480 nm and a fluorescence wavelength of 540 nm. The increase in intracellular calcium concentration was evaluated by the signal intensity at the fluorescence wavelength, and the activity of each compound was calculated with the signal intensity when S1P was added instead of the compound as 100% activity.
- FDSS6000 fluorescent drug screening system
- Table 1 shows the agonistic activity (EC 50 value) of the compounds of the present invention against the S1P 1 receptor or S1P 5 receptor.
- Table 1 shows the agonistic activity (EC 50 value) of the compounds of the present invention against the S1P 1 receptor or S1P 5 receptor.
- 1- ⁇ [1-methyl-6- (octyloxy) -3 described in Example 31 (58) of Patent Document 1 is used as the comparative compound A.
- Biological Experimental Example 2 Measurement of Clearance in Rats Compound solution was administered intraperitoneally to fasted male SD rats. At regular intervals after administration, the rats were retained by manual procedures, and heparin sodium was collected from the jugular vein. The blood was centrifuged at 10,000 g, 3 min, 4 ° C. to obtain plasma. Compound concentration in plasma was measured by LC / MS / MS. Using the pharmacokinetic analysis software Phoenix WinNonlin (Certara USA, Inc.), the clearance was calculated from the change in plasma concentration.
- Binding Buffer 50 mmol / L, Tris pH 7.5, 5 mmol / L, MgCl 2 , 0.5% BSA, Complete EDTA free (1 table / 50 mL)) or double concentration (DMSO)
- Binding Buffer 50 mmol / L, Tris pH 7.5, 5 mmol / L, MgCl 2 , 0.5% BSA, Complete EDTA free (1 table / 50 mL)
- DMSO double concentration
- suction filtration is performed using 96-hole UNIFILTER, washed with a washing buffer (50 mmol / L, Tris pH 7.5, 0.5% BSA) (150 mL), and then dried at 50 to 60 ° C. for 30 to 60 minutes. It was. MicroScint (trade name) 20 (50 ⁇ L / well) was added, the plate was covered with TopSeal-A, and then radioactivity was measured with TopCount (manufactured by Perkin Elmer).
- a washing buffer 50 mmol / L, Tris pH 7.5, 0.5% BSA
- the compound concentration at which 50% of the specific binding of [ 33 P] -S1P to human S1P 1 and human S1P 5 was displaced was used as an evaluation item.
- the specific binding amount is determined from [ 33 P] -S1P total binding amount (cpm) and the average value (cpm) of [ 33 P] -S1P binding amount (cpm) in vehicle or compound treatment to [ 33 P] -S1P nonspecific This was determined by subtracting the amount of mechanical binding (cpm). With the specific binding amount of [ 33 P] -S1P as 100%, the relative value (%) of the specific binding amount at each concentration of the compound was calculated.
- the treatment concentration showing the relative value closest to 50% is selected, the relative value (%) is set to Y in the following formula, and the treatment concentration Was substituted for X, and the IC 50 value was calculated.
- Y 100 / (1 + 10 X-log IC50 )
- Comparative Compound C exhibited 1.0 nmol / L or 8.5 nmol / L inhibitory activity (IC 50 value) for binding of [ 33 P] -S1P to S1P 1 or S1P 5 , respectively.
- a 2 mg / mL solution of MOG35-55 and an equal amount of FCA H37Ra (Difco Laboratories) were mixed to prepare an emulsion and used as an inducing agent. Immunization was performed by subcutaneously administering 0.2 mL of the inducer into the flank of the mouse using a glass syringe equipped with a 26G injection needle. The day of immunization was taken as day 0 of immunization, and 0.2 mL of a 1 ⁇ g / mL solution of Pertussis toxin (List Biological Laboratories) was administered into the tail vein on days 0 and 2 (Cell Mol Immunol, Vol. 2, 439-448). Page, 2005).
- the body weight was measured on the day before the immunization, and the groups were equally divided so that no significant difference was observed in the average value of the weight of each group.
- administration of a test substance (the compound of the present invention), a positive control compound (FTY720; fingolimod), or a medium (0.5 w / v% methylcellulose 400 cP solution) was started on the same day, and any test substance was immunized.
- Oral administration was repeated once a day for 30 days from the day before the treatment to the 28th day of immunization. The dose volume was calculated based on the individual body weight on the day of administration.
- Evaluation of the neurological symptom was made by scoring the degree of paralysis as a neurological symptom score (0: normal, 1: tail relaxation, 2: hindlimb weakness, 3: hindlimb paralysis, 4: limb paralysis, 5: drowning). The observation period was the day before immunization and every day from immunization 5 to 29, and was observed before administration of the test substance, etc. (see Proc. Natl. Acad. Sci. USA, Vol. 103, pages 13451-13456, 2006). ).
- Formulation Example 1 About 10,000 tablets containing 10 mg of the active ingredient in one tablet can be obtained by mixing each of the following components by a conventional method and then tableting.
- Microcrystalline cellulose 870 g
- Formulation Example 2 After mixing the following components in a conventional manner, filtered through a dust filter, filled in 5 ml ampoules and heat sterilized in an autoclave to obtain about 10,000 ampoules containing 20 mg of active ingredient in one ampule. It is done. 3-Fluoro-1-[[(3S) -3-methyl-6-[(E) -4,4,4-trifluorobut-2-enoxy] -3,4-dihydronaphthalen-2-yl] Methyl] azetidine-3-carboxylic acid ... 200 g ⁇ Mannitol: 20g ⁇ Distilled water: 50L
- SlP 5 mediated diseases are useful in the treatment of such neurodegenerative diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
S1P受容体結合能を有するジヒドロナフタレン化合物として、一般式(a)
[1] 一般式(V)
ここで、L中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
Yは、
ここで、各基は矢印で示される結合手によってZに結合し、
Aは、置換されていてもよいC3~7シクロアルキレン基、または置換されていてもよいC1~4アルキレン基を表し、
R1は、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R2は、C1~4アルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R3、R4およびR5は、それぞれ独立して水素原子、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、またはC1~4ハロアルキル基を表し、
Zは、(1)1個のC1~8アルキル基で置換されていてもよいカルボキシル基、(2)1個のC1~8アルキル基で置換されていてもよい水酸基、(3)1~2個のC1~8アルキル基で置換されていてもよいヒドロキサム酸基、(4)1個のC1~8アルキル基で置換されていてもよいスルホン酸基、(5)1~2個のC1~8アルキル基で置換されていてもよいボロン酸基、(6)(i)1~2個のC1~8アルキル基、または(ii)C1~4アルキル基で置換されていてもよい1~2個のスルホニル基で置換されていてもよい、カルバモイル基、(7)(i)1~2個のC1~8アルキル基、または(ii)1~2個のC2~8のアシル基で置換されていてもよい、スルファモイル基、(8)1~2個のC1~8アルキル基で置換されていてもよいスルホキシイミン基、または(9)テトラゾリル基を表し、
ring2は、3~7員の含窒素ヘテロ環を表し、
mは、0~6の整数を表し、
nは、0~5の整数を表し、
mが2以上のとき、複数のR1は同じでも異なっていてもよく、
nが2以上のとき、複数のR2は同じでも異なっていてもよく、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物、またはその薬学的に許容される塩、
[2] 前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩を含有する医薬組成物、
[3] 前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の有効量を哺乳動物に投与することを特徴とする、S1P5介在性疾患の予防および/または治療方法、
[4] S1P5介在性疾患の予防および/または治療に使用される前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩、および
[5] S1P5介在性疾患の予防および/または治療剤を製造するための前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の使用等の実施態様を提供する。
本発明において、「S1P1受容体に対するS1P5受容体作動活性のバランスを改善させる」とは、「S1P1受容体に対するS1P5受容体作動活性の選択性を高める」ことを意味する。
本発明において、R1としては、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、C1~4ハロアルキル基、またはハロゲン原子が好ましく、C1~4アルキル基、C3~6シクロアルキル基、またはハロゲン原子がより好ましく、メチル基、シクロプロピル基、またはフッ素が特に好ましい。
ここで、L1中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
ring2-1は、3~7員の含窒素飽和ヘテロ環を表し、
m-1は、0~2の整数を表し、
n-1は、0~2の整数を表し、
m-1が2のとき、複数のR1は同じでも異なっていてもよく、
n-1が2のとき、複数のR2は同じでも異なっていてもよく、
その他の記号は前記と同じ意味を表し、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]で示される化合物が好ましい。
その他の記号は前記と同じ意味を表し、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]で示される化合物が好ましい。
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]で示される化合物がより好ましい。
本発明化合物は、公知の方法、例えば、Comprehensive Organic Transformations : A Guide to Functional Group Preparations, 3rd Edition (Richard C. Larock, John Wiley & Sons Inc, 2018)に記載された方法、または実施例に示す方法等を適宜改良し、組み合わせて用いることで製造することができる。
(1)アルカリ加水分解、
(2)酸性条件下における脱保護反応、
(3)加水素分解による脱保護反応、
(4)シリル基の脱保護反応、
(5)金属を用いた脱保護反応、
(6)金属錯体を用いた脱保護反応等が挙げられる。
(1)アルカリ加水分解による脱保護反応は、例えば、有機溶媒(メタノール、テトラヒドロフラン、ジオキサン等)中、アルカリ金属の水酸化物(水酸化ナトリウム、水酸化カリウム、水酸化リチウム等)、アルカリ土類金属の水酸化物(水酸化バリウム、水酸化カルシウム等)または炭酸塩(炭酸ナトリウム、炭酸カリウム等)あるいはその水溶液もしくはこれらの混合物を用いて、0~40℃の温度で行われる。
(2)酸条件下での脱保護反応は、例えば、有機溶媒(ジクロロメタン、クロロホルム、ジオキサン、酢酸エチル、アニソール等)中、有機酸(酢酸、トリフルオロ酢酸、メタンスルホン酸、p-トシル酸等)、または無機酸(塩酸、硫酸等)もしくはこれらの混合物(臭化水素/酢酸等)中、0~100℃の温度で行われる。
(3)加水素分解による脱保護反応は、例えば、溶媒(エーテル系(テトラヒドロフラン、ジオキサン、ジメトキシエタン、ジエチルエーテル等)、アルコール系(メタノール、エタノール等)、ベンゼン系(ベンゼン、トルエン等)、ケトン系(アセトン、メチルエチルケトン等)、ニトリル系(アセトニトリル等)、アミド系(ジメチルホルムアミド等)、水、酢酸エチル、酢酸またはそれらの2以上の混合溶媒等)中、触媒(パラジウム-炭素、パラジウム黒、水酸化パラジウム、酸化白金、ラネーニッケル等)の存在下、常圧または加圧下の水素雰囲気下またはギ酸アンモニウム存在下、0~200℃の温度で行われる。
(4)シリル基の脱保護反応は、例えば、水と混和しうる有機溶媒(テトラヒドロフラン、アセトニトリル等)中、テトラブチルアンモニウムフルオライドを用いて、0~40℃の温度で行われる。
(5)金属を用いた脱保護反応は、例えば、酸性溶媒(酢酸、pH4.2~7.2の緩衝液またはそれらの溶液とテトラヒドロフラン等の有機溶媒との混合液)中、粉末亜鉛の存在下、必要であれば超音波をかけながら、0~40℃の温度で行われる。
(6)金属錯体を用いる脱保護反応は、例えば、有機溶媒(ジクロロメタン、ジメチルホルムアミド、テトラヒドロフラン、酢酸エチル、アセトニトリル、ジオキサン、エタノール等)、水またはそれらの混合溶媒中、トラップ試薬(水素化トリブチルスズ、トリエチルシラン、ジメドン、モルホリン、ジエチルアミン、ピロリジン等)、有機酸(酢酸、ギ酸、2-エチルヘキサン酸等)および/または有機酸塩(2-エチルヘキサン酸ナトリウム、2-エチルヘキサン酸カリウム等)の存在下、ホスフィン系試薬(トリフェニルホスフィン等)の存在下または非存在下、金属錯体(テトラキストリフェニルホスフィンパラジウム(0)、二塩化ビス(トリフェニルホスフィン)パラジウム(II)、酢酸パラジウム(II)、塩化トリス(トリフェニルホスフィン)ロジウム(I)等)を用いて、0~40℃の温度で行われる。
本発明化合物の毒性は十分に低いものであり、医薬品として安全に使用することができる。
本発明化合物は、S1P5(EDG-8)受容体作動活性を有するため、S1P5介在性疾患の予防および/または治療剤として有用である。S1P5介在性疾患としては、神経変性疾患、自己免疫疾患、感染症、癌等が挙げられる。
1)その化合物の予防および/または治療効果の補完および/または増強、
2)その化合物の動態・吸収改善、投与量の低減、および/または
3)その化合物の副作用の軽減のために他の薬物と組み合わせて、併用薬として投与してもよい。
本発明化合物の自己免疫疾患に対する予防および/または治療効果の補完および/または増強のための他の薬物としては、免疫抑制薬(例えば、フマル酸ジメチル、グラチラマー酢酸塩、インターフェロンベータ-1a、インターフェロンベータ-1b、フィンゴリモド)、ステロイド、疾患修飾型抗リウマチ薬、エラスターゼ阻害薬、カンナビノイド-2受容体刺激薬、プロスタグランジン、プロスタグランジン合成酵素阻害薬、ホスホジエステラーゼ阻害薬、メタロプロテアーゼ阻害薬、接着分子阻害薬、抗TNF-α製剤、抗IL-1製剤、抗IL-6製剤等の抗サイトカインタンパク製剤、サイトカイン阻害薬、非ステロイド性抗炎症薬、抗CD20抗体等が挙げられる。
[1] 一般式(V)
ここで、L中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
Yは、
ここで、各基は矢印で示される結合手によってZに結合し、
Aは、置換されていてもよいC3~7シクロアルキレン基、または置換されていてもよいC1~4アルキレン基を表し、
R1は、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R2は、C1~4アルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R3、R4およびR5は、それぞれ独立して水素原子、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、またはC1~4ハロアルキル基を表し、
Zは、(1)1個のC1~8アルキル基で置換されていてもよいカルボキシル基、(2)1個のC1~8アルキル基で置換されていてもよい水酸基、(3)1~2個のC1~8アルキル基で置換されていてもよいヒドロキサム酸基、(4)1個のC1~8アルキル基で置換されていてもよいスルホン酸基、(5)1~2個のC1~8アルキル基で置換されていてもよいボロン酸基、(6)(i)1~2個のC1~8アルキル基、または(ii)C1~4アルキル基で置換されていてもよい1~2個のスルホニル基で置換されていてもよい、カルバモイル基、(7)(i)1~2個のC1~8アルキル基、または(ii)1~2個のC2~8のアシル基で置換されていてもよい、スルファモイル基、(8)1~2個のC1~8アルキル基で置換されていてもよいスルホキシイミン基、または(9)テトラゾリル基を表し、
ring2は、3~7員の含窒素ヘテロ環を表し、
mは、0~6の整数を表し、
nは、0~5の整数を表し、
mが2以上のとき、複数のR1は同じでも異なっていてもよく、
nが2以上のとき、複数のR2は同じでも異なっていてもよく、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物、またはその薬学的に許容される塩、
[2] 一般式(V-1)
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物である前記[1]記載の化合物、またはその薬学的に許容される塩、
[3] Lが、(1)-O-(C2~7アルキル)、(2)-O-(C2~7アルケニル)、(3)-O-(C2~7アルキニル)、(4)-O-(C1~5アルキレン)-OCH3、(5)-O-(C1~4アルキレン)-OCH2CH3、(6)-CH2O-(C1~6アルキル)、(7)-CH2O-(C2~6アルケニル)、(8)-CH2O-(C2~6アルキニル)、(9)-CH2CH2O-(C1~5アルキル)、(10)-CH2CH2O-(C2~5アルケニル)、(11)-CH2CH2O-(C2~5アルキニル)、(12)-S-(C2~7アルキル)、(13)-S-(C2~7アルケニル)、(14)-S-(C2~7アルキニル)、(15)-NR6-(C2~7アルキル)、(16)-NR6-(C2~7アルケニル)、(17)-NR6-(C2~7アルキニル)、(18)C3~8アルキル基、(19)C3~8アルケニル基、または(20)C3~8アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい前記[1]または[2]に記載の化合物、またはその薬学的に許容される塩、
[4] Lが、主鎖の原子数が4~7である分岐または直鎖の鎖状基である前記[1]または[2]に記載の化合物、またはその薬学的に許容される塩、
[5] Lが、(1)-O-(C3~6アルキル)、(2)-O-(C3~6アルケニル)、(3)-O-(C3~6アルキニル)、(4)-O-(C1~4アルキレン)-OCH3、(5)-O-(C1~3アルキレン)-OCH2CH3、(6)-CH2O-(C2~5アルキル)、(7)-CH2O-(C2~5アルケニル)、(8)-CH2O-(C2~5アルキニル)、(9)-CH2CH2O-(C1~4アルキル)、(10)-CH2CH2O-(C2~4アルケニル)、(11)-CH2CH2O-(C2~4アルキニル)、(12)-S-(C3~6アルキル)、(13)-S-(C3~6アルケニル)、(14)-S-(C3~6アルキニル)、(15)-NR6-(C3~6アルキル)、(16)-NR6-(C3~6アルケニル)、(17)-NR6-(C3~6アルキニル)、(18)C4~7アルキル基、(19)C4~7アルケニル基、または(20)C4~7アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい前記[1]または[2]に記載の化合物、またはその薬学的に許容される塩、
[6] ring2が、3~7員の含窒素飽和ヘテロ環(好ましくは、アゼチジン、ピロリジン、ピペリジン、またはパーヒドロアゼピン)である前記[1]~[5]のいずれか一項に記載の化合物、またはその薬学的に許容される塩、
[7] 一般式(V-2)
ここで、L1中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
ring2-1は、3~7員の含窒素飽和ヘテロ環を表し、
m-1は、0~2の整数を表し、
n-1は、0~2の整数を表し、
m-1が2のとき、複数のR1は同じでも異なっていてもよく、
n-1が2のとき、複数のR2は同じでも異なっていてもよく、
その他の記号は前記[1]と同じ意味を表し、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物である前記[1]または[2]記載の化合物、またはその薬学的に許容される塩、
[8] Zが、1個のC1~8アルキル基で置換されていてもよいカルボキシル基、またはテトラゾリル基である前記[1]~[7]のいずれか一項に記載の化合物、またはその薬学的に許容される塩、
[9] L1が、(1)-O-(C3~6アルキル)、(2)-O-(C3~6アルケニル)、(3)-O-(C3~6アルキニル)、(4)-O-(C1~4アルキレン)-OCH3、(5)-O-(C1~3アルキレン)-OCH2CH3、(6)-CH2O-(C2~5アルキル)、(7)-CH2O-(C2~5アルケニル)、(8)-CH2O-(C2~5アルキニル)、(9)-CH2CH2O-(C1~4アルキル)、(10)-CH2CH2O-(C2~4アルケニル)、(11)-CH2CH2O-(C2~4アルキニル)、(12)-S-(C3~6アルキル)、(13)-S-(C3~6アルケニル)、(14)-S-(C3~6アルキニル)、(15)-NR6-(C3~6アルキル)、(16)-NR6-(C3~6アルケニル)、(17)-NR6-(C3~6アルキニル)、(18)C4~7アルキル基、(19)C4~7アルケニル基、または(20)C4~7アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい前記[7]または[8]に記載の化合物、またはその薬学的に許容される塩、
[10] R1が、C1~4アルキル基、またはハロゲン原子である前記[1]~[9]のいずれか一項に記載の化合物、またはその薬学的に許容される塩、
[11] ring2-1が、アゼチジン、ピロリジン、ピペリジン、またはパーヒドロアゼピンである前記[7]~[10]のいずれか一項に記載の化合物、またはその薬学的に許容される塩、
[12] (1)1-[((3R)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(2)1-[((3S)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(3)1-[((3S)-3-メチル-6-ペントキシ-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(4)1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(5)3-フルオロ-1-[[(3S)-3-メチル-6-(3,4,4-トリフルオロブタ-3-エノキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(6)1-[[(3S)-3-メチル-6-(1,1,2,2,3,3,4,4,4-ノナデューテリオブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(7)(3R)-1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]ピロリジン-3-カルボン酸、(8)1-[[(3S)-3-メチル-6-((R)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(9)1-[[(3S)-3-メチル-6-((S)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(10)3-フルオロ-1-[[(3S)-3-メチル-6-[(E)-4,4,4-トリフルオロブタ-2-エノキシ]-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(11)3-フルオロ-1-{[(3S)-3-メチル-6-(3,3,3-トリフルオロプロポキシ)-3,4-ジヒドロ-2-ナフタレニル]メチル}-3-アゼチジンカルボン酸、(12)cis-3-({1-[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロ-2-ナフタレニル]エチル}アミノ)シクロブタンカルボン酸、または(13)1-{[(3S)-3-メチル-6-(プロポキシメチル)-3,4-ジヒドロ-2-ナフタレニル]メチル}-3-アゼチジンカルボン酸である前記[1]または[2]に記載の化合物、またはその薬学的に許容される塩、
[13] 前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩を含有する医薬組成物、
[14] S1P5作動剤である前記[13]に記載の医薬組成物、
[15] S1P5介在性疾患の予防および/または治療剤である前記[13]または[14]に記載の医薬組成物、
[16] S1P5介在性疾患が、神経変性疾患、自己免疫疾患、感染症または癌である前記[15]に記載の医薬組成物、
[17] S1P5介在性疾患が、神経変性疾患であり、神経変性疾患が、統合失調症、ビンスワンガー病、多発性硬化症、視神経脊髄炎、アルツハイマー病型認知症、認知障害、筋萎縮性側索硬化症、脊髄小脳変性症、多系統萎縮症、パーキンソン病、またはレビー小体型認知症である前記[16]に記載の医薬組成物、
[18] 前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の有効量を哺乳動物に投与することを特徴とする、S1P5介在性疾患の予防および/または治療方法、
[19] S1P5介在性疾患の予防および/または治療に使用される前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩、
[20] S1P5介在性疾患の予防および/または治療剤を製造するための前記[1]記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の使用、
[21] 一般式(I)
ここで、L中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
R1は、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R2は、C1~4アルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
Zは、(1)1個のC1~8アルキル基で置換されていてもよいカルボキシル基、(2)1個のC1~8アルキル基で置換されていてもよい水酸基、(3)1~2個のC1~8アルキル基で置換されていてもよいヒドロキサム酸基、(4)1個のC1~8アルキル基で置換されていてもよいスルホン酸基、(5)1~2個のC1~8アルキル基で置換されていてもよいボロン酸基、(6)(i)1~2個のC1~8アルキル基、または(ii)C1~4アルキル基で置換されていてもよい1~2個のスルホニル基で置換されていてもよい、カルバモイル基、(7)(i)1~2個のC1~8アルキル基、または(ii)1~2個のC2~8のアシル基で置換されていてもよい、スルファモイル基、(8)1~2個のC1~8アルキル基で置換されていてもよいスルホキシイミン基、または(9)テトラゾリル基を表し、
ring1は、4~7員の含窒素ヘテロ環を表し、
mは、0~6の整数を表し、
nは、0~5の整数を表し、
mが2以上のとき、複数のR1は同じでも異なっていてもよく、
nが2以上のとき、複数のR2は同じでも異なっていてもよく、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物、またはその薬学的に許容される塩、
[22] Lが、主鎖の原子数が4~7である分岐または直鎖の鎖状基である前記[21]に記載の化合物、またはその薬学的に許容される塩、
[23] ring1が、4~7員の含窒素飽和ヘテロ環である前記[21]または[22]に記載の化合物、またはその薬学的に許容される塩、
[24] 一般式(I-1)
ここで、L1中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
ring1-1は、4~7員の含窒素飽和ヘテロ環を表し、
m-1は、0~2の整数を表し、
n-1は、0~2の整数を表し、
m-1が2のとき、複数のR1は同じでも異なっていてもよく、
n-1が2のとき、複数のR2は同じでも異なっていてもよく、
その他の記号は前記[21]と同じ意味を表し、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物である前記[21]記載の化合物、またはその薬学的に許容される塩、
[25] Zが、1個のC1~8アルキル基で置換されていてもよいカルボキシル基である前記[24]記載の化合物、またはその薬学的に許容される塩、
[26] L1が、-O-(C3~6アルキル基)、-O-(C3~6アルケニル基)、-O-(C3~6アルキニル基)、-O-(C2~4アルキレン基)-OCH3、または-O-(C2~3アルキレン基)-OCH2CH3であり、ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい前記[24]または[25]に記載の化合物、またはその薬学的に許容される塩、
[27] R1が、C1~4アルキル基、またはハロゲン原子である前記[24]~[26]のいずれかに記載の化合物、またはその薬学的に許容される塩、
[28] ring1-1が、アゼチジン、ピロリジン、ピペリジン、またはパーヒドロアゼピンである前記[24]~[27]のいずれかに記載の化合物、またはその薬学的に許容される塩、
[29] (1)1-[((3R)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(2)1-[((3S)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(3)1-[((3S)-3-メチル-6-ペントキシ-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(4)1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(5)3-フルオロ-1-[[(3S)-3-メチル-6-(3,4,4-トリフルオロブタ-3-エノキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(6)1-[[(3S)-3-メチル-6-(1,1,2,2,3,3,4,4,4-ノナデューテリオブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(7)(3R)-1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]ピロリジン-3-カルボン酸、(8)1-[[(3S)-3-メチル-6-((R)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(9)1-[[(3S)-3-メチル-6-((S)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、または(10)3-フルオロ-1-[[(3S)-3-メチル-6-[(E)-4,4,4-トリフルオロブタ-2-エノキシ]-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸である前記[21]に記載の化合物、またはその薬学的に許容される塩、
[30] 前記[21]記載の一般式(I)で示される化合物、またはその薬学的に許容される塩を含有してなる医薬組成物、
[31] S1P5作動剤である前記[30]に記載の医薬組成物、
[32] S1P5介在性疾患の予防および/または治療剤である前記[30]または[31]に記載の医薬組成物、
[33] S1P5介在性疾患が、神経変性疾患、自己免疫疾患、感染症または癌である前記[32]に記載の医薬組成物、
[34] 神経変性疾患が、統合失調症、ビンスワンガー病、多発性硬化症、視神経脊髄炎、アルツハイマー病型認知症、認知障害、筋萎縮性側索硬化症、脊髄小脳変性症、多系統萎縮症、パーキンソン病、またはレビー小体型認知症である前記[33]に記載の医薬組成物、
[35] 前記[21]記載の一般式(I)で示される化合物、またはその薬学的に許容される塩の有効量を哺乳動物に投与することを特徴とする、S1P5介在性疾患の予防および/または治療方法、
[36] S1P5介在性疾患の予防および/または治療のための前記[21]記載の一般式(I)で示される化合物、またはその薬学的に許容される塩、および
[37] S1P5介在性疾患の予防および/または治療剤を製造するための前記[21]記載の一般式(I)で示される化合物、またはその薬学的に許容される塩の使用。
NMRの箇所に示されているカッコ内は測定に使用した溶媒を示す。
カラム:YMC Triart C18 2.0mm×30mm,1.9μm;流量:1.0mL/分;温度:30℃;移動相A:0.1%TFA水溶液;移動相B:0.1%TFAアセトニトリル溶液:グラジエント(移動相(A):移動相(B)の比率を記載):
0~0.10分:(95%:5%);0.10~1.20分:(95%:5%)から(5%:95%);1.20~1.50分:(5%:95%)。
6-ヒドロキシ-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:3470-50-6)(24.3g)のアセトン(160mL)溶液に室温で臭化ベンジル(29.4mL)および炭酸カリウム(31.1g)を加え、40℃で3.5時間撹拌した。不溶物を濾別後、濃縮した。残渣をtert-ブチルメチルエーテル(MTBE)-ヘキサン(1:4)混合溶媒にて洗浄し、以下の物性値を有する標題化合物(34.5g)を得た。
TLC: Rf 0.38(ヘキサン:酢酸エチル=3:1)。
実施例1で製造した化合物(34.5g)のテトラヒドロフラン(THF)(300mL)溶液にメチルマグネシウムブロミド(3mol/Lジエチルエーテル溶液、55mL)を0℃で加え、室温で1時間撹拌した。反応液を0℃に冷却し、氷-飽和塩化アンモニウム水溶液へ注いだ。2mol/L 塩酸を加えた後、溶液を室温で3時間撹拌した。酢酸エチルにて抽出し、有機層を水、飽和食塩水にて順次洗浄し、硫酸マグネシウムで乾燥後濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:1)にて精製し、以下の物性値を有する標題化合物(24.8g)を得た。
TLC: Rf 0.57(ヘキサン:酢酸エチル=15:1)。
オキシ塩化リン(26.7g)に0℃でN,N-ジメチルホルムアミド(DMF)(60mL)を滴下し、20分撹拌した。さらに、実施例2で製造した化合物(24.8g)の塩化メチレン(DCM)(60mL)溶液をゆっくり滴下し、室温で90分撹拌した。反応液を0℃に冷却し、氷中に注ぎ、30分撹拌後、ヘキサン-酢酸エチル(1:2)混合溶媒にて抽出した。有機層を水、飽和食塩水にて順次洗浄し、硫酸マグネシウムで乾燥後濃縮した。得られた残渣をMTBEにて洗浄、乾燥することにより、以下の物性値を有する標題化合物(19.9g)を得た。
TLC: Rf 0.50(ヘキサン:酢酸エチル=3:1)。
チオアニソール(35mL)に0℃でトリフルオロ酢酸(140mL)を加え、さらに実施例3で製造した化合物(9.17g)を少しずつ加え、室温にて4時間撹拌した。反応液を氷中に注いだ後、5mol/L 水酸化ナトリウム水溶液を加えMTBEにて洗浄した。水層に1mol/L 塩酸を加え、酢酸エチルにて抽出した。有機層を硫酸マグネシウムで乾燥後濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=5:1→2:1)にて精製し、以下の物性値を有する標題化合物(6.03g)を得た。
TLC: Rf 0.26(ヘキサン:酢酸エチル=3:1)。
実施例4で製造した化合物(8.0g)のDCM(340mL)溶液に、メチル アゼチジン-3-カルボキシラート 塩酸塩(8.4g)(CAS登録番号:100202-39-9)およびジイソプロピルエチルアミン(9.6mL)を加え室温で30分撹拌した。反応液に水素化トリアセトキシホウ素ナトリウム(11.7g)を加え、室温で16時間撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加えた後、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄、硫酸マグネシウムにて乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(DIOL silica gel、ヘキサン:酢酸エチル=65:35→35:65)によって精製することにより、以下の物性値を有する標題化合物(10.6g)を得た。
1H-NMR(CDCl3):δ 7.11, 6.63, 6.57, 3.70, 3.58, 3.45-3.25, 2.60, 2.23, 2.07。
実施例5で製造した化合物(123mg)のDMF(4mL)溶液に、水素化ナトリウム(60% inミネラルオイル、17mg)を加え、窒素雰囲気下、室温で15分撹拌した。反応液に1-ブロモペンタン(62mg)を加え6時間撹拌した。反応液を酢酸エチルで希釈し、水、5%リチウムクロリド水溶液で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=8:2→2:8)によって精製することにより、以下の物性値を有する標題化合物(108mg)を得た。
1H-NMR(CDCl3):δ 7.18, 6.71, 6.68, 3.95, 3.70, 3.53, 3.35-3.27, 2.67, 2.26, 2.08, 1.78, 1.45-1.35, 0.93。
1H-NMR(DMSO-d6):δ7.16, 6.74, 6.71, 3.94, 3.40, 3.19, 2.59, 2.16, 2.02, 1.70, 1.36, 0.90;
LCMS:保持時間 0.91分。
実施例4で製造した化合物またはその代わりに相当するアルデヒド誘導体、メチル アゼチジン-3-カルボキシラート塩酸塩、および1-ブロモペンタンの代わりに相当するハロゲン化アルキルを用いて、実施例5→実施例6→実施例7と同様の反応に付すか、または実施例4で製造した化合物またはその代わりに相当するアルデヒド誘導体、メチル アゼチジン-3-カルボキシラート塩酸塩、および1-ブタノールの代わりに相当するアルコールを用いて、実施例5→後述の実施例8→実施例7と同様の反応に付すことにより、以下の物性値を有する実施例化合物を得た。
1H-NMR(DMSO-d6):δ 7.16, 7.10, 6.74-6.70, 3.94, 3.42, 3.23-3.18, 2.59, 2.26, 2.02, 1.70-1.65, 1.46-1.39, 0.93;
LCMS:保持時間 0.90分。
1H-NMR(Acetic Acid-d4):δ 7.29, 6.76, 6.72, 4.64, 4.43-4.41, 4.18, 3.83-3.80, 2.71, 2.30, 2.21, 1.72-1.68, 1.59-1.37, 1.28, 0.94;
LCMS:保持時間 0.93分。
1H-NMR(DMSO-d6):δ 7.16, 6.74, 6.71, 3.40, 3.18, 2.59, 2.16, 2.02;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 7.21, 6.87, 6.86, 6.67, 4.56, 3.60-3.00, 2.61, 2.18, 2.03;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 7.18, 6.77, 6.75, 4.14, 3.60-3.00, 2.80, 2.60, 2.17, 2.03;
LCMS:保持時間0.82分。
1H-NMR(DMSO-d6):δ 7.16, 6.74, 6.71, 3.94, 3.40, 3.19, 2.59, 2.16, 2.02, 1.66;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 7.16, 6.74, 6.71, 3.40, 3.19, 2.59, 2.16, 2.02;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 7.18, 6.75, 6.73, 5.83, 5.68, 4.46, 3.60-3.00, 2.60, 2.16, 2.04, 1.70;
LCMS:保持時間0.81分。
1H-NMR(CDCl3):δ 7.24, 6.73, 6.68, 4.35, 4.05, 3.96, 3.91, 3.52-3.35, 2.66, 2.30, 1.76, 1.48, 1.11, 0.97;
LCMS:保持時間0.89分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.69, 6.28, 4.00, 3.20, 3.07, 2.68, 2.13, 1.91;
LCMS:保持時間0.82分。
6-ヒドロキシ-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:3470-50-6)(2.0g)のTHF(40mL)溶液に1-ブタノール(2.3mL)、トリフェニルホスフィン(6.5g)、2.2mol/Lアゾジカルボン酸ジエチルのトルエン溶液を加え、室温で5時間撹拌した。反応液を濃縮後、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→8:2)によって精製することにより、以下の物性値を有する標題化合物(2.7g)を得た。
1H-NMR (CDCl3):δ 8.00, 6.81, 6.70, 4.01, 2.91, 2.60, 2.11, 1.78, 1.49, 0.98。
実施例8で製造した化合物(770mg)のクロロホルム(12mL)/DMF(1.37mL)溶液を氷冷し、リン酸トリブロマイド(0.83mL)を加え室温で72時間撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→7:3)によって精製することにより、以下の物性値を有する標題化合物(621mg)を得た。
1H-NMR (CDCl3):δ 10.20, 7.82, 6.82, 6.72, 4.02, 2.80, 2.61, 1.79, 1.50, 0.99。
実施例9で製造した化合物(320mg)のトルエン(5mL)溶液にシクロプロピルホウ酸(133mg)、2mol/Lリン酸カリウム水溶液(1.6mL)、トリシクロヘキシルホスフィン(0.064mL)、酢酸パラジウム(23mg)を加え90℃で5時間撹拌した。反応液をセライト(商品名)でろ過後、濾液を酢酸エチルで2回抽出した。有機層を水、飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→8:2)によって精製することにより、以下の物性値を有する標題化合物(271mg)を得た。
1H-NMR (CDCl3):δ 10.66, 7.78, 6.80, 6.71, 4.00, 2.67, 2.47, 1.89, 1.78, 1.50, 1.15, 0.98, 0.59。
1H-NMR(DMSO-d6):δ 7.44, 6.74, 6.67, 3.94, 3.84-2.91, 2.14, 1.67, 1.54, 1.42, 0.96-0.91, 0.24;
LCMS:保持時間0.96分。
6-メトキシ-3-メチル-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:5563-21-3)(1g)のメタノール(100mL)溶液に、0℃で水素化ホウ素ナトリウム(398mg)を加えた。反応溶液を室温へ昇温し、2時間撹拌した後、塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:1)で粗精製し、そのまま次の反応に用いた。得られた粗精製物のDMF(100mL)溶液に、オキシ塩化リン(2.2g)を加えた。反応溶液を60℃に加熱し、8時間撹拌した。その後反応溶液を氷水に注ぎ、5分間撹拌後、有機層を分離した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥し、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:1→5:1)で精製し、以下の物性値を有する標題化合物(299mg)を得た。
1H-NMR (CDCl3): δ 9.57, 7.30-7.24, 6.82-6.78, 3.85, 3.08, 2.65, 0.92。
実施例12で製造した化合物(299mg)のジクロロメタン(100mL)溶液に、0℃で三臭化ホウ素(815mg)を滴下した。0℃で3時間撹拌した後、反応溶液を氷水に注ぎ、5分間撹拌後、有機層を分離した。有機層を飽和食塩水で洗浄、無水硫酸ナトリウムで乾燥し、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=5:1)で精製し、以下の物性値を有する標題化合物(200mg)を得た。
1H-NMR (CDCl3): δ 9.57, 7.18, 6.72, 3.08, 2.60, 0.94。
実施例13で製造した化合物をHPLC(使用カラム:株式会社ダイセル CHIRALCEL OJ-H(4.6mmI.D.×250mmL)、移動相:ノルマルヘキサン:2-プロパノール=80:20、流速:1mL/min、温度:40℃、波長:245nm)を用いて光学分割を行うことにより、第一ピーク(保持時間約6.9分)に標題化合物を得た。
実施例14の光学分割により、第二ピーク(保持時間約8.1分)に標題化合物を得た。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.26, 3.92, 3.60-3.00, 2.84, 2.34, 1.68, 1.45-1.26, 0.89, 0.84;
LCMS:保持時間0.91分。
実施例14または実施例14(1)で製造した化合物、メチル アゼチジン-3-カルボキシラート塩酸塩またはその代わりに相当するアミン誘導体、および1-ブロモペンタンの代わりに相当するハロゲン化アルキルを用いて、実施例5→実施例6→実施例7と同様の反応に付すか、または実施例14または実施例14(1)で製造した化合物、メチル アゼチジン-3-カルボキシラート塩酸塩またはその代わりに相当するアミン誘導体、および1-ブタノールの代わりに相当するアルコールを用いて、実施例5→実施例8→実施例7と同様の反応に付すことにより、以下の実施例化合物を得た。
LCMS:保持時間0.91分。
1H-NMR(DMSO-d6):δ 6.96, 6.71, 6.67, 6.22, 3.92, 3.42, 3.21, 2.98, 2.84, 2.33, 1.68, 1.41, 1.31, 0.86;
LCMS:保持時間 0.97分。
1H-NMR(DMSO-d6):δ 6.96, 6.71, 6.67, 6.22, 3.92, 3.42, 3.21, 2.98, 2.84, 2.33, 1.68, 1.41, 1.31, 0.86;
LCMS:保持時間 0.97分。
1H-NMR(DMSO-d6):δ 6.97, 6.72, 6.69, 6.25, 3.96, 3.65-3.00, 2.85, 2.34, 1.72, 1.59-1.47, 1.38, 1.18, 0.90, 0.88-0.83;
LCMS:保持時間0.95分。
1H-NMR(DMSO-d6):δ 6.97, 6.72, 6.69, 6.25, 3.96, 3.65-3.00, 2.85, 2.34, 1.72, 1.59-1.47, 1.38, 1.18, 0.90, 0.88-0.83;
LCMS:保持時間0.95分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.24, 3.89, 3.60-2.90, 2.84, 2.32, 1.70, 0.96, 0.85;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.24, 3.89, 3.60-2.90, 2.84, 2.32, 1.70, 0.96, 0.85;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.25, 3.92, 3.60-3.00, 2.84, 2.33, 1.68, 1.39, 1.35-1.20, 0.87, 0.85;
LCMS:保持時間1.02分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.25, 3.92, 3.60-3.00, 2.84, 2.33, 1.68, 1.39, 1.35-1.20, 0.87, 0.85;
LCMS:保持時間1.02分。
1H-NMR(DMSO-d6):δ 6.95, 6.68, 6.66, 6.22, 4.40, 3.60-2.95, 2.83, 2.32, 1.61, 1.50, 1.45-1.28, 1.20, 0.89, 0.85;
LCMS:保持時間0.88分。
1H-NMR(DMSO-d6):δ 6.95, 6.68, 6.66, 6.22, 4.40, 3.60-2.95, 2.83, 2.32, 1.61, 1.50, 1.45-1.28, 1.20, 0.89, 0.85;
LCMS:保持時間0.88分。
1H-NMR (CDCl3):δ 6.97, 6.70-6.60, 6.45, 4.46-4.22, 4.15-3.97, 3.92, 3.60-3.30, 3.02, 2.61-2.47, 1.69, 1.59-1.31, 1.28, 0.93;
LCMS:保持時間0.88分。
s1H-NMR (CDCl3):δ 6.97, 6.70-6.60, 6.45, 4.46-4.22, 4.15-3.97, 3.92, 3.60-3.30, 3.02, 2.61-2.47, 1.69, 1.59-1.31, 1.28, 0.93;
LCMS:保持時間0.88分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.69, 6.23, 3.96, 3.60-3.00, 2.84, 2.33, 1.77, 1.59, 0.93, 0.85;
LCMS:保持時間0.91分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.69, 6.23, 3.96, 3.60-3.00, 2.84, 2.33, 1.77, 1.59, 0.93, 0.85;
LCMS:保持時間0.91分。
1H-NMR(DMSO-d6):δ 6.95, 6.68, 6.67, 6.23, 4.39, 3.60-2.97, 2.83, 2.33, 1.62, 1.52, 1.43-1.25, 1.20, 0.89-0.83;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.95, 6.68, 6.67, 6.23, 4.39, 3.60-2.97, 2.83, 2.33, 1.62, 1.52, 1.43-1.25, 1.20, 0.89-0.83;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.97, 6.72, 6.68, 6.25, 3.80, 3.72, 3.60-2.97, 2.85, 2.34, 1.86, 1.48-1.24, 1.18, 0.96, 0.88, 0.85;
LCMS:保持時間0.96分。
1H-NMR(DMSO-d6):δ 6.97, 6.72, 6.68, 6.25, 3.80, 3.72, 3.60-2.97, 2.85, 2.34, 1.86, 1.48-1.24, 1.18, 0.96, 0.88, 0.85;
LCMS:保持時間0.96分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.26, 3.92, 3.60-3.01, 2.85, 2.33, 1.69, 1.57, 1.29, 0.89, 0.85;
LCMS:保持時間0.95分。
1H-NMR(DMSO-d6):δ 6.97, 6.71, 6.68, 6.26, 3.92, 3.60-3.01, 2.85, 2.33, 1.69, 1.57, 1.29, 0.89, 0.85;
LCMS:保持時間0.95分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.21, 3.59, 3.21, 2.96, 2.84, 2.55, 2.32, 0.99, 0.84;
LCMS:保持時間0.92分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.21, 3.59, 3.21, 2.96, 2.84, 2.55, 2.32, 0.99, 0.84;
LCMS:保持時間0.92分。
1H-NMR(DMSO-d6):δ 6.96, 6.68, 6.66, 6.22, 4.46, 3.60-2.90, 2.83, 2.33, 1.73, 1.59, 1.33, 1.19, 0.91, 0.88, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 6.96, 6.69, 6.67, 6.22, 4.46, 3.60-2.90, 2.84, 2.33, 1.73, 1.59, 1.34, 1.20, 0.91, 0.88, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 6.95, 6.71, 6.68, 6.22, 3.98, 3.24, 3.02, 2.84, 2.55, 2.33, 1.63, 0.95, 0.84;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.95, 6.71, 6.68, 6.22, 3.98, 3.24, 3.02, 2.84, 2.55, 2.33, 1.63, 0.95, 0.84;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.96, 6.69, 6.67, 6.22, 4.46, 3.60-2.90, 2.84, 2.33, 1.73, 1.59, 1.34, 1.20, 0.91, 0.88, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 6.96, 6.68, 6.66, 6.22, 4.46, 3.60-2.90, 2.83, 2.33, 1.73, 1.59, 1.33, 1.19, 0.91, 0.88, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 6.95, 6.69, 6.67, 6.23, 4.24, 3.60-2.90, 2.84, 2.33, 1.56, 1.34, 0.88;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.95, 6.69, 6.67, 6.23, 4.24, 3.60-2.90, 2.84, 2.33, 1.56, 1.34, 0.88;
LCMS:保持時間0.94分。
1H-NMR(DMSO-d6):δ 6.93, 6.69, 6.68, 6.21, 4.12, 3.60-2.90, 2.83, 2.32, 1.91, 1.51, 1.39, 1.29, 0.91, 0.88, 0.86;
LCMS:保持時間0.98分。
1H-NMR(DMSO-d6):δ 6.93, 6.69, 6.68, 6.21, 4.12, 3.60-2.90, 2.83, 2.32, 1.91, 1.51, 1.39, 1.29, 0.91, 0.88, 0.86;
LCMS:保持時間0.98分。
LCMS:保持時間0.85分。
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 6.96, 6.71, 6.68, 6.23, 5.82, 5.68, 4.44, 3.90-2.95, 2.84, 2.33, 1.70, 0.85;
LCMS:保持時間0.82分。
1H-NMR(DMSO-d6):δ 6.96, 6.71, 6.68, 6.23, 5.82, 5.68, 4.44, 3.90-2.95, 2.84, 2.33, 1.70, 0.85;
LCMS:保持時間0.82分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.23, 5.41, 4.48, 3.80-2.95, 2.84, 2.33, 1.74, 1.70, 0.85;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.23, 5.41, 4.48, 3.80-2.95, 2.84, 2.33, 1.74, 1.70, 0.85;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 6.99, 6.74, 6.71, 6.24, 4.13, 3.75-2.95, 2.84, 2.78, 2.33, 0.84;
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 6.99, 6.74, 6.71, 6.24, 4.13, 3.75-2.95, 2.84, 2.78, 2.33, 0.84;
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.65, 6.31, 3.93, 3.85-3.05, 2.87, 2.37, 1.68, 1.48, 0.92, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.65, 6.31, 3.93, 3.85-3.05, 2.87, 2.37, 1.68, 1.48, 0.92, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.01, 6.74, 6.71, 6.31, 4.01, 3.94-3.01, 2.87, 2.40, 1.92, 0.85;
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 7.01, 6.74, 6.71, 6.31, 4.01, 3.94-3.01, 2.87, 2.40, 1.92, 0.85;
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.69, 6.29, 5.83, 5.68, 4.44, 3.85-3.00, 2.87, 2.40-2.34, 1.70, 0.86;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.69, 6.29, 5.83, 5.68, 4.44, 3.85-3.00, 2.87, 2.40-2.34, 1.70, 0.86;
LCMS:保持時間0.79分。
1H-NMR(DMSO-d6):δ 7.01, 6.76-6.71, 6.30, 4.70, 3.84-2.98, 2.87, 2.42-2.34, 1.83, 0.86;
LCMS:保持時間0.74分。
1H-NMR(DMSO-d6):δ 7.01, 6.76-6.71, 6.30, 4.70, 3.84-2.98, 2.87, 2.42-2.34, 1.83, 0.86;
LCMS:保持時間0.74分。
H-NMR(DMSO-d6):δ 6.99, 6.73, 6.69, 6.29, 5.41, 4.49, 3.85-3.04, 2.87, 2.41-2.34, 1.74, 1.70, 0.86;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 6.99, 6.73, 6.69, 6.29, 5.41, 4.49, 3.85-3.04, 2.87, 2.41-2.34, 1.74, 1.70, 0.86;
LCMS:保持時間0.84分。
LCMS:保持時間0.81分。
LCMS:保持時間0.81分。
1H-NMR(DMSO-d6):δ 6.98, 6.69, 6.67, 6.29, 4.41, 3.85-2.98, 2.86, 2.41-2.34, 1.61, 1.49, 1.44-1.31, 1.20, 0.89, 0.86;
LCMS:保持時間0.87分。
1H-NMR(DMSO-d6):δ 6.98, 6.69, 6.67, 6.29, 4.41, 3.85-2.98, 2.86, 2.41-2.34, 1.61, 1.49, 1.44-1.31, 1.20, 0.89, 0.86;
LCMS:保持時間0.87分。
1H-NMR(DMSO-d6):δ 6.98, 6.71, 6.68, 6.29, 3.99, 3.60-2.97, 2.87, 2.38, 1.30, 0.86;
LCMS:保持時間0.71分。
1H-NMR(DMSO-d6):δ 6.98, 6.71, 6.68, 6.29, 3.99, 3.60-2.97, 2.87, 2.38, 1.30, 0.86;
LCMS:保持時間0.71分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.69, 6.31, 3.89, 3.60-3.00, 2.87, 2.38, 1.70, 0.96, 0.86;
LCMS:保持時間0.78分。
1H-NMR(DMSO-d6):δ 6.99, 6.72, 6.69, 6.31, 3.89, 3.60-3.00, 2.87, 2.38, 1.70, 0.96, 0.86;
LCMS:保持時間0.78分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.29, 3.90, 3.70-3.10, 2.89, 2.36, 2.10, 1.70, 0.97, 0.88;
LCMS:保持時間0.80分。
1H-NMR(DMSO-d6):δ 6.96, 6.72, 6.68, 6.29, 3.90, 3.70-3.10, 2.89, 2.36, 2.10, 1.70, 0.97, 0.88;
LCMS:保持時間0.80分。
1H-NMR(DMSO-d6):δ 7.03, 6.75, 6.73, 6.41, 3.81, 3.74, 3.10, 2.89, 1.81-1.75,1.62-1.56, 1.53-1.47, 1.43-1.38, 1.37-1.33, 1.28-1.20, 1.18, 0.96, 0.90, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 7.03, 6.76, 6.73, 6.42, 3.82, 3.73, 3.09, 2.89, 2.55, 1.82-1.75, 1.62-1.57,1.52-1.47, 1.45-1.33,1.26-1.19, 1.18, 0.96, 0.90, 0.88, 0.85;
LCMS:保持時間0.92分。
1H-NMR(DMSO-d6):δ 7.03, 6.76, 6.73, 6.42, 3.82, 3.73, 3.09, 2.89, 2.55, 1.82-1.75, 1.62-1.57,1.52-1.47, 1.45-1.33,1.26-1.19, 1.18, 0.96, 0.90, 0.88, 0.85;
LCMS:保持時間0.92分。
1H-NMR(DMSO-d6):δ 7.03, 6.75, 6.73, 6.41, 3.81, 3.74, 3.10, 2.89, 1.81-1.75,1.62-1.56, 1.53-1.47, 1.43-1.38, 1.37-1.33, 1.28-1.20, 1.18, 0.96, 0.90, 0.85;
LCMS:保持時間0.93分。
1H-NMR(DMSO-d6):δ 7.00, 6.73, 6.69, 6.29, 3.71, 3.10, 2.88, 2.02-1.95, 1.18, 0.97, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.00, 6.73, 6.69, 6.29, 3.71, 3.10, 2.88, 2.02-1.95, 1.18, 0.97, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.04, 6.75, 6.72, 6.43, 3.72, 3.09, 2.89, 2.54, 2.03-1.95, 1.18, 0.96, 0.85;
LCMS:保持時間0.86分。
1H-NMR(DMSO-d6):δ 7.04, 6.75, 6.72, 6.43, 3.72, 3.09, 2.89, 2.54, 2.03-1.95, 1.18, 0.96, 0.85;
LCMS:保持時間0.86分。
LCMS:保持時間0.85分。
LCMS:保持時間0.85分。
LCMS:保持時間0.84分。
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 6.97, 6.75, 6.70, 6.31, 4.01, 3.65-2.80, 2.60-2.30, 2.20-2.03, 1.91, 0.88;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 6.97, 6.75, 6.70, 6.31, 4.01, 3.65-2.80, 2.60-2.30, 2.20-2.03, 1.91, 0.88;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.00, 6.79, 6.75-6.70, 6.27-6.20, 4.72, 3.60-3.24, 2.86, 2.33, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.00, 6.79, 6.75-6.70, 6.27-6.20, 4.72, 3.60-3.24, 2.86, 2.33, 0.85;
LCMS:保持時間0.84分。
1H-NMR(DMSO-d6):δ 7.00, 6.79, 6.76-6.70, 6.25-6.21, 4.72, 2.86, 2.52, 2.35, 0.85;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 7.00, 6.79, 6.76-6.70, 6.25-6.21, 4.72, 2.86, 2.52, 2.35, 0.85;
LCMS:保持時間0.85分。
1H-NMR(DMSO-d6):δ 6.98, 6.70, 6.67, 6.29, 4.60, 3.81-3.67, 3.21, 2.86, 2.87, 1.88-1.83, 1.80-1.73, 1.23, 0.87;
LCMS:保持時間0.78分。
1H-NMR(DMSO-d6):δ 6.98, 6.70, 6.67, 6.29, 4.60, 3.81-3.67, 3.21, 2.86, 2.87, 1.88-1.83, 1.80-1.73, 1.23, 0.87;
LCMS:保持時間0.78分。
LCMS:保持時間0.83分。
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 7.04, 6.80, 6.76, 6.71, 6.32, 6.26-6.16, 4.72, 2.90, 0.85;
LCMS:保持時間0.83分。
1H-NMR(DMSO-d6):δ 7.04, 6.80, 6.76, 6.71, 6.32, 6.26-6.16, 4.72, 2.90, 0.85;
LCMS:保持時間0.83分。
LCMS:保持時間0.78分。
LCMS:保持時間0.78分。
実施例14(1)で製造した化合物(2.5g)およびメチル アゼチジン-3-カルボキシラート塩酸塩(2.6g)を用いて、実施例5と同様の反応に付すことにより(S)-メチル 1-((6-ヒドロキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル)アゼチジン-3-カルボキシラート(3.8g)を得た。(S)-メチル 1-((6-ヒドロキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル)アゼチジン-3-カルボキシラート(50mg)および3,3,3-トリフルオロ-2-メチル-プロパン-1-オール(31.7mg)を用いて、実施例8と同様の反応に付すことにより、標題化合物(18.0mg)を得た。
実施例16で製造した化合物をSFC(使用カラム:株式会社ダイセル CHIRALPAK IC(10mm×250mm)、移動相:CO2:(0.1%DEA/EA/IPA)=9:1、流速:30mL/min、圧力:100bar、波長:254nm、カラム温度:35℃)を用いて光学分割を行った。前記光学分割条件において、第一ピーク(保持時間:約9.00分)および第二ピーク(保持時間:約12.16分)にそれぞれ実施例16で製造した化合物の光学活性体を得た。
第一ピーク由来
1H-NMR(DMSO-d6):δ 7.03, 6.75, 6.73, 6.41, 3.80, 3.75, 3.40, 3.10, 2.89, 2.62, 2.57-2.46, 2.42-2.36, 1.80-1.75, 1.62-1.57, 1.53-1.47, 1.43-1.38, 1.38-1.33, 1.25-1.20, 1.18, 0.96, 0.90, 0.85;
LCMS:保持時間0.84分。
第二ピーク由来
1H-NMR(DMSO-d6):δ 6.99, 6.75, 6.71, 6.22, 6.10, 4.02, 3.23-3.12, 2.95, 2.91-2.87,2.85, 2.33, 1.19, 0.85;
LCMS:保持時間0.85分。
実施例14で製造した化合物、メチル アゼチジン-3-カルボキシラート塩酸塩、および3,3,3-トリフルオロ-2-メチル-プロパン-1-オールを用いて、実施例5→実施例8→実施例17→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
LCMS:保持時間0.84分。
または
1H-NMR(DMSO-d6):δ 6.99, 6.75, 6.71, 6.22, 6.10, 4.02, 3.23-3.12, 2.95, 2.91-2.87,2.85, 2.33, 1.19, 0.85;
LCMS:保持時間0.85分。
実施例13で製造した化合物(250mg)およびメチル アゼチジン-3-カルボキシラート塩酸塩(242mg)を用いて、実施例5と同様の反応に付すことにより、相当するエステル誘導体を得た。得られたエステル誘導体(100mg)および1-ブタノール(39mg)を用いて、実施例8と同様の反応に付すことにより、標題化合物(120mg)を得た。
実施例19で製造した化合物をSFC(使用カラム:株式会社ダイセル CHIRALPAK ID(10mmI.D.×250mmL)、移動相:CO2:(0.1%DEA/MeOH)=95:5、流速:30mL/min、圧力:100bar、波長:220nm、カラム温度:35℃)を用いて光学分割を行った。前記光学分割条件において、第一ピーク(保持時間:約4.62分)および第二ピーク(保持時間:約7.02分)にそれぞれ実施例19で製造した化合物の光学活性体を得た。
第一ピーク由来
1H-NMR(CDCl3):δ 6.96, 6.73-6.61, 6.45, 4.34, 4.24, 4.11, 4.05, 3.98-3.86, 3.60-3.38, 3.02, 2.62-2.48, 1.75, 1.48, 0.97, 0.91;
LCMS:保持時間 0.86分。
第二ピーク由来
1H-NMR(DMSO-d6):δ 6.96, 6.71, 6.68, 6.24, 3.93, 3.60-2.90, 2.84, 2.34, 1.67, 1.43, 0.93, 0.85;
LCMS:保持時間 0.86分。
6-メトキシ-3-メチル-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:5563-21-3)(10.0g)のアセトニトリル(60mL)溶液にセレクトフルオル(商品名)(21.6g)を加え40℃で25時間撹拌した。反応液に水を加え、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→8:2)によって精製することにより、標題化合物を含む混合物(3.68g)を得た。
実施例22で製造した混合物(3.68g)のメタノール(35mL)溶液に水素化ホウ素ナトリウム(1.34g)を0℃で加え、室温で1.5時間撹拌した。反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を未精製のまま次の反応に用いた。
実施例23で製造した化合物(3.71g)のDMF(35mL)溶液にオキシ塩化リン(5.0mL)を加え70℃で16時間撹拌した。反応液を氷冷下で水酸化ナトリウム水溶液へ注ぎ、室温で30分撹拌した。酢酸エチルで2回抽出した後に有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→7:3)によって精製することにより、以下の物性値を有する標題化合物(419mg)を得た。
1H-NMR (CDCl3):δ9.59, 7.15, 7.07, 6.83, 3.93, 3.11, 3.05, 2.78, 0.94。
実施例24で製造した化合物(460mg)、メチル アゼチジン-3-カルボキシラート塩酸塩(226mg)、および4,4,4-トリフルオロブタン-1-オール(84mg)を用いて、実施例13→実施例5→実施例8と同様の反応に付すことにより、標題化合物(150mg)を得た。
1H-NMR(CDCl3):δ 6.78-6.68, 6.22, 4.06, 3.72, 3.65-3.50, 3.43-3.22, 3.05, 2.85, 2.75, 2.50-2.25, 2.08, 0.94。
実施例25で製造した化合物をSFC(使用カラム:株式会社ダイセル CHIRALPAK IC(10mm×250mm)、移動相:CO2:(0.1%DEA/EA)=95:5、流速:30mL/min、圧力:100bar、波長:254nm、カラム温度:35℃)を用いて光学分割を行った。前記光学分割条件において、第一ピーク(保持時間:約5.99分)および第二ピーク(保持時間:約7.67分)にそれぞれ実施例25の光学活性体を得た。
実施例26で光学分割した第一ピーク化合物(72mg)または第二ピーク化合物(52mg)をそれぞれ実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(第一ピーク由来:43mg、第二ピーク由来:39mg)を得た。
第一ピーク
1H-NMR(CDCl3):δ 6.80, 6.71, 6.47, 4.39, 4.30, 4.09-3.97, 3.91, 3.54, 3.44, 2.90, 2.81, 2.62, 2.33, 2.07, 0.94;
LCMS:保持時間0.86分。
第二ピーク
1H-NMR(CDCl3):δ 6.80, 6.71, 6.47, 4.38, 4.29, 4.09-3.97, 3.90, 3.53, 3.43, 2.90, 2.81, 2.62, 2.33, 2.07, 0.93;
LCMS:保持時間0.85分。
実施例24で製造した化合物(370mg)、4,4,4-トリフルオロブタン-1-オール(124mg)、およびメチル 3-フルオロアゼチジン-3-カルボキシラート 塩酸塩(48.8mg)を用いて、実施例13→実施例8→実施例5→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(34.9mg)を得た。
1H-NMR(DMSO-d6):δ 6.95-6.86, 6.32, 4.08, 3.80-2.89, 2.73, 2.47-2.37, 1.94, 0.87;
LCMS:保持時間0.82分。
2,4,6-トリイソプロピルベンゼンスルホニルクロライド(CAS登録番号:6553-96-4)(10g)のTHF(30mL)溶液に0℃でヒドラジン水和物(2.3g)を徐々に加え0℃で2時間撹拌した。反応液に水を加え、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をヘキサンで洗浄後、乾燥することにより、以下の物性値を有する標題化合物(7.1g)を得た。
1H-NMR (CDCl3):δ 5.46, 4.18, 2.92, 1.30-1.24。
6-メトキシ-3-メチル-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:5563-21-3)(4.0g)のメタノール(40mL)溶液に実施例29で製造した化合物(7.0g)を加え室温で72時間撹拌した。反応液を減圧濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(NH silica gel、ヘキサン:酢酸エチル=8:2→5:5)によって精製することにより、以下の物性値を有する標題化合物(4.2g)を得た。
1H-NMR (DMSO-d6):δ 10.45, 7.69, 7.23, 6.72-6.67, 4.34, 3.73, 2.91, 2.84, 2.72, 2.40, 2.04-1.80, 1.26-1.17, 1.02。
実施例30で製造した化合物(2.0g)のTHF(21mL)溶液に-78℃で1.55Mのn-ブチルリチウムのヘキサン溶液(6.0mL)を加え-78℃で30分、0℃で20分撹拌した。再度-78℃に冷却後、N-フルオロベンゼンスルホンイミド(3.3g)のTHF溶液(6.0mL)を加え-78℃で30分撹拌、室温で18時間撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→8:2)によって精製することにより、標題化合物を含む混合物(550mg)を得た。
実施例31で製造した混合物(550mg)のDMF(5mL)溶液にオキシ塩化リン(1.2g)を加え室温で16時間撹拌した。反応液に水を注ぎ、酢酸エチルで2回抽出した。有機層を飽和食塩水で洗浄、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=10:0→7:3)によって精製することにより、以下の物性値を有する標題化合物(154mg)を得た。
1H-NMR (DMSO-d6):δ 10.11, 7.59, 6.99, 6.96, 3.84, 3.10-2.95, 2.69, 0.86。
1H-NMR (DMSO-d6):δ 7.22, 6.85, 6.81, 4.05, 3.60-3.00, 2.92, 2.42, 1.93, 0.89;
LCMS:保持時間0.86分。
DCM(7.5L)およびDMF(1.5L)の混合溶液に、三臭化リン(1.5L)を0~5℃で滴下し、25~30℃で1時間撹拌した。6-メトキシ-3-メチル-3,4-ジヒドロナフタレン-1(2H)-オン(CAS登録番号:5563-21-3)(750g)のDCM(3.75L)溶液を25~30℃で滴下した後、90℃で1時間加熱した。反応液を25℃に冷却し、砕いた氷に注いだ。得られた溶液を2Nの水酸化ナトリウム溶液でpH7-8に調整した後、DCMで抽出した。有機層を冷水で洗浄後、硫酸ナトリウムで乾燥し、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフィーで精製することにより、以下の物性値を有する標題化合物(500g)を得た。
1H-NMR (CDCl3):δ 10.18, 7.82, 6.82, 6.74, 3.85, 3.21, 3.07, 2.60, 0.84。
実施例34で製造した化合物(525g)のDCM(4.2L)溶液に、1mol/Lの三臭化ホウ素のDCM溶液(5.6L)を10~20℃で滴下し、20~30℃で6時間撹拌した。反応液を氷冷水に注ぎ、30分間撹拌した。反応液にDCMを加えた後、有機層を分離した。水層を10%メタノールを含むDCMで抽出した。合わせた有機層を水で洗浄後、硫酸ナトリウムで乾燥し、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフィーで精製することにより、以下の物性値を有する標題化合物(350g)を得た。
1H-NMR (CDCl3):δ 10.18, 7.81, 6.79, 6.67, 5.22, 3.22, 3.04, 2.58, 0.85。
実施例35で製造した化合物(350g)の1,4-ジオキサン(4.9L)溶液に、アルゴン雰囲気下で、メチルボロン酸(235.2g)、炭酸カリウム(726g)、Rac BINAP(2,2’-ビス(ジフェニルホスフィノ)-1,1’-ビナフチル、40.78g)を添加し、30分間撹拌した。酢酸パラジウム(17.64g)を25~30℃で加えた後、反応液を90℃で4時間加熱した。得られた反応液を25℃に冷却した後、氷冷水に注いだ。反応液をセライトでろ過し、酢酸エチルで洗浄した。濾液を2Nの塩酸溶液でpH2~3に調整し、有機層を分離した。水層を酢酸エチルで抽出した。合わせた有機層を飽和食塩水で洗浄後、硫酸ナトリウムで乾燥し、溶媒留去した。得られた残渣をシリカゲルカラムクロマトグラフィーで精製することにより、以下の物性値を有する標題化合物(151g)を得た。
1H-NMR (DMSO-d6):δ 10.21, 9.89, 7.48, 6.70, 6.65, 2.97, 2.81, 2.58-2.45, 2.44, 0.71。
実施例36で製造した化合物をSFC(使用カラム:株式会社ダイセル CHIRALCEL OJ-H(30mm×250mm)、移動相:CO2:2-プロパノール=85:15、流速:90g/min、圧力:100.0bar、波長:320nm)を用いて光学分割を行った。前記光学分割条件において得られた実施例36の光学活性体をSFC(使用カラム:株式会社ダイセル CHIRALPAK-IG(46mm×250mm)、移動相:CO2:メタノール=80:20、流速:3mL/min、圧力:100bar、波長:214nm、カラム温度:30℃)で分析した結果、第一ピークおよび第二ピークの保持時間はそれぞれ2.45分および4.77分であった。
1H-NMR (DMSO-d6):δ 7.19, 6.77-6.72, 4.02, 3.90-2.88, 2.80, 2.48-2.36, 2.02, 1.92, 0.74;
LCMS:保持時間0.81分。
実施例14(1)で製造した化合物(300mg)、および1-ブロモブタン(240mg)を用いて、実施例6と同様の反応に付すことにより、以下の物性値を有する標題化合物(351mg)を得た。
1H-NMR (DMSO-d6):δ 9.54, 7.42, 7.37, 6.88, 6.85, 4.03, 3.01-2.84, 2.67, 1.71, 1.44, 0.94, 0.82;
LCMS:保持時間1.25分。
実施例14で製造した化合物、および1-ブロモブタンを用いて、実施例6と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 9.54, 7.42, 7.37, 6.88, 6.85, 4.03, 3.01-2.84, 2.67, 1.71, 1.44, 0.94, 0.82;
LCMS:保持時間1.25分。
実施例39で製造した化合物(55mg)、およびエチル 3-メチルアゼチジン-3-カルボキシラート(25mg)を用いて、実施例5→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(28.6mg)を得た。
1H-NMR (CD3OD):δ 7.06, 6.78-6.70, 6.56, 4.40, 4.34, 4.07-3.94, 3.93-3.83, 3.04, 2.66, 2.42, 1.77, 1.60-1.46, 1.01, 0.96;
LCMS:保持時間0.89分。
実施例39または実施例39(1)で製造した化合物、およびエチル アゼチジン-3-カルボキシラートまたはその代わりに相当するアミン誘導体を用いて、実施例5→実施例7と同様の反応に付すことにより、以下の実施例化合物を得た。
1H-NMR (CD3OD):δ 7.06, 6.78-6.70, 6.56, 4.40, 4.34, 4.07-3.94, 3.93-3.83, 3.04, 2.66, 2.42, 1.77, 1.60-1.46, 1.01, 0.96;
LCMS:保持時間0.89分。
1H-NMR (CD3OD):δ 7.07, 6.78-6.70, 6.58, 4.46, 4.40, 4.23-4.06, 4.03-3.92, 3.36, 3.05, 2.66, 2.44, 1.77, 1.52, 1.01, 0.97;
LCMS:保持時間0.88分。
1H-NMR (CD3OD):δ 7.07, 6.78-6.70, 6.58, 4.46, 4.40, 4.23-4.06, 4.03-3.92, 3.36, 3.05, 2.66, 2.44, 1.77, 1.52, 1.01, 0.97;
LCMS:保持時間0.88分。
実施例14(1)で製造した化合物(312mg)、および1-ブロモ-4,4,4-トリフルオロブタン(348mg)を用いて、実施例6と同様の反応に付すことにより、以下の物性値を有する標題化合物(502mg)を得た。
1H-NMR (DMSO-d6):δ 9.55, 7.43, 7.39, 6.90, 6.87, 4.10, 3.02-2.85, 2.68, 2.47-2.35, 1.95, 0.82;
LCMS:保持時間1.13分。
実施例14で製造した化合物、および1-ブロモ-4,4,4-トリフルオロブタンを用いて、実施例6と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 9.55, 7.43, 7.39, 6.90, 6.87, 4.10, 3.02-2.85, 2.68, 2.47-2.35, 1.95, 0.82;
LCMS:保持時間1.13分。
実施例41で製造した化合物(50mg)、およびメチル 3-ヒドロキシアゼチジン-3-カルボキシラート塩酸塩(42mg)を用いて、実施例5→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(8.0mg)を得た。
1H-NMR (CD3OD):δ 6.94, 6.69-6.60, 6.41, 4.22, 3.99-3.79, 2.92, 2.53, 2.38-2.17, 1.92, 0.85;
LCMS:保持時間0.81分。
実施例41(1)で製造した化合物、およびメチル 3-ヒドロキシアゼチジン-3-カルボキシラート塩酸塩を用いて、実施例5→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (CD3OD):δ 6.94, 6.69-6.60, 6.41, 4.22, 3.99-3.79, 2.92, 2.53, 2.38-2.17, 1.92, 0.85;
LCMS:保持時間0.81分。
実施例39で製造した化合物(55mg)、およびtert-ブチル 3-(メチルアミノ)プロパノアート(47mg)を用いて、実施例5と同様の反応に付すことにより、標題化合物を含む混合物(23.9mg)を得た。
実施例39(1)で製造した化合物、およびtert-ブチル 3-(メチルアミノ)プロパノアートを用いて、実施例5と同様の反応に付すことにより、標題化合物を含む混合物を得た。
実施例43で製造した混合物(23.9mg)のジクロロメタン(0.48mL)溶液にトリフルオロ酢酸(0.15mL)を加え室温で撹拌した。反応液を減圧濃縮後、得られた残渣をシリカゲルカラムクロマトグラフィー(DCM:(DCM:メタノール:濃水酸化アンモニウム水溶液=80:18:2)=9:1→0:10)によって精製することにより、以下の物性値を有する標題化合物(12.0mg)を得た。
1H-NMR (CD3OD):δ 7.04, 6.77-6.70, 6.57, 3.99, 3.85, 3.73, 3.32-3.24, 3.23-3.14, 3.10, 2.67, 2.59, 2.56-2.47, 1.77, 1.53, 1.04-0.97;
LCMS:保持時間0.95分。
実施例39または実施例39(1)で製造した化合物、およびtert-ブチル 3-(メチルアミノ)プロパノアートまたはその代わりに相当するアミン誘導体を用いて、実施例5→実施例44と同様の反応に付すことにより、以下の実施例化合物を得た。
1H-NMR (CD3OD):δ 7.04, 6.77-6.70, 6.57, 3.99, 3.85, 3.73, 3.32-3.24, 3.23-3.14, 3.10, 2.67, 2.59, 2.56-2.47, 1.77, 1.53, 1.04-0.97;
LCMS:保持時間0.95分。
1H-NMR (CD3OD):δ 7.06, 6.79-6.70, 6.62, 4.08-3.94, 3.71, 3.46-3.40, 3.28-3.17, 3.11, 2.87, 2.75-2.50, 1.77, 1.53, 1.05-0.94;
LCMS:保持時間0.93分。
1H-NMR (CD3OD):δ 7.06, 6.79-6.70, 6.62, 4.08-3.94, 3.71, 3.46-3.40, 3.28-3.17, 3.11, 2.87, 2.75-2.50, 1.77, 1.53, 1.05-0.94;
LCMS:保持時間0.93分。
実施例41で製造した化合物(502mg)のTHF(2.5mL)溶液を-78℃に冷却し、3mol/LメチルマグネシウムクロライドのTHF(2.8mL)溶液を加え撹拌した。反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=5:1→1:1)によって精製することにより、以下の物性値を有する標題化合物(410mg)を得た。
1H-NMR (DMSO-d6):δ 7.02-6.95, 6.74, 6.70, 6.32, 6.23, 4.81, 4.74, 4.25-4.13, 4.10-3.94, 2.86, 2.45-2.31, 1.93, 1.26, 1.24, 0.88, 0.86。
実施例41(1)で製造した化合物を用いて、実施例45と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 7.02-6.95, 6.74, 6.70, 6.32, 6.23, 4.81, 4.74, 4.25-4.13, 4.10-3.94, 2.86, 2.45-2.31, 1.93, 1.26, 1.24, 0.88, 0.86。
実施例45で製造した化合物(410mg)のジクロロメタン(4.1mL)溶液に氷冷下でデス-マーチンペルヨージナン(CAS登録番号:87413-09-0)(1.5g)を加え室温で24時間撹拌した。反応液に水を加え、酢酸エチルで抽出した。有機層をチオ硫酸ナトリウム水溶液,飽和炭酸水素ナトリウム水溶液,飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を未精製のまま次の反応に用いた。
実施例45(1)で製造した化合物を用いて、実施例46と同様の反応に付すことにより、標題化合物を得た。
実施例46で製造した化合物(40mg)、およびメチル アゼチジン-3-カルボキシラート 塩酸塩(39mg)を用いて実施例5→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(14.2mg)を得た。
1H-NMR (DMSO-d6):δ 7.03-6.95, 6.73, 6.72-6.66, 6.27, 6.25, 4.01, 3.50-2.99, 2.93-2.70, 2.46-2.28, 1.92, 1.07, 1.03, 0.89, 0.83;
LCMS:保持時間0.96分。
実施例46または実施例46(1)で製造した化合物、およびメチル アゼチジン-3-カルボキシラート 塩酸塩またはその代わりに相当するアミン誘導体を用いて実施例5→実施例7と同様の反応に付すことにより、以下の実施例化合物を得た。
1H-NMR (DMSO-d6):δ 7.03-6.95,6.73, 6.72-6.66, 6.27, 6.25, 4.01, 3.50-2.99, 2.93-2.70, 2.46-2.28, 1.92, 1.07, 1.03, 0.89, 0.83;
LCMS:保持時間0.96分。
LCMS:保持時間0.65分。
LCMS:保持時間0.65分。
実施例39で製造した化合物(80mg)、およびアゼチジン-3-カルボニトリル塩酸塩(CAS登録番号:345954-83-8)(58mg)を用いて、実施例5と同様の反応に付すことにより、以下の物性値を有する標題化合物(38mg)を得た。
1H-NMR (CDCl3):δ 6.93, 6.70-6.64, 6.22, 3.95, 3.71-3.55, 3.39-3.24, 3.02, 2.95, 2.53, 2.39, 1.75, 1.49, 0.97, 0.93。
実施例48(1):1-{[(3R)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル]メチル}アゼチジン-3-カルボニトリル
実施例39(1)で製造した化合物、およびアゼチジン-3-カルボニトリル塩酸塩を用いて、実施例5と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (CDCl3):δ 6.93, 6.70-6.64, 6.22, 3.95, 3.71-3.55, 3.39-3.24, 3.02, 2.95, 2.53, 2.39, 1.75, 1.49, 0.97, 0.93。
実施例48で製造した化合物(36mg)のトルエン(2.0mL)溶液にジブチルチンオキシド(CAS登録番号:818-08-6)(87mg)およびトリメチルシリルアジド(CAS登録番号:4648-54-8)(40mg)を加え110℃で4時間撹拌した。反応液を減圧濃縮し,得られた残渣をシリカゲルカラムクロマトグラフィー(Diol silica gel、ジクロロメタン:メタノール=100:0→95:5)によって精製することにより、以下の物性値を有する標題化合物(5.0mg)を得た。
1H-NMR (CD3OD):δ 6.94, 6.69-6.57, 6.48, 4.51-4.40, 4.40-4.13, 3.97, 3.90-3.81, 2.94, 2.55, 2.33, 1.65, 1.41, 0.92-0.84;
LCMS:保持時間0.85分。
実施例48(1)で製造した化合物を用いて、実施例49と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (CD3OD):δ 6.94, 6.69-6.57, 6.48, 4.51-4.40, 4.40-4.13, 3.97, 3.90-3.81, 2.94, 2.55, 2.33, 1.65, 1.41, 0.92-0.84;
LCMS:保持時間0.85分。
実施例14(1)で製造した化合物(1.0g)、およびメチル アゼチジン-3-カルボキシラート塩酸塩(1.0g)を用いて、実施例5と同様の反応に付すことにより、以下の物性値を有する標題化合物(1.5g)を得た。
1H-NMR (DMSO-d6):δ 9.24, 6.84, 6.53, 6.50, 6.16, 3.63, 3.48-3.24, 3.23-3.07, 2.92, 2.80, 2.43, 2.36-2.26, 0.85。
実施例14で製造した化合物、およびメチル アゼチジン-3-カルボキシラート塩酸塩を用いて、実施例5と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 9.24, 6.84, 6.53, 6.50, 6.16, 3.63, 3.48-3.24, 3.23-3.07, 2.92, 2.80, 2.43, 2.36-2.26, 0.85。
実施例50で製造した化合物(1250mg)のジクロロメタン(12.5mL)溶液にジイソプロピルエチルアミン(2.3mL)およびN-フェニルビス(トリフルオロメタンスルホンイミド)(CAS登録番号:37595-74-7)(1.7g)を氷冷下で加え室温で24時間撹拌した。反応液に水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3→5:5)によって精製することにより、以下の物性値を有する標題化合物(1630mg)を得た。
1H-NMR (CDCl3):δ 7.09-6.98, 6.26, 3.64-3.52, 3.41-3.25, 3.08, 3.00, 2.60, 2.43, 0.94。
実施例50(1)で製造した化合物を用いて、実施例51と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (CDCl3):δ 7.09-6.98, 6.26, 3.64-3.52, 3.41-3.25, 3.08, 3.00, 2.60, 2.43, 0.94。
実施例51で製造した化合物(50mg)の1,4-ジオキサン(0.5mL)溶液に、N-メチルブチルアミン(13.5mg)、炭酸セシウム(51mg)、XPhos(11mg)およびジベンジリデンアセトンジパラジウム(5.5mg)を加え80℃で16時間撹拌した。反応液に酢酸エチルを加え、アミノシリカでろ過し、濾液を濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(NH2 silica gel、ヘキサン:酢酸エチル=1:2)によって精製することにより、標題の化合物を含む混合物を得た。
実施例51(1)で製造した化合物、およびN-メチルブチルアミンを用いて、実施例52と同様の反応に付すことにより、標題化合物を含む混合物を得た。
実施例52で製造した混合物(21mg)を用いて、実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(4.4mg)を得た。
1H-NMR (DMSO-d6):δ 6.84, 6.46, 6.42, 6.14, 3.50-3.07, 3.00-2.87, 2.86, 2.84-2.76, 2.52, 2.47-2.42, 2.35-2.22, 1.47, 1.30, 0.90, 0.85;
LCMS:保持時間0.79分。
実施例52(1)で製造した混合物を用いて、実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 6.84, 6.46, 6.42, 6.14, 3.50-3.07, 3.00-2.87, 2.86, 2.84-2.76, 2.52, 2.47-2.42, 2.35-2.22, 1.47, 1.30, 0.90, 0.85;
LCMS:保持時間0.79分。
実施例51で製造した化合物(150mg)の1,4-ジオキサン(1.5mL)溶液に、1-ブタンチオール(64.5mg)、ジイソプロピルエチルアミン(0.15mL)、Xantphos(41mg)およびジベンジリデンアセトンジパラジウム(33mg)を加え100℃で24時間撹拌した。反応液をセライトろ過し、濾液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=8:2→5:5)によって精製することにより、以下の物性値を有する標題化合物(83mg)を得た。
1H-NMR (CDCl3):δ 7.09, 7.06, 6.93, 6.23, 3.71, 3.65-3.52, 3.42-3.22, 3.04, 2.96, 2.90, 2.53, 2.40, 1.68-1.56, 1.51-1.37, 0.97-0.88。
実施例51(1)で製造した化合物、および1-ブタンチオールを用いて、実施例54と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (CDCl3):δ 7.09, 7.06, 6.93, 6.23, 3.71, 3.65-3.52, 3.42-3.22, 3.04, 2.96, 2.90, 2.53, 2.40, 1.68-1.56, 1.51-1.37, 0.97-0.88。
実施例54で製造した化合物(77mg)を用いて、実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(57mg)を得た。
1H-NMR (DMSO-d6):δ 7.10-7.04, 7.00, 6.27, 3.55-3.17, 3.05, 2.94, 2.86, 2.57-2.52, 2.42-2.31, 1.55, 1.40, 0.88, 0.85;
LCMS:保持時間0.98分。
実施例54(1)で製造した化合物を用いて、実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物を得た。
1H-NMR (DMSO-d6):δ 7.10-7.04, 7.00, 6.27, 3.55-3.17, 3.05, 2.94, 2.86, 2.57-2.52, 2.42-2.31, 1.55, 1.40, 0.88, 0.85;
LCMS:保持時間0.98分。
実施例51で製造した化合物(95mg)の1,4-ジオキサン(1.0mL)、テトラヒドロフラン(0.95mL)、水(0.19mL)混合溶液にペンチルボロン酸(31.5mg)、炭酸セシウム(221mg)、1,1’-ビス(ジフェニルホスフィノ)フェロセン-パラジウム(II)ジクロリド ジクロロメタン付加物(18.5mg)を加え90℃で19時間撹拌した。反応液に飽和食塩水を加え、酢酸エチルで抽出した。有機層を5%炭酸カリウム水溶液で洗浄し、硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=6:4→4:6)によって精製することにより、標題化合物を含む混合物(23mg)を得た。
LCMS:保持時間1.01分。
実施例51(1)で製造した化合物、およびペンチルボロン酸を用いて、実施例56と同様の反応に付すことにより、標題化合物を含む混合物を得た。
LCMS:保持時間1.01分。
実施例56で製造した化合物(23mg)を用いて、実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(10.7mg)を得た。
1H-NMR (DMSO-d6):δ 6.97-6.92, 6.25, 3.50-3.15, 3.02, 2.86, 2.48-2.44, 2.40-2.29, 1.54, 1.17-1.21, 0.90-0.82;
LCMS:保持時間1.00分。
実施例51または実施例51(1)で製造した化合物、およびペンチルボロン酸またはその代わりに相当するボロン酸誘導体を用いて、実施例56→実施例7と同様の反応に付すことにより、以下の実施例化合物を得た。
1H-NMR (DMSO-d6):δ 6.97-6.92, 6.25, 3.50-3.15, 3.02, 2.86, 2.48-2.44, 2.40-2.29, 1.54, 1.17-1.21, 0.90-0.82;
LCMS:保持時間1.00分。
1H-NMR (DMSO-d6):δ 7.09-7.05, 7.02, 6.27, 4.38, 3.50-3.10, 2.98, 2.88, 2.52, 2.46-2.32, 1.54, 0.88, 0.86;
LCMS:保持時間0.89分。
1H-NMR (DMSO-d6):δ 7.09-7.05, 7.02, 6.27, 4.38, 3.50-3.10, 2.98, 2.88, 2.52, 2.46-2.32, 1.54, 0.88, 0.86;
LCMS:保持時間0.89分。
1H-NMR (CDCl3):δ 7.05-6.95, 6.50, 4.55-4.08, 3.92, 3.69, 3.60, 3.49, 3.00, 2.83, 2.57, 2.49, 1.19, 0.91;
LCMS:保持時間0.86分。
1H-NMR (CDCl3):δ 7.05-6.95, 6.50, 4.55-4.08, 3.92, 3.69, 3.60, 3.49, 3.00, 2.83, 2.57, 2.49, 1.19, 0.91;
LCMS:保持時間0.86分。
実施例14(1)で製造した化合物(300mg)、メチル 3-フルオロアゼチジン-3-カルボキシラート塩酸塩(297mg)およびメタノール(6.3mg)を用いて、実施例5→実施例8→実施例7と同様の反応に付すことにより、以下の物性値を有する標題化合物(17mg)を得た。
1H-NMR (DMSO-d6):δ 6.99, 6.71, 6.68, 6.27, 3.82-3.64, 3.63-3.35, 3.30-3.15, 2.86, 2.52, 2.36, 0.85;
LCMS:保持時間0.65分。
ヒトS1P1(EDG-1)またはヒトS1P5(EDG-8)遺伝子をそれぞれ過剰発現させたチャイニーズハムスターオーバリー(CHO)細胞を、10%FBS(ウシ胎児血清)、ペニシリン/ストレプトマイシンおよびジェネティシン(0.25mg/mL)含有のHam’s F-12培地で培養した。カルシウムアッセイを行う1日前とアッセイ当日に培地を交換した。培地交換から4時間後に、培地を除去し、リン酸緩衝生理食塩水で1回洗浄した。0.05%Trypsin EDTAを加えて細胞を剥離した後、培地を添加して細胞を回収した。回収した細胞懸濁液を遠心して上清を除去し、リン酸緩衝生理食塩で懸濁して細胞数をカウントした。1.1×106cells/mLになるようにCalcium 6 Assay Reagent(Molecular Devices社製)、20mM HEPES、2.5mM Probenecid含有Hanks液で細胞を懸濁し、37℃で約1時間インキュベーションした。その後、遠心して上清を除去し、2.2×106cells/mLになるように20mM HEPES、2.5mM Probenecid、0.1% BSA含有Hanks液で懸濁した。懸濁液を80μL/wellで96穴プレートに播種した。蛍光ドラッグスクリーニングシステム(FDSS6000)にプレートをセットし、化合物およびS1Pを順次添加し、添加前後の細胞内カルシウム濃度の上昇を励起波長480nm、蛍光波長540nmで測定した。細胞内カルシウム濃度の上昇を蛍光波長でのシグナル強度で評価し、化合物の代わりにS1Pを加えた時のシグナル強度を100%活性として各化合物の作動活性を算出した。
本発明化合物のS1P1受容体またはS1P5受容体に対する作動活性(EC50値)を表1に示した。また、比較化合物として本明細書に記載の比較例の他、比較化合物Aとして、特許文献1の実施例31(58)に記載の1-{[1-メチル-6-(オクチルオキシ)-3,4-ジヒドロ-2-ナフタレニル]メチル}-3-アゼチジンカルボン酸 塩酸塩を、比較化合物Bとして、特許文献2の実施例37に記載の1-({6-[(2-メトキシ-4-プロピルベンジル)オキシ]-1-メチル-3,4-ジヒドロ-2-ナフタレニル}メチル)-3-アゼチジンカルボン酸を用いた。比較例はS1P1およびS1P5受容体作動活性を有していなかった。比較化合物Aおよび比較化合物Bは、S1P1およびS1P5受容体作動活性を共に有し、S1P5受容体作動活性よりもS1P1受容体作動活性のほうが強かった。それに対して、本発明化合物は、いずれもS1P5受容体に対して選択的な作動活性を有し、S1P1受容体に対するS1P5受容体の作動活性のバランスが改善されていることがわかった。
絶食下の雄性SDラットに化合物溶液を尾静脈内投与した。投与後、一定時間ごとに、ラットを用手法で保定し、頸静脈よりヘパリンナトリウム加採血した。血液を10,000g、3min、4℃で遠心分離し、血漿を得た。LC/MS/MSで血漿中の化合物濃度を測定した。薬物動態解析ソフトウェアPhoenix WinNonlin(Certara USA, Inc.)を使用し、血漿中濃度推移からクリアランスを算出した。
本発明化合物はクリアランスが低いため、高いバイオアベイラビリティが期待できる。
ヒトS1P1(EDG-1)またはヒトS1P5遺伝子をそれぞれ過剰発現させたチャイニーズハムスターオーバリー(CHO)細胞膜画分を用いて、膜画分60μg protein/mLを使用し、96穴アッセイプレート内で反応した。各ウェルにBinding Buffer(50mmol/L、Tris pH7.5、5mmol/L、MgCl2、0.5%BSA、Complete EDTA free(1 tablet/50mL))で希釈したvehicle(DMSO)溶液または2倍濃度の化合物溶液100μLとBinding Bufferで希釈した50μLの0.16nmol/L [33P]-S1P(American Radiolabeled Chemicals社製)を加えた後、膜画分溶液(50μL)を加えて室温で60分反応させた。反応後、96穴UNIFILTERを用いて吸引ろ過し、洗浄バッファー(50mmol/L、Tris pH7.5、0.5% BSA)(150mL)で洗浄した後、50~60℃で30~60分間乾燥させた。MicroScint(商品名)20(50μL/well)を加えて、プレートをTopSeal-Aでカバーした後、TopCount(Perkin Elmer社製)で放射活性を計測した。
ヒトS1P1及びヒトS1P5への[33P]-S1Pの特異的結合を50%置換する化合物濃度(IC50値)を評価項目とした。特異的結合量は、[33P]-S1P全結合量(cpm)およびvehicleまたは化合物処置における[33P]-S1P結合量(cpm)の平均値(cpm)から[33P]-S1P非特異的結合量(cpm)を差し引いて求めた。[33P]-S1Pの特異的結合量を100%として、化合物の各濃度での特異的結合量の相対値(%)を算出した。相対値(%)が25~75%を示すvehicleまたは化合物の処置濃度のうち,50%に最も近い相対値を示す処置濃度を選択し、相対値(%)を下式のYに、処置濃度をXに代入し、IC50値を算出した。
Y = 100 / (1+10X-logIC50)
比較化合物Cとして、特許文献1の実施例31(45)に記載の3-({[6-(3-シクロヘキシルプロポキシ)-1-メチル-3,4-ジヒドロ-2-ナフタレニル]メチル}アミノ)プロパン酸 塩酸塩を用いた。比較化合物Cは、[33P]-S1PのS1P1またはS1P5への結合に対して、それぞれ1.0nmol/Lまたは8.5nmol/Lの阻害活性(IC50値)を示した。
雌性C57BL/Jマウス(日本チャールス・リバー株式会社、実験開始時週齢:7又は8週齢)を使用した。Myelin Oligodendrocyte Glycoprotein[sequence 35-55 MEVGWYRSPFSRVVHLYRNGK (AnaSpec Inc、以下MOG35-55)]を生理食塩液(株式会社大塚製薬工場)に溶解し、2mg/mL溶液を調製した。MOG35-55の2mg/mL溶液と等量のFCA H37Ra(Difco Laboratories)を混合してエマルジョンを調製し惹起剤とした。惹起剤0.2mLを、26G注射針を装着したガラスシリンジを用いてマウス側腹に皮下投与することで免疫処置した。免疫処置日を免疫0日目とし、免疫0及び2日目にPertussis toxin(List Biological Laboratories)の1μg/mL溶液0.2mLを尾静脈内投与した(Cell Mol Immunol、第2巻、439-448ページ、2005年参照)。
本発明化合物は、本モデルにおいて有効性を示す。
製剤例1
以下の各成分を常法により混合した後打錠することにより、一錠中に10mgの活性成分を含有する錠剤約1万錠が得られる。
・1-[((3S)-3-メチル-6-ペントキシ-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸…100g
・カルボキシメチルセルロースカルシウム(崩壊剤) … 20g
・ステアリン酸マグネシウム(潤滑剤) … 10g
・微結晶セルロース … 870g
以下の各成分を常法により混合した後、除塵フィルターでろ過し、5mlずつアンプルに充填し、オートクレーブで加熱滅菌することにより、1アンプル中20mgの活性成分を含有するアンプル約1万本が得られる。
・3-フルオロ-1-[[(3S)-3-メチル-6-[(E)-4,4,4-トリフルオロブタ-2-エノキシ]-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸…200g
・マンニトール … 20g
・蒸留水 … 50L
Claims (20)
- 一般式(V)
ここで、L中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
Yは、
ここで、各基は矢印で示される結合手によってZに結合し、
Aは、置換されていてもよいC3~7シクロアルキレン基、または置換されていてもよいC1~4アルキレン基を表し、
R1は、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R2は、C1~4アルキル基、ハロゲンで置換されていてもよいC1~4アルコキシ基、C1~4ハロアルキル基、ハロゲン原子、または水酸基を表し、
R3、R4およびR5は、それぞれ独立して水素原子、C1~4アルキル基、ハロゲンで置換されていてもよいC3~6シクロアルキル基、またはC1~4ハロアルキル基を表し、
Zは、(1)1個のC1~8アルキル基で置換されていてもよいカルボキシル基、(2)1個のC1~8アルキル基で置換されていてもよい水酸基、(3)1~2個のC1~8アルキル基で置換されていてもよいヒドロキサム酸基、(4)1個のC1~8アルキル基で置換されていてもよいスルホン酸基、(5)1~2個のC1~8アルキル基で置換されていてもよいボロン酸基、(6)(i)1~2個のC1~8アルキル基、または(ii)C1~4のアルキル基で置換されていてもよい1~2個のスルホニル基で置換されていてもよい、カルバモイル基、(7)(i)1~2個のC1~8アルキル基、または(ii)1~2個のC2~8のアシル基で置換されていてもよい、スルファモイル基、(8)1~2個のC1~8アルキル基で置換されていてもよいスルホキシイミン基、または(9)テトラゾリル基を表し、
ring2は、3~7員の含窒素ヘテロ環を表し、
mは、0~6の整数を表し、
nは、0~5の整数を表し、
mが2以上のとき、複数のR1は同じでも異なっていてもよく、
nが2以上のとき、複数のR2は同じでも異なっていてもよく、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物、またはその薬学的に許容される塩。 - Lが、(1)-O-(C2~7アルキル)、(2)-O-(C2~7アルケニル)、(3)-O-(C2~7アルキニル)、(4)-O-(C1~5アルキレン)-OCH3、(5)-O-(C1~4アルキレン)-OCH2CH3、(6)-CH2O-(C1~6アルキル)、(7)-CH2O-(C2~6アルケニル)、(8)-CH2O-(C2~6アルキニル)、(9)-CH2CH2O-(C1~5アルキル)、(10)-CH2CH2O-(C2~5アルケニル)、(11)-CH2CH2O-(C2~5アルキニル)、(12)-S-(C2~7アルキル)、(13)-S-(C2~7アルケニル)、(14)-S-(C2~7アルキニル)、(15)-NR6-(C2~7アルキル)、(16)-NR6-(C2~7アルケニル)、(17)-NR6-(C2~7アルキニル)、(18)C3~8アルキル基、(19)C3~8アルケニル基、または(20)C3~8アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい請求項1または2に記載の化合物、またはその薬学的に許容される塩。 - Lが、主鎖の原子数が4~7である分岐または直鎖の鎖状基である請求項1または2に記載の化合物、またはその薬学的に許容される塩。
- Lが、(1)-O-(C3~6アルキル)、(2)-O-(C3~6アルケニル)、(3)-O-(C3~6アルキニル)、(4)-O-(C1~4アルキレン)-OCH3、(5)-O-(C1~3アルキレン)-OCH2CH3、(6)-CH2O-(C2~5アルキル)、(7)-CH2O-(C2~5アルケニル)、(8)-CH2O-(C2~5アルキニル)、(9)-CH2CH2O-(C1~4アルキル)、(10)-CH2CH2O-(C2~4アルケニル)、(11)-CH2CH2O-(C2~4アルキニル)、(12)-S-(C3~6アルキル)、(13)-S-(C3~6アルケニル)、(14)-S-(C3~6アルキニル)、(15)-NR6-(C3~6アルキル)、(16)-NR6-(C3~6アルケニル)、(17)-NR6-(C3~6アルキニル)、(18)C4~7アルキル基、(19)C4~7アルケニル基、または(20)C4~7アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい請求項1または2に記載の化合物、またはその薬学的に許容される塩。 - ring2が、3~7員の含窒素飽和ヘテロ環である1~5のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- 一般式(V-2)
ここで、L1中の炭素原子は、1~13個のハロゲン原子で置換されていてもよく、
ring2-1は、3~7員の含窒素飽和ヘテロ環を表し、
m-1は、0~2の整数を表し、
n-1は、0~2の整数を表し、
m-1が2のとき、複数のR1は同じでも異なっていてもよく、
n-1が2のとき、複数のR2は同じでも異なっていてもよく、
その他の記号は請求項1と同じ意味を表し、
ここで、各水素原子は、重水素原子、または三重水素原子であってもよい。]
で示される化合物である請求項1または2記載の化合物、またはその薬学的に許容される塩。 - Zが、1個のC1~8アルキル基で置換されていてもよいカルボキシル基、またはテトラゾリル基である請求項1~7のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- L1が、(1)-O-(C3~6アルキル)、(2)-O-(C3~6アルケニル)、(3)-O-(C3~6アルキニル)、(4)-O-(C1~4アルキレン)-OCH3、(5)-O-(C1~3アルキレン)-OCH2CH3、(6)-CH2O-(C2~5アルキル)、(7)-CH2O-(C2~5アルケニル)、(8)-CH2O-(C2~5アルキニル)、(9)-CH2CH2O-(C1~4アルキル)、(10)-CH2CH2O-(C2~4アルケニル)、(11)-CH2CH2O-(C2~4アルキニル)、(12)-S-(C3~6アルキル)、(13)-S-(C3~6アルケニル)、(14)-S-(C3~6アルキニル)、(15)-NR6-(C3~6アルキル)、(16)-NR6-(C3~6アルケニル)、(17)-NR6-(C3~6アルキニル)、(18)C4~7アルキル基、(19)C4~7アルケニル基、または(20)C4~7アルキニル基であり、
R6は、水素原子またはC1~4アルキル基を表し、
ここで、各基中の炭素原子は、1~13個のハロゲン原子で置換されていてもよい請求項7または8に記載の化合物、またはその薬学的に許容される塩。 - R1が、C1~4アルキル基、またはハロゲン原子である請求項1~9のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- ring2-1が、アゼチジン、ピロリジン、ピペリジン、またはパーヒドロアゼピンである請求項7~10のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- (1)1-[((3R)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(2)1-[((3S)-6-ブトキシ-3-メチル-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(3)1-[((3S)-3-メチル-6-ペントキシ-3,4-ジヒドロナフタレン-2-イル)メチル]アゼチジン-3-カルボン酸、(4)1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(5)3-フルオロ-1-[[(3S)-3-メチル-6-(3,4,4-トリフルオロブタ-3-エノキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(6)1-[[(3S)-3-メチル-6-(1,1,2,2,3,3,4,4,4-ノナデューテリオブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(7)(3R)-1-[[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]ピロリジン-3-カルボン酸、(8)1-[[(3S)-3-メチル-6-((R)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(9)1-[[(3S)-3-メチル-6-((S)-3,3,3-トリフルオロ-2-メチルプロポキシ)-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、または(10)3-フルオロ-1-[[(3S)-3-メチル-6-[(E)-4,4,4-トリフルオロブタ-2-エノキシ]-3,4-ジヒドロナフタレン-2-イル]メチル]アゼチジン-3-カルボン酸、(11)3-フルオロ-1-{[(3S)-3-メチル-6-(3,3,3-トリフルオロプロポキシ)-3,4-ジヒドロ-2-ナフタレニル]メチル}-3-アゼチジンカルボン酸、(12)cis-3-({1-[(3S)-3-メチル-6-(4,4,4-トリフルオロブトキシ)-3,4-ジヒドロ-2-ナフタレニル]エチル}アミノ)シクロブタンカルボン酸、または(13)1-{[(3S)-3-メチル-6-(プロポキシメチル)-3,4-ジヒドロ-2-ナフタレニル]メチル}-3-アゼチジンカルボン酸である請求項1または2に記載の化合物、またはその薬学的に許容される塩。
- 請求項1記載の一般式(V)で示される化合物、またはその薬学的に許容される塩を含有する医薬組成物。
- S1P5作動剤である請求項13に記載の医薬組成物。
- S1P5介在性疾患の予防および/または治療剤である請求項13または14に記載の医薬組成物。
- S1P5介在性疾患が、神経変性疾患、自己免疫疾患、感染症または癌である請求項15に記載の医薬組成物。
- S1P5介在性疾患が、神経変性疾患であり、神経変性疾患が、統合失調症、ビンスワンガー病、多発性硬化症、視神経脊髄炎、アルツハイマー病型認知症、認知障害、筋萎縮性側索硬化症、脊髄小脳変性症、多系統萎縮症、パーキンソン病、またはレビー小体型認知症である請求項16に記載の医薬組成物。
- 請求項1記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の有効量を哺乳動物に投与することを特徴とする、S1P5介在性疾患の予防および/または治療方法。
- S1P5介在性疾患の予防および/または治療に使用される請求項1記載の一般式(V)で示される化合物、またはその薬学的に許容される塩。
- S1P5介在性疾患の予防および/または治療剤を製造するための請求項1記載の一般式(V)で示される化合物、またはその薬学的に許容される塩の使用。
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3091216A CA3091216A1 (en) | 2018-02-22 | 2019-02-21 | Compounds having s1p5 receptor agonistic activity |
EP19756600.3A EP3757091A4 (en) | 2018-02-22 | 2019-02-21 | COMPOUND WITH S1P5 RECEPTOR AGONIST ACTIVITY |
RU2020127745A RU2781541C2 (ru) | 2018-02-22 | 2019-02-21 | Соединения, обладающие агонистической активностью по отношению к рецептору s1p5 |
BR112020017036-4A BR112020017036A2 (pt) | 2018-02-22 | 2019-02-21 | Compostos com atividade agonista do receptor s1p5 |
AU2019224344A AU2019224344A1 (en) | 2018-02-22 | 2019-02-21 | Compound having S1P5 receptor agonist activity |
NZ766972A NZ766972A (en) | 2018-02-22 | 2019-02-21 | Compounds having s1p5 receptor agonistic activity |
JP2020501047A JP7211410B2 (ja) | 2018-02-22 | 2019-02-21 | S1p5受容体作動活性を有する化合物 |
CN201980014718.7A CN111757869B (zh) | 2018-02-22 | 2019-02-21 | 具有s1p5受体激动活性的化合物 |
MX2020008523A MX2020008523A (es) | 2018-02-22 | 2019-02-21 | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). |
US16/970,865 US11198672B2 (en) | 2018-02-22 | 2019-02-21 | Compounds having S1P5 receptor agonistic activity |
KR1020207023907A KR20200124668A (ko) | 2018-02-22 | 2019-02-21 | S1p5 수용체 작동 활성을 갖는 화합물 |
SG11202007896YA SG11202007896YA (en) | 2018-02-22 | 2019-02-21 | Compounds having s1p5 receptor agonistic activity |
IL276656A IL276656A (en) | 2018-02-22 | 2020-08-11 | Compounds with S1P5 receptor agonistic activity |
PH12020551297A PH12020551297A1 (en) | 2018-02-22 | 2020-08-20 | Compounds having s1p5 receptor agonistic activity |
US17/521,004 US20220055986A1 (en) | 2018-02-22 | 2021-11-08 | Compounds having s1p5 receptor agonistic activity |
JP2023001815A JP7485103B2 (ja) | 2018-02-22 | 2023-01-10 | S1p5受容体作動活性を有する化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018029549 | 2018-02-22 | ||
JP2018-029549 | 2018-02-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/970,865 A-371-Of-International US11198672B2 (en) | 2018-02-22 | 2019-02-21 | Compounds having S1P5 receptor agonistic activity |
US17/521,004 Division US20220055986A1 (en) | 2018-02-22 | 2021-11-08 | Compounds having s1p5 receptor agonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019163917A1 true WO2019163917A1 (ja) | 2019-08-29 |
Family
ID=67688486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/006637 WO2019163917A1 (ja) | 2018-02-22 | 2019-02-21 | S1p5受容体作動活性を有する化合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11198672B2 (ja) |
EP (1) | EP3757091A4 (ja) |
JP (2) | JP7211410B2 (ja) |
KR (1) | KR20200124668A (ja) |
CN (1) | CN111757869B (ja) |
AU (1) | AU2019224344A1 (ja) |
BR (1) | BR112020017036A2 (ja) |
CA (1) | CA3091216A1 (ja) |
IL (1) | IL276656A (ja) |
MX (1) | MX2020008523A (ja) |
NZ (1) | NZ766972A (ja) |
PH (1) | PH12020551297A1 (ja) |
SG (1) | SG11202007896YA (ja) |
TW (2) | TWI821061B (ja) |
WO (1) | WO2019163917A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2021033729A1 (ja) * | 2019-08-20 | 2021-02-25 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ766972A (en) * | 2018-02-22 | 2024-02-23 | Ono Pharmaceutical Co | Compounds having s1p5 receptor agonistic activity |
WO2024006985A1 (en) * | 2022-07-01 | 2024-01-04 | Autobahn Therapeutics, Inc. | Amide prodrugs and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | S1p受容体結合能を有する化合物およびその医薬用途 |
WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
WO2006064757A1 (ja) | 2004-12-13 | 2006-06-22 | Ono Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体およびその医薬用途 |
WO2016088834A1 (ja) * | 2014-12-04 | 2016-06-09 | 小野薬品工業株式会社 | ジヒドロナフタレン誘導体 |
WO2017131149A1 (ja) * | 2016-01-29 | 2017-08-03 | 小野薬品工業株式会社 | テトラヒドロナフタレン誘導体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
CN1874991A (zh) | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
CA2641718A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
WO2012109108A1 (en) | 2011-02-07 | 2012-08-16 | Biogen Idec Ma Inc. | S1p modulating agents |
NZ766972A (en) * | 2018-02-22 | 2024-02-23 | Ono Pharmaceutical Co | Compounds having s1p5 receptor agonistic activity |
-
2019
- 2019-02-21 NZ NZ766972A patent/NZ766972A/en unknown
- 2019-02-21 WO PCT/JP2019/006637 patent/WO2019163917A1/ja active Application Filing
- 2019-02-21 CA CA3091216A patent/CA3091216A1/en active Pending
- 2019-02-21 CN CN201980014718.7A patent/CN111757869B/zh active Active
- 2019-02-21 US US16/970,865 patent/US11198672B2/en active Active
- 2019-02-21 TW TW111146609A patent/TWI821061B/zh active
- 2019-02-21 EP EP19756600.3A patent/EP3757091A4/en active Pending
- 2019-02-21 SG SG11202007896YA patent/SG11202007896YA/en unknown
- 2019-02-21 AU AU2019224344A patent/AU2019224344A1/en active Pending
- 2019-02-21 JP JP2020501047A patent/JP7211410B2/ja active Active
- 2019-02-21 TW TW108105841A patent/TWI789495B/zh active
- 2019-02-21 BR BR112020017036-4A patent/BR112020017036A2/pt unknown
- 2019-02-21 MX MX2020008523A patent/MX2020008523A/es unknown
- 2019-02-21 KR KR1020207023907A patent/KR20200124668A/ko not_active Application Discontinuation
-
2020
- 2020-08-11 IL IL276656A patent/IL276656A/en unknown
- 2020-08-20 PH PH12020551297A patent/PH12020551297A1/en unknown
-
2021
- 2021-11-08 US US17/521,004 patent/US20220055986A1/en active Pending
-
2023
- 2023-01-10 JP JP2023001815A patent/JP7485103B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | S1p受容体結合能を有する化合物およびその医薬用途 |
WO2006007448A2 (en) | 2004-06-17 | 2006-01-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions and related methods of use |
WO2006064757A1 (ja) | 2004-12-13 | 2006-06-22 | Ono Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体およびその医薬用途 |
WO2016088834A1 (ja) * | 2014-12-04 | 2016-06-09 | 小野薬品工業株式会社 | ジヒドロナフタレン誘導体 |
WO2017131149A1 (ja) * | 2016-01-29 | 2017-08-03 | 小野薬品工業株式会社 | テトラヒドロナフタレン誘導体 |
Non-Patent Citations (11)
Title |
---|
"Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 2018, JOHN WILEY & SONS INC. |
"''Iyakuhin no kaihatsu'', Vol. 7, ''Bunshi sekkei''", vol. 7, 1990, HIROKAWA-SHOTEN LTD., pages: 163 - 198 |
CELL MOL IMMUNOL, vol. 2, 2005, pages 439 - 448 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 345594-83-8 |
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 43, 2013, pages 1667 - 1675 |
NATURE IMMUNOLOGY, vol. 8, no. 12, 2007, pages 1337 - 1344 |
PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 13451 - 13456 |
SCIENCE, vol. 350, no. 6263, 2015, pages 985 - 990 |
T. W. GREENE: "Protective Groups in Organic Synthesis", 2014, WILEY |
THE FASEB JOURNAL, vol. 21, 2007, pages 01503 - 1514 |
THE JOURNAL OF NEUROSCIENCE, vol. 25, no. 6, 2005, pages 1459 - 1469 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2021033729A1 (ja) * | 2019-08-20 | 2021-02-25 | ||
WO2021033729A1 (ja) | 2019-08-20 | 2021-02-25 | 小野薬品工業株式会社 | S1p5受容体作動活性を有する化合物の塩および結晶形 |
KR20220050886A (ko) | 2019-08-20 | 2022-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | S1p5 수용체 작동 활성을 갖는 화합물의 염 및 결정형 |
EP4019496A4 (en) * | 2019-08-20 | 2023-01-11 | ONO Pharmaceutical Co., Ltd. | SALT AND CRYSTALLINE FORM OF A COMPOUND HAVING AGONIST ACTIVITY AGAINST THE S1P5 RECEPTOR |
JP7409383B2 (ja) | 2019-08-20 | 2024-01-09 | 小野薬品工業株式会社 | S1p5受容体作動活性を有する化合物の塩および結晶形 |
Also Published As
Publication number | Publication date |
---|---|
US11198672B2 (en) | 2021-12-14 |
US20210087141A1 (en) | 2021-03-25 |
TWI789495B (zh) | 2023-01-11 |
BR112020017036A2 (pt) | 2020-12-15 |
CN111757869A (zh) | 2020-10-09 |
JP7211410B2 (ja) | 2023-01-24 |
EP3757091A1 (en) | 2020-12-30 |
IL276656A (en) | 2020-09-30 |
JP7485103B2 (ja) | 2024-05-16 |
CN111757869B (zh) | 2024-03-08 |
TWI821061B (zh) | 2023-11-01 |
MX2020008523A (es) | 2020-09-18 |
EP3757091A4 (en) | 2022-04-06 |
RU2020127745A3 (ja) | 2022-03-22 |
CA3091216A1 (en) | 2019-08-29 |
RU2020127745A (ru) | 2022-03-22 |
TW202313002A (zh) | 2023-04-01 |
JPWO2019163917A1 (ja) | 2021-02-04 |
AU2019224344A1 (en) | 2020-09-03 |
JP2023029542A (ja) | 2023-03-03 |
KR20200124668A (ko) | 2020-11-03 |
TW202000644A (zh) | 2020-01-01 |
PH12020551297A1 (en) | 2021-05-31 |
SG11202007896YA (en) | 2020-09-29 |
US20220055986A1 (en) | 2022-02-24 |
NZ766972A (en) | 2024-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7485103B2 (ja) | S1p5受容体作動活性を有する化合物 | |
EP3409658B1 (en) | Tetrahydronaphthalene derivative | |
WO2006001463A1 (ja) | S1p受容体結合能を有する化合物およびその用途 | |
JP6673218B2 (ja) | ジヒドロナフタレン誘導体 | |
JP7354960B2 (ja) | S1p5介在性疾患の予防および/または治療剤 | |
KR20080076910A (ko) | 히스타민 h3 수용체의 길항제로서의 이소퀴놀린 및벤조[h]이소퀴놀린 유도체, 그의 제조 및 치료 용도 | |
RU2781541C2 (ru) | Соединения, обладающие агонистической активностью по отношению к рецептору s1p5 | |
US20220289675A1 (en) | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
WO2005000789A1 (ja) | 2-アミノ-3-アルコキシビシクロ[3.1.0]ヘキサン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19756600 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020501047 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3091216 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019224344 Country of ref document: AU Date of ref document: 20190221 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020127745 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019756600 Country of ref document: EP Effective date: 20200922 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020017036 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020017036 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200820 |